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I. Embryology: the vascular system and endothelial cells
The vertebrate circulatory system is formed by two distinct processes during embryogenesis. 
At first, there is vasculogenesis, defined as de novo blood vessel formation by differentiation 
of mesoderm-derived endothelial precursor cells [(haem)angioblasts]1, 2. This is followed by 
angiogenesis, which includes the proliferation of endothelial cells and formation of new blood 
vessels from pre-existing vessels1,2.
The vascular system, consisting of blood vessels and the heart, is the first identifiable structure 
in the developing embryo3,4. The first signs of blood vessel formation occur in the gastrulation 
stage at day 7.5 in the blood islands of the yolk sac1,5. Subsequently, the blood island fuses and 
forms an immature vascular network, known as the primary plexus. In a next phase, vascular 
remodelling in the yolk sac leads to the formation of the complex yolk sac vasculature1,2. At the 
same time, angioblasts aggregate into solid endothelial strands along both sides of the neural 
tube in the embryo2,5. They differentiate into the dorsal aorta, vitelline vessels and primary 
plexuses of lungs, spleen and heart1. Although the exact embryogenesis is not fully elucidated, it 
is clear that these two processes are driven by different signalling pathways and transcriptional 
regulators. Fibroblast growth factor 2 (FGF2), bone morphogenetic protein 4 (BMP4), its 
downstream target Indian Hedgehog (IHH), vascular endothelial growth factor A(VEGF-A) and 
E-twenty six (ETS) transcription factors are key players in vasculogenesis and are important for 
the differentiation of endothelial and hematopoietic cells6. VEGF-A, retinoic acid, transforming 
growth factor beta (TGF-b), Notch and VEGF signalling pathways are more important during 
endothelial cell proliferation and angiogenic sprouting, which is also known as angiogenesis6.
II. Endothelial markers
The starting point of an adequate diagnosis is conventional histological examination using 
haematoxylin and eosin stained slides, in combination with clinical and/ or radiographical 
information. In addition, immunohistochemistry is a very useful and sometimes even an 
essential diagnostic tool to evaluate or confirm the line of differentiation in tumours. Because 
the classification of vascular tumours can be difficult, different antibodies have been described 
and used to demonstrate endothelial differentiation. The most commonly used markers are 
described below.
CD31, also known as platelet endothelial cell adhesion molecule 1 (PECAM-1), is a single- 
chain type I transmembrane protein member of the immunoglobulin (Ig) superfamily and has 
a molecular weight of ~83kDa. The extracellular domain contains six Ig-like homology units 
of the C2 subclass, similar to cell-cell adhesion molecules. CD31 plays a role in angiogenesis7,8 
and diapedesis of leukocytes9. It is abundantly expressed on the surface of embryonic vascular 
and adult endothelial cells10,11. Therefore, it has been regarded over the past years as the most 
sensitive immunohistochemical marker for endothelial cell differentiation. However, it is not an 
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absolutely specific marker because it is also expressed in macrophages, dendritic cells, platelets, 
monocytes, neutrophils and a subset of T- en B-lymphocytes and natural killer cells10,11. In 
cultured endothelial cells it is diffusely distributed in the plasma membrane, but when cell-cell 
contacts are formed it is concentrated at the regions of cell-cell contact12 where it plays a role 
in endothelial cell contact10.
CD34, also known as hematopoietic progenitor cell antigen CD34, is a heavily glycosylated 
type I transmembrane protein with a molecular weight of ~41kDa. The function of CD34 is 
still not completely elucidated. To date, it is accepted that CD34 plays a role in cell adhesion 
and cell transduction10,13. CD34 is expressed on the most primitive pluripotential stem cells 
and hematopoietic progenitor cells of all lineages. The expression is eventually gradually lost 
when lineage committed progenitors differentiate. It is also present in dendritic interstitial cells, 
dermal dendrocytes, endometrial stroma, some lymphatic endothelial cells, interstitial cells of 
Cajal and a subset of fibroblasts4,10,14. Because of the expression on endothelial cells and vascular 
tumours, CD34 is used as a vascular marker. However, compared to CD31, CD34 is less sensitive 
and less specific10.
von Willebrand Factor (vWF), also known as Factor VIII-related antigen, is a multimeric 
plasma glycoprotein with a molecular weight of ~250 kDa. It is synthesized by endothelial cells, 
megakaryocytes and platelets. In endothelial cells it is located within the Weibel-Palade bodies. 
vWF has a dual key role in both primary and secondary hemostasis by mediating the adhesion 
of platelets towards the wound site and chaperoning clotting factor VIII10, 15. Mutations of the 
vWF gene are known to cause von Willebrand disease and are characterized by ecchymoses, 
hemorrhage and a prolonged bleeding time. vWF is a highly specific endothelial marker. 
However, it is much less sensitive compared to CD31 and CD344,10.
FLI1 (Friend leukaemia integration 1 transcription factor) is a member of the ETS family of 
DNA binding transcription factors and has a molecular weight of ~51kDa16. FLI1 is involved 
in cellular proliferation and tumourigenesis. It was first discovered in Ewing sarcoma, since 
approximately 90% of these tumours have a specific translocation, t(11;22)(q24;q12), resulting 
in the EWSR1-FLI1 fusion protein17. However, a study of small blue round cell tumours 
revealed also nuclear expression of FLI1 in normal endothelial cells and small lymphocytes16 and 
therefore FLI1 was reported as the first nuclear marker of endothelial differentiation. However, 
it is also expressed in a small subset of melanomas, Merkel cell carcinomas, synovial sarcomas, 
breast carcinomas18, and nearly all epithelioid sarcomas show positive staining for FLI13.
ERG, also known as avian v-ets erytroblastosis virus E26 oncogene homolog, is a member of the 
ETS family of transcription factors and has a molecular weight of ~55 kDa. It is constitutively 
expressed by endothelial cells and it has been shown to play a role in the regulation of 
angiogenesis and apoptosis of endothelial cells4,10,19. Recent immunohistochemical studies have 




it also plays an important role in carcinogenesis of a subset of prostate carcinomas containing 
the TMPRSS2-ERG fusion4,20-22. Moreover, some myeloid precursor cells4,23 and rare cases of 
Ewing sarcomas, containing the EWSR1-ERG fusion, are positive as well4. Recent publications 
have shown that ERG expression is also present in one and up to two third of the epithelioid 
sarcomas, especially when an antibody directed against the ERG N-terminus was used3,4.
D2-40 is a commercially available monoclonal antibody directed against human podoplanin. 
Podoplanin, also known as type I alveolar cell marker hT1alpha-2 and Aggrus, is a type I 
transmembrane glycoprotein with extensive O-glycosylation and a molecular weight of 
~40kDa. Some studies have demonstrated that it is regulated by the lymphatic-specific 
homeobox gene Prox 1, a transcription factor responsible for the development of lymphatic 
progenitors from embryonic veins24. Podoplanin promotes platelet aggregation, and possesses a 
platelet aggregation-stimulating (PLAG) domain25. Podoplanin is expressed in a large number 
of normal tissue cells, such as mesothelial cells, osteocytes and osteoblasts, follicular dendritic 
cells of lymphoid tissue, etc…, but also in a variety of different tumour types, in example a 
subset of vascular tumours, epithelioid mesothelioma, adrenal cortical carcinoma, seminoma/
dysgerminoma26.
Ulex Europaeus Agglutinin 1 (UEA-1) is one of the oldest endothelial markers and has 
been used for some time. UEA-1 binds to glycoproteins and glycolipids in endothelial cells. 
However, these glycoproteins and glycolipids are also found in red blood cells and epithelial cells 
of ABH blood group secretors27. Because UEA-1 also reacts with all kinds of epithelial cells, it 
has no longer any diagnostic value since the discovery of more sensitive and specific endothelial 
markers such as CD34 and CD31.
Other endothelial markers
Over the years, many other markers such as LYVE-1, Prox1, claudin 5, WT1, VEGF and 
GLUT1 have been used or are still used as endothelial markers, sometimes to emphasize specific 
differentiation of the endothelium. However, these markers are not exclusively positive on 
endothelial cells and therefore not widely used and studied.
III. Vascular tumours
It is generally accepted that vascular tissue or tissue with the immunohistochemical repertoire 
of endothelial cells as discussed above can give rise to tumours and tumour-like malformations 
in the skin, soft tissue and viscera. These lesions are part of a wide spectrum of entities, and for 
clinical purposes classification schemes have been proposed and evolved over the years. Benign 
haemangiomas are one of the most common soft tissue tumours, whereas angiosarcomas are 
their malignant counterpart and are extremely rare, highly aggressive and comprise less than 
1% of all sarcomas28. Other vascular lesions, originally grouped as haemangioendotheliomas, are 
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more aggressive as compared to benign haemangiomas while they are not full blown malignant 
angiosarcomas. To overcome problems with ambiguous terms such as “intermediate malignancy” 
or “borderline malignant potential”, the 2002 World Health Organization classification 
endeavoured to classify soft tissue tumours into four categories: overtly benign lesions, locally 
aggressive not metastasizing lesions, locally aggressive rarely metastasizing lesions and frankly 
malignant lesions. In 2013, also vascular tumours of bone were classified as such29 (Table 1)
Table 1. Overview of all vascular tumours of soft tissue and bone as listed in the 2013 WHO Classification 
of Tumours of Soft Tissue and Bone.




  arteriovenous haemangioma/ malformation














Malignant Epithelioid haemangioendothelioma Epithelioid haemangioendothelioma
Angiosarcoma of soft tissue Angiosarcoma
IV. Vascular tumours of bone
In bone, the nutrient arteries penetrate the cortex and branch into an abundant network of 
small arteries and capillaries. The terminology of vascular tumours of bone has been a matter of 
debate over the years, which has led to the use of different terminology and different classification 
systems used simultaneously over the years (Table 2). None of these classification systems 
have been generally accepted due to the lack of consistent terminology, accepted histological 
criteria and only a limited correlation with clinical outcome. In particular, the classification of 
vascular tumours of bone belonging to the intermediate category, or representing low-grade 
vascular tumours of bone, previously simply grouped as “haemangioendotheliomas”, has been 
extremely difficult. Solitary haemangiomas are relatively common in bone. Autopsy studies have 




an asymptomatic incidental finding in the skull or spine, although extraspinal locations are also 
reported. However, despite the rich vascularity of bone primary malignant vascular tumours 
of bone are extremely rare31. They represent less than 1% of primary malignant bone tumours 
reported by the Netherlands Committee on Bone tumours32 and 0,5% of those registered at 
the Mayo Clinic33. Because of their rareness, little systematic knowledge is available. Clinically 
they seem to be extremely aggressive and have a very poor prognosis. Currently, epithelioid 
haemangioma, previously also known as haemangioendothelioma of bone, has been recognized 
as a locally aggressive vascular neoplasm with distinct histological criteria and an excellent 
prognosis29,34. The term “haemangiopericytoma” of soft tissue was already abandoned in the 
2002 World Health Organisation (WHO) Classification of Tumours of Soft Tissue and Bone.
It has been accepted that it merely represents a nonspecific growth pattern exhibited by a 
large number of tumours, and “haemangiopericytoma of soft tissue” could be reclassified as 
solitary fibrous tumours, monophasic synovial sarcoma, and (infantile) myofibromatosis or 
myofibroblastic laesions29,35,36. Similar lesions occur in bone, which led us to question whether 
also “haemangiopericytoma of bone” is a true entity (see Chapter 7). In the 2013 WHO 
classification “haemangiopericytoma of bone” is also no longer recognized as a separate entity.
The characteristics of the different histological types of vascular lesions of bone are described in 
more detail in Chapter 2 of this thesis.
V. Multifocality
Both benign and malignant vascular tumours of bone can occur multifocally, and multifocal 
disease in bone is even more common as compared to the same tumours occurring in soft 
tissue. The distribution of these lesions can be either contiguous, involving adjacent bones, 
or non-contiguous, involving two or more distant sites37. Multiple benign vascular lesions, 
known as haemangiomatosis, are considered a developmental disorder (vascular hamartomas)37. 
Up to one third of the angiosarcoma of bone and nearly two third of the epithelioid 
haemangioendotheliomas of bone occur multifocally29. Although the exact mechanism remains 
unclear, one could speculate i) they could be metastatic lesions (skip metastasis in bone), ii) 
there could be a genetic disorder (somatic mosaicism) facilitating tumour formation at multiple 
locations; iii) the production of multiple circulating growth factors in the bone marrow 
could lead to vascular proliferation resulting in multifocal malignancy. However, Pansuriya 
and co-workers identified IDH1 and IDH2 mutations in a large proportion of echondromas 
and spindle cell haemangiomas38. These mutations occurred also in the majority of multiple 
lesions within one patient38. More recently, Antonescu et al. demonstrated the presence of the 
characteristic WWTR1-CAMTA1 fusion transcript product with the presence of an identical 
breakpoint in WWTR1 and CAMTA1 in all different tumour nodules of two patients with 
multicentric epithelioid haemangioendothelioma of the liver39. These findings support the 
hypothesis of clonal disease and suggest that the tumour nodules are metastatic implants, rather 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































VI. Molecular alterations in vascular tumours
So far, only few studies focussed on molecular genetic changes in vascular tumours of bone. The 
identification of the molecular genetic background could help to better classify these vascular 
tumours of bone and provide new therapeutic options to improve survival and prognosis. For 
its soft tissue counterpart, few of the molecular genetic changes are known. Over the past years, 
researchers have shown a great interest in vascular tumours, mostly of soft tissue, resulting into 
new insights in molecular changes and a possible role in tumourigenesis. Genetic analysis of 
angiosarcomas of soft tissue, which has been mostly single case reports or publications of very 
small tumour groups, showed complex genomic aberrations suggesting angiosarcoma belongs to 
the groups of sarcomas with a complex genetic profile. In this context the retinoblastoma (Rb) 
pathway or TP53 pathway is most often involved. Therefore, some authors have suggested p53 
gene mutations40,41 and chromosomal anomalies to be essential in their development. Although 
nearly 50% of the angiosarcomas showed p53 overexpression by immunohistochemistry, only 
in 4% a p53 mutation was detected42. Moreover, Antonescu and colleagues identified a subset 
(10%) of angiosarcomas to contain KDR (kinase insert domain receptor encoding for VEGFR2) 
mutations which correlated with a strong KDR protein expression and breast localisation42,43. 
Furthermore, high level MYC amplification was shown in radiation-induced and lymphedema-
associated angiosarcoma and not in primary angiosarcomas or radiation-induced atypical vascular 
lesions42-45, suggesting a possible role in tumourigenesis specifically in secondary angiosarcomas. 
In 25% of the secondary angiosarcomas FLT4 co-amplification was also present42, 45. However, 
recent publications have shown that MYC amplification can also occur in a small subset of 
primary angiosarcomas42,46. A recent whole-genome sequencing study of both spontaneous 
(primary) and secondary angiosarcomas demonstrated that not all secondary angiosarcomas 
harbour a MYC amplification, in this study only 11 of 19 well documented secondary 
angiosarcomas (58%) showed a MYC amplification47 (Table 3). Moreover, they described two 
new mutations in secondary angiosarcomas: 45% of the secondary angiosarcomas harboured 
an inactivating mutation in the PTPRB (VE-PTP) gene, a negative regulator of angiogenesis 
by inhibition of vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial 
(VE)-cadherin and angiopoietin signalling. Moreover, three of these secondary angiosarcomas 
also demonstrated a mutation in PLCG147. The PLCG1 gene encodes for phospholipase Cγ1 
(PLCγ1), a tyrosine kinase signal transducer in the PIK3CA signalling pathway. In contrast, 
only a minority of the spontaneous (primary) angiosarcomas showed genetic alterations in 
well-known cancer genes, such as PIK3CA, CDKN2A, NRAS, KRAS, and none of these 
alterations were recurrent47. Thus, a significant subset of angiosarcomas, especially breast (KDR) 

















































































































































































































































































































































































































































































Over the years, in two epithelioid haemangioendothelioma of soft tissue a translocation t(1;3)
(p36.3;q25) had been described, suggesting a recurrent genetic aberration29,48. However, only 
recently the genes involved in this translocation have been identified: WWTR1 (also known 
as TAZ) on 3q25 fuses with CAMTA1 on 1p36, resulting in a fusion gene and eventually 
activating a novel transcriptional program39. Moreover, a YAP1-TFE3 gene fusion has been 
identified in epithelioid haemangioendothelioma lacking the WWTR1-CAMTA1 fusion49. 
The latter subgroup seems to have a more distinct morphology including well-formed vessels 
as compared to classic epithelioid hemangioendothelioma. Although most of these tumours 
are located within the soft tissue also one of the reported cases was located within the bone 
(vertebral body)42,49.
Pseudomyogenic haemangioendothelioma is a more recently described intermediate malignant 
vascular tumour affecting children and young adults. It is characterized by loose fascicles or 
sheets of round or oval shaped cells with vesicular nuclei and prominent nucleoli, surrounded by 
abundant homogeneous eosinophilic cytoplasm50. These lesions also have a tendency to occur 
multifocally. A recent genetic study has identified a balances translocation t(7;19)(q22;q13) in 
two patient (one lesion of one patient and three lesions of the same patient) and a unbalanced 
der(7)t(7;19) translocation in another case, resulting in fusion of SERPINE1 and FOSB genes. 
This entity has been originally described in soft tissue51,52. However currently, there have 
been some reports of primary bone lesions as well53,54. Also in a subset (20%) of epithelioid 
haemangioma, a benign vascular tumour, a ZFP36-FOSB fusion has been detected55.
VII. Technological challenges/research pitfalls
Since malignant vascular tumours of bone are extremely rare, the collaboration of multiple 
pathology laboratories- mostly with a special interest in bone and soft tissue pathology – is 
needed to collect a substantial number of tumours. Many of those laboratories, including 
our department, had to search within their archives with the consequence that over the years 
different decalcification techniques had been used which possibly could have an impact on 
immunohistochemistry or the performed molecular tests. Since the decalcification method 
never has been specified within the pathology report, it hampers or complicates additional 
testing, such as reliable immunohistochemical evaluation.
Decalcification of bone is needed in order to be able to cut and evaluate tissue material 
containing or coming from bone. Decalcification is a chemical process by which calcium 
hydroxyapatite crystals and other minerals present in bone (or pathological calcifications) dissolve 
in a decalcification solution, and therefore bone or bony tissue gets the physical characteristics of 
dense connective tissue56. In general, there are three main groups of decalcifying agents:
a. strong mineral acids (e.g. hydrochloric or nitric acid at concentrations up to 10%)
b. weak organic acids (e.g. formic acid, Kristensen buffer)
c. chelating agent (e.g. ethylenediaminetetracetic acid (EDTA))
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Strong acids, such as hydrochlorid or nitric acid at concentrations up to 10%, have the advantage 
of being the most rapid method of decalcification. However, they cause tissue swelling and 
cellular damage after the usage of 24 to 48 hours and therefore negatively affect the cellular 
morphology and immunoreactivity of the tissue.
Weak organic acids, such as formic acid, are the most frequently and widely used decalcification 
agents. Although these acids decalcify more slowly compared to the strong acids, they are gentler 
and therefore suitable for most routine specimens enabling additional immunohistochemical 
staining. Since formic acid can damage tissue, and therefore hamper antigens and enzyme 
histochemical staining, sodium formate (buffered formic acid by Kristensen) can be added 
as a buffer to counteract the injurious effects of the acid. Moreover, formic acid affects the 
DNA and leads to defragmentation of the DNA. Ethylene-diamine-tetracid acid (EDTA), a 
chelating agent, binds metallic ions, such as calcium, on the surface of the apatite crystal thereby 
slowly reducing its size. This implicates that it is a very slow process, so not suitable for routine 
diagnostics. However it is a very gentle technique with little tissue and DNA damage and little 
effect on tissue stainability. Moreover, this method is highly suitable for techniques such as 
Fluorescent In Situ Hybridization (FISH) and Polymerase Chain Reactions (PCR)56.
Because of the increasing importance of molecular testing, especially within bone and soft 
tissue tumours and the knowledge of effects of decalcification, EDTA decalcification should be, 
whenever possible, the preferred method. Although the pathology reports of the material used 
in this project do not specify the decalcification method, we can assume that most tissue samples 
are decalcified by either weak organic acids (formic acid) or strong mineral acids.
VIII. Aim of this study and outline of the thesis
The aim of the research described in this thesis is to investigate whether we could determine 
certain histomorphological characteristics and molecular genetic features which could be 
helpful in the classification of primary vascular tumours of bone. We compared our dataset 
of vascular tumours of bone with a small group of angiosarcomas of soft tissue in order to see 
whether these are truly different tumours or whether they should be regarded as one entity with 
a different localization.
In Chapter 2 a detailed summary of the literature and the history of the classification of the 
different types of primary vascular tumours of bone are presented.
In Chapter 3 we collected a multi-institute retrospective series of 42 angiosarcomas of bone 
and investigated their clinicopathological characteristics in relation to outcome.
In Chapters 4-6 the underlying molecular and genetic changes in primary vascular tumours of 
bone are investigated. We analysed the well characterized series that we described in chapter 3 
using immunohistochemistry to investigate expression of proteins involved in angiogenesis, the 
cell cycle, or in tumourigenesis in angiosarcoma of soft tissue (Chapter 4). For comparison we 
included a series of angiosarcomas of soft tissue. Because the use of acids during decalcification 




we next optimized the array-Comparative Genomic Hybridization (array-CGH) technique 
for use on decalcified formalin fixed paraffin embedded tissue in Chapter 5. Subsequently, in 
Chapter 6 we applied this technique to detect genomic aberrations in angiosarcomas of bone 
in comparison to a small group of angiosarcoma of soft tissue.
Finally, in Chapter 7 we question whether the rare vascular tumour previously designated as 
“haemangiopericytoma of bone” is a true entity or not. We collected a number of primary 
haemangiopericytoma of bone and re-analysed these lesions in Chapter 7 using histology, 
immunohistochemistry and Fluorescent In Situ Hybridization (FISH) analysis.
Finally, results are summarized in Chapter 8 and it is discussed how the results of our studies, 
integrating morphology and genetics, have contributed to the 2013 WHO classification of 
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Vascular tumors of bone are a heterogeneous group. Numerous terms have been introduced as 
well as different classification systems. None of the classification schemes have been accepted 
due to lack of consistent terminology, accepted histologic criteria, and limited correlation with 
clinical outcome. It is acknowledged that vascular tumors of bone originate from endothelial 
cells, resulting in variable expression of endothelial markers. None of these markers are useful 
to discriminate between benign and malignant lesions. Although radiologic appearance 
is not specific, radiologic multifocality should trigger to include a vascular neoplasm in the 
differential diagnosis. This review gives an overview of current literature by describing all 
different histologic subtypes in correspondence with clinical, radiologic and genetic data. 
We propose the classification of vascular tumors of bone according to the three-tiered World 
Health Organization classification scheme for soft tissue tumors dividing entities into a benign, 
intermediate and malignant category. Hemangioma is the most often and commonly recognized 
benign lesion. Epithelioid hemangioma has been better defined over the past few years. Based 
on its locally aggressive behavior and occurrence of lymph node metastases, classification within 
the intermediate category could be considered. Angiosarcoma is the only accepted term for 
high-grade malignant vascular tumor of bone and so far, epithelioid hemangioendothelioma 
is the only accepted low-grade malignant vascular tumor of bone. It is still unclear whether 
other low-grade malignant vascular tumors of bone (e.g. hemangioendothelioma) truly exist. 
Unfortunately, molecular / genetic studies of vascular tumors of bone which might support the 
proposed classification are very sparse.




Today, vascular tumors of bone consist of a wide variety of different clinicopathologic entities, 
ranging from benign lesions on one hand and frankly malignant tumors at the other hand. 
Since the first report on malignant vascular tumors of bone in 1921 by Wells [1], various entities 
have been described and many different terms have been proposed. Over the years, terms such 
as angiosarcoma, hemangiosarcoma and hemangioendothelioma have been used sometimes as 
synonyms or to stress different histologic entities, confusing numerous medical experts [2-6]. 
Also the classification of vascular tumors of bone is highly controversial, especially considering 
the lack of consistent terminology, accepted histological criteria, and the limited correlation 
with clinical outcome. As a consequence, so far none of the suggested classification schemes 
have been generally accepted [3, 4, 6, 7]. Wenger and Wold acknowledged the confusing 
terminology and proposed in 2000 a new classification system for benign and malignant vascular 
tumors and stated that these lesions should be regarded as a spectrum [6, 8]. However, this is 
still controversial since a spectrum implicates the possibility of progression of a benign lesion 
towards a malignancy over time and only single case reports have described this phenomenon 
[9-16].
Since 1942, it is generally accepted that vascular tumors of bone originate from endothelial 
cells [17]. The exact mechanism or possible genetic aberrations resulting in tumorigenesis still 
remains unknown. In this review we want to give an overview and update of the current 
classification of vascular tumors of bone (Table 1) by describing all different histologic subtypes 
in correspondence with clinical, radiologic and when available genetic or biologic data. Vascular 
tumors, for which a primary bone origin is extremely rare, are not discussed within this review. 
Since molecular studies on vascular tumors of bone are sparse, their value in the classification 
of these lesions is limited.
Radiographic Imaging
Because of the heterogeneity of vascular tumors of bone, imaging is not very specific. However, 
some radiographic alterations can indicate the probability of a benign or malignant osseous 
vascular tumor (Figure 1, 2, 4 and 5). By conventional radiographs, the majority of the 
hemangiomas show a well demarcated, lucent lesion with frequent coarse trabeculations [8, 18, 
19]. Although cortical expansion can be seen in hemangiomas, cortical disruption and invasion 
into the surrounding soft tissue is most often characteristic of malignancy. Moreover, malignant 
vascular tumors of bone are most often characterized by an ill-defined, osteolytic lesion with 
cortical disruption and endosteal scalloping. Up to one third of the malignant vascular tumors 
of bone presents with synchronic multiple osseous lesions which can be either contiguous 
(adjacent bones affected) or disseminated [20]. Although the radiographic features of malignant 
vascular tumors of bone are non-specific, multifocal lesions in one anatomic region should 
trigger the radiologist to include a vascular neoplasm in the differential diagnosis [20, 21].
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Table 1. Proposed classification of vascular tumors of bone






Non-aggressive, disseminated (cystic angiomatosis)
Aggressive or massive osteolysis or Gorham Stout’s Disease
Intermediate (locally aggressive, rarely metastasizing) vascular tumors of bone
Epithelioid hemangioma







It is generally accepted that vascular tumors, both of soft tissue and bone, originate from endothelial 
cells resulting in a variable expression of endothelial markers such as CD31, CD34, Fli-1 and 
von Willebrand Factor (Factor VIII) [22-24]. Although it has been reported that CD31 and von 
Willebrand Factor are the best diagnostic markers for malignant vascular tumors of bone, the use 
of a panel of endothelial markers is essential to confirm the diagnosis because a minority of the 
malignant tumors only express CD34 [25]. Based on the expression of the endothelial markers 
it is impossible to discriminate between benign and malignant vascular tumors. Vascular tumors 
variably express D2-40 (31%) [25], a presumed lymph-endothelial marker, and its expression in 
angiosarcoma is associated with a worse prognosis, suggesting lymphangiosarcoma of bone may 
exist [26, 25]. Cytokeratin (69%) [25] and/ or epithelial membrane antigen (4-35%) [27, 28], are 
also expressed, in particular but not exclusively in neoplasms with an epithelioid morphology 
[20, 25]. Since these lesions have a tendency to occur multifocal (contiguous or disseminated), 
the epithelioid morphology and keratin positivity may easily lead to an erroneous diagnosis of 
metastatic carcinoma.
Benign Vascular Tumors of Bone
Hemangioma
Hemangioma of bone (Figure 1, Table 2) is the most common benign vascular tumor of bone 
[8]. Its etiology is still unknown. Moreover, it is still unclear whether these lesions are true 
neoplasms or should be regarded as hamartomas [18, 29]. Despite the lack of appropriate data 
regarding the incidence or prevalence of hemangioma, autopsy reports have demonstrated that 
vertebral hemangioma occurs in approximately 10% of adults [18]. Hemangiomas occur in both 
men and women, with a wide age range and are mostly located in skull and vertebra [8, 18]. 
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Although these lesions can cause various signs and symptoms, the majority of patients present 
with an asymptomatic and incidental radiographic finding [8, 18]. Several different histologic 
subtypes are described, such as cavernous, capillary and sclerotic hemangioma [18]. Malignant 
transformation is only described in a few cases [9-15]. In general, hemangiomas have a very 
good prognosis and a low recurrence rate.
Figure 1. Hemangioma of bone: A. conventional X-ray of the scalp showing multiple small well-














































































































































































































































































































































































































































































































































































































































































































































Skeletal angiomatosis (Figure 2, Table 2) is a rare disorder and is defined as multiple cystic bone 
lesions with or without soft tissue involvement. Soft tissue involvement is present in 60-70%, 
and in general the spleen is affected [30]. Clinical presentation is dependent on localization, the 
size and the number of lesions and can vary from an incidental finding to local pain, swelling 
and/ or pathological fracture [31-34]. These lesions are classified based on their clinical behavior 
(aggressive or nonaggressive) and pattern of skeletal involvement (regional or disseminated) [20, 
31, 35]. Regional involvement is defined as corrosion of one or more bones of one anatomic 
region, whereas disseminated involvement is characterized by multifocal disease with typically 
involvement of the trunk bones [35]. Gorham’s Disease, also known as massive osteolysis or 
disappearing bone disease, is an aggressive form of regional skeletal angiomatosis. Although 
the etiology still remains unknown, half of the cases are associated with trauma [36, 37]. This 
disease results in progressive destruction of one bone and sometimes also adjacent bones. It is 
merely a clinicoradiologic diagnosis, since the histology is reminiscent of hemangioma [35, 
20]. Malignant transformation to angiosarcoma is highly unusual, but has been described [16]. 
In extraordinary cases, angiomatosis is associated with syndromes such as von Hippel-Lindau 
syndrome, Maffucci’s syndrome, Klippel-Trenaunay syndrome, Kasabach Merritt syndrome, 
Parkers-Weber syndrome and Osler-Weber-Rendu disease [35, 38]. In the majority of these 
syndromes the etiology and pathogenic mechanisms are unknown. However, von Hippel-
Lindau syndrome and Osler-Weber-Rendu disease are caused by genetic aberrations in the 
VHL gene and HHT genes, respectively [39,40]. Prognosis of angiomatosis is dependent on the 
extent and localization of the disease [35, 38, 41]. Extended visceral involvement bears a more 
aggressive course, especially due to massive hemorrhaging [35, 38, 41].
Figure 2. Angiomatosis of bone (Gorham- Stout disease, vanishing bone disease): A. Radiology: 
conventional x-ray of the femur showing bone deformation with multiple osteolytic lesions; B. Gross 
examination of an amputation specimen showing multiple cystic lesions within the bone marrow of the 
femur (scale in centimeters); C. Histology demonstrating the morphology of a hemangioma consistent of 






Currently, epithelioid hemangioma (Figure 3, Table 2) (previously known as angiolymphoid 
hyperplasia with eosinophilia or histiocytoid hemangioma) is a recently described and accepted 
clinicopathologic entity in bone [7, 42]. The majority of epithelioid hemangiomas present as 
solitary lesions. Rarely, local cortical destruction and extension into the surrounding soft tissue 
have been reported. Also, small foci of necrosis can be present. The precise classification of 
this newly described entity is still controversial. Some authors such as Wenger and Wold have 
considered this a benign lesion [8]. Although Nielsen and colleagues have demonstrated that 
epithelioid hemangioma is a locally aggressive, rarely metastasizing tumor, they argue about 
the true malignant potential of this neoplasm [42]. In the 2002 World Health Organisation 
Classification of Tumours of Soft Tissue and Bone, all soft tissue tumors are categorized into 
a four-tiered classification system: benign, intermediate locally aggressive, intermediate rarely 
metastasizing and malignant. The intermediate category is defined by an infiltrative and locally 
destructive growth pattern, often recurring and occasionally (< 2%) metastasizing [20]. If these 
criteria are applied to epithelioid hemangioma of bone, recurring in 11% and metastasizing 
in 2.7% [42], this entity fits best within this intermediate category, in between hemangioma 
(benign) and angiosarcoma (malignant) of bone [20]. Curettage or limited local surgery 
(marginal en bloc resection) is considered to be an adequate therapy and has an excellent 
prognosis [42]. Although an allergic reaction, trauma, and an auto-immune process have been 
implicated as possible causes in the soft tissue counterpart [43, 44], no data regarding genetic 
alterations or pathophysiologic mechanisms have been reported so far for bone.
Figure 3. Epithelioid hemangioma of bone. A. Histologic overview of an epithelioid hemangioma 
of bone composed of two distinct areas (marked with * and #) haematoxilin-eosin staining, 10x): B (#). 
the peripheral area with numerous small arteriolar-like vessels and an infiltrate consistent of numerous 
eosinophilic granulocytes (haematoxylin-eosin staining, 40x) and C (*). the cellular central area with large, 
polyhedral, epithelioid cells with a more solid growth pattern intermixed with eosinophilic granulocytes 
(haematoxylin-eosin staining, 40x).
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Malignant Vascular Tumors of Bone
Epithelioid Hemangioendothelioma
Epithelioid hemangioedothelioma of bone (Figure 4, Table 2) is, similar to its soft tissue 
counterpart, considered a low grade malignant vascular tumor. All bones can be affected, however 
approximately 50% of these tumors occur in the long tubular bones of the extremities [4, 6, 
45]. Multifocality is more frequently seen - in about 50 to 64% - as compared to angiosarcoma 
of bone and it is unclear whether this is a synchronous involvement or is caused by metastatic 
spread [4, 6, 20]. Pain is the most common clinical presentation, however non-specific [6, 20, 
36]. Gross examination can vary from a soft, red nodular mass to a firm tan-white mass [4, 20, 
36]. So far, no genetic alterations are described within epithelioid hemangioendothelioma of 
bone. However, in two cases of epithelioid hemangioendothelioma of soft tissue (one arising in 
the liver and one arising in the soft tissue of an extremity) an identical translocation involving 
chromosomes 1 and 3 [t(1;3)(p36.3;q25)] have been described, suggesting a tumor-specific 
translocation [36, 46, 47]. Literature about the behavior and prognosis of this entity is somewhat 
conflicting [4]. It seems that tumors with a visceral involvement behave worse [6, 45, 48, 49].
Figure 4. Epithelioid hemangioendothelioma of bone A. Radiology: conventional X-ray of the 
distal humerus showing an excentric osteolytic lesion (arrow); B. Histology: characteristic strands and cords 
of epithelioid endothelial cells surrounded by a hyalinized stroma (haematoxilin-eosin staining, 20x) with 
inset: showing the nuclear detail and presence of cytoplasmic vacuoles (haematoxilin-eosin staining, 63x).
Angiosarcoma
Today, angiosarcoma (Figure 5, Table 2) is the most accepted term for high-grade vascular 
malignancy in bone [20]. These tumors are rare and account for less than 1% of malignant 
bone tumors. The majority of these tumors arising in bone are primary, however, a very small 
percentage is either radiation induced or associated with bone infarction. Although there is no 
specific clinical presentation, the majority of the patients present with a chronic dull pain and/
or tumor mass [20, 29]. The latter is more often seen in patients with a solitary lesion [29]. About 
one third of the tumors are multifocal. It is still unclear whether this is due to synchronous 
34
2
involvement of different bones by multiple separate foci or is caused by metastatic spread [7, 29, 
42]. At the histologic level, angiosarcoma of bone represents a heterogeneous group of lesions, 
ranging from well-differentiated tumors with a clear vasoformative growth pattern to poorly 
differentiated tumors with a more solid growth pattern sometimes even mimicking metastatic 
carcinoma [20, 25]. Due to the heterogeneity of these tumors and the overlap in nomenclature 
over the past years, there is no full agreement regarding exact histologic criteria defining these 
tumors, although there is some consensus about the presence of nuclear atypia and mitoses [3, 4, 
6]. We recently reported that primary angiosarcoma of bone exhibiting more than 3 mitoses per 
10 HPF, with a prominent nucleolus and fewer than five eosinophilic granulocytes per 10 HPF 
have a more aggressive course and worse outcome, indicating that these histologic criteria have 
prognostic value [25]. Recently, a novel t(1;14)(p21;q24) translocation has been described in an 
angiosarcoma of bone [50]. This is the first cytogenetic aberration reported in angiosarcoma 
of bone. However, small series have shown the involvement of tumor-suppressor genes such as 
p53 and p16, mainly in angiosarcoma of soft tissue, suggesting a possible role in tumorigenesis 
in a subset of angiosarcomas. P53 gene mutations are most commonly found in angiosarcoma 
of the liver associated with toxic vinyl chloride exposure [51-53] and angiosarcoma of the scalp 
[54, 55]. However, it was sporadically reported in angiosarcoma of the breast, extremities, heart, 
lung, liver (not toxic induced) and also in one angiosarcoma of bone [52, 54-57]. Moreover, 
the involvement of c-MYC, K-RAS and KDR (VEGFR2) has been recently described [53, 56, 
58-60]. Whereas high levels of c-MYC amplification are found in angiosarcoma secondary to 
irradiation or chronic lymphedema [59], KDR mutations are present in primary angiosarcoma 
of the breast [58], suggesting that angiosarcoma (of soft tissue) can be separated in different 
subtypes each with tumor-specific alterations and as a consequence different therapeutic targets. 
It is still unclear whether primary angiosarcoma of bone is a true separate entity or is similar to 
primary angiosarcoma of deep soft tissues. It is generally accepted that angiosarcomas have an 
aggressive course with a one and 5-year survival rate of 55% and 33%, respectively [25].
Figure 5. Angiosarcoma of bone. A. Radiology: conventional X-ray of the foot with multiple not 
sharply demarcated osteolytic lesions; B. Histology: epithelioid angiosarcoma of bone with a solid growth 
pattern, consisting of atypical endothelial cells with an epithelioid morphology (haematoxilin-eosin staining, 
20x); C. CD31 showing a diffuse positive staining of the tumor cells (20x); D. cytokeratin: showing positive 
staining in a part of the tumor cells (20x).
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Controversial/ Disputable entities: do they exist?
Hemangioendothelioma
The existence of hemangioendothelioma of bone as a true, separate entity has been highly 
controversial in the literature [42, 61]. Some authors and investigators believe that there is a 
subgroup of vascular tumors of bone representing a low-grade malignancy, preferably called 
hemangioendothelioma [3, 5, 6, 35, 62]. However, the absence of apparent histologic criteria 
and restricted correlation with clinical outcome have hampered the general acceptance of this 
entity. Nielsen and colleagues have demonstrated that over the years many authors have reported 
vascular tumors of bone labeled as hemangioendothelioma, which demonstrate histologic 
features that are identical to epithelioid hemangiomas [42]. To date, it is therefore unclear 
whether a low-grade angiosarcoma other than epithelioid hemangioendothelioma truly exists.
Hemangiopericytoma
This tumor was first described by Stout and Murray in 1942 as a vascular soft tissue neoplasm, 
composed of a proliferation of endothelial sprouts and tubules surrounded by rounded or spindle-
shaped cells typically supported by a meshwork of reticulin fibers [63]. Occasional solitary bone 
lesions have been reported ever since. In the early nineties it became clear that many different 
tumor types could mimic a hemangiopericytoma-like growth pattern. Therefore, it was stated 
by several authors that this is most likely a non-specific histologic growth pattern, rather than 
a true diagnosis [64-66]. Today, the 2002 WHO Classification of Tumours of Soft tissue and 
Bone Tumors does not recognize this entity any longer [67] and in soft tissue it is accepted 
that most of these lesions can be classified as solitary fibrous tumors, monophasic synovial 
sarcomas or myofibromatoses [64,65,67,68]. Also in bone it has recently been demonstrated 
that these tumors are most probably solitary fibrous tumors or synovial sarcoma of bone [25]. 
Positive immunohistochemical reaction for epithelial membrane antigen and/ or cytokeratin as 
well as the detection of the tumor-specific translocation t(X;18)(p11.2;q11.2) is helpful for the 
diagnosis of synovial sarcoma of bone, whereas diffuse CD34 reactivity is seen in the majority 
of solitary fibrous tumors of bone [25]. Although heterogeneous cytogenetic aberrations have 
been reported for larger solitary fibrous tumors of soft tissue [69], this has not been confirmed 
in solitary fibrous tumors of bone.
Summary/ Conclusion
Vascular tumors of bone consist of a heterogeneous group of entities, which over the past 
decade have been better delineated, especially regarding the entity epithelioid hemangioma. 
Based on its locally aggressive behavior as well as the occurrence of lymph node metastases 
(in 2%) classification within the intermediate category, in between hemangioma (benign) and 
angiosarcoma (malignant), could be considered (table 1). Epithelioid hemangioendothelioma 
is a separate entity morphologically identical to its soft tissue counterpart and is the only 
accepted low-grade malignant vascular tumor of bone. It is still debatable whether other 
36
2
low-grade malignant vascular tumors of bone exist. Therefore, it is recommended to avoid 
the term hemangioendothelioma of bone because it could confuse clinicians and radiologists. 
Unfortunately no molecular genetic data are available to support the proposed classification. 
Future molecular studies might reveal whether there is indeed a continuum between hemangioma 
and angiosarcoma i.e. according to a multistep genetic progression model as is also known for 
instance for chondrosarcoma [70], liposarcoma [71], or colorectal cancer [72]. Also, molecular 
studies may shed light on whether angiosarcoma of bone is comparable to angiosarcoma of 
deep soft tissue or whether it represents a separate entity within the heterogeneous group of 
angiosarcomas.
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Aims: To define the histological criteria of primary angiosarcoma of bone.
Methods and results: Forty-two angiosarcomas of bone in 23 males and 15 females were studied. 
Histological criteria were related to patients’ outcome. Eleven patients had multifocal lesions. 
Lesions were located in the long and short tubular bones followed by the pelvis, spine and trunk. 
Tumour cells were positive for CD31 in 38 of 40, von Willebrand Factor in 21 of 35, CD34 
in 15 of 38, smooth muscle actin in 22 of 36, D2-40 in 11 of 35, and keratinAE1/AE3 in 27 
of 39. Thirty-nine tumours showed an epithelioid phenotype. One- and 5-year survival rates 
were 55% and 33%, respectively. Survival analysis showed that a macronucleolus, three or more 
mitoses per 10 high power field (HPF) and less than five eosinophilic granulocytes per 10 HPF 
within a tumour was associated with an even worse survival compared to the overall group.
Conclusions: Because keratin positivity is seen in the majority of cases, pathologists should 
avoid misinterpretation as metastatic carcinoma. A macronucleolus, three or more mitoses per 
10 HPF and fewer than five eosinophilic granulocytes per 10 HPF can be used to further define 
angiosarcoma of bone.




Vascular tumours of bone, other than ordinary hemangiomas, are uncommon1 and represent 
less than 1% of primary malignant bone tumours reported by large registries such as the 
Netherlands Committee on Bone Tumours2 or the Mayo Clinic.3 Clinically, these tumours 
present with widely varying signs and symptoms, and also at microscopic level a wide diversity 
of histological features are seen, varying from an easily recognizable vasoformative proliferation 
to an undifferentiated tumour and, occasionally, even mimicking metastatic carcinoma.4-11 Their 
behaviour is unpredictable although, clinically, they can be extremely aggressive.3, 11-13
Over the years, the terminology and classification of vascular tumours of bone has been a matter 
of debate due to the lack of uniform terminology, accepted histological criteria, and the lack of 
good correlation with clinical outcome of the proposed entities. Although several classification 
schemes have been suggested, so far none has been generally accepted.4-6 Various entities are 
described in the literature, sometimes used as synonyms or to stress different histological entities, 
confusing not only pathologists, but also radiologists, oncologists, and orthopaedic surgeons.4-6,8,9 
In 2000 Wenger and Wold4 acknowledged the confusing terminology, and suggested that 
endothelial malignancies of bone should be regarded as a spectrum. This spectrum is formed 
with, on one end, the overtly benign lesions, and at the other end the frankly malignant lesions 
(Figure 1). In general, ordinary haemangioma is often easy to diagnose, being characterized by 
mature blood-filled vessels lined by flattened endothelial cells without marked cytonuclear atypia 
and lacking mitotic figures.11 At the other end of the spectrum, angiosarcoma is the most widely 
accepted term for high-grade malignant vascular tumour of bone. Overt malignant features, 
such as high number of mitoses and frank cytonuclear atypia, facilitate this diagnosis, although 
there is no consensus in the literature regarding the exact criteria.4-6 Another vascular tumour 
that is considered malignant is epithelioid haemangioendothelioma of bone, with a distinct 
well-characterized morphology, similar to its soft tissue counterpart, that can be differentiated 
most often from other endothelial lesions.11
There is no consensus regarding the nomenclature of tumours intermediate between ordinary 
haemangioma and angiosarcoma. Epithelioid haemangioma is a well-described entity (Figure 
1).14 Epithelioid haemangioma can be multifocal, can destroy the cortex and extend into the 
soft tissue, has a local recurrence rate of 8% and metastasizes to lymph nodes in 2%.14 One 
could therefore consider epithelioid haemangioma as belonging to the intermediate category as 
recognized by the World Health Organization (WHO) 2002 classification for soft tissue tumours, 
which is either locally aggressive or rarely (<2%) metastasizing.11 Epithelioid haemangioma14 
overlaps greatly with the entity described as ‘haemangioendothelioma of bone’ by Evans et 
al.,5 which is a controversial and confusing entity that is presumed to be of the intermediate 
category or of low-grade malignancy, although consistent histological criteria defining this 
group of lesions are lacking. Criteria to distinguish bone epithelioid haemangioma and bone 
haemangioendothelioma, except perhaps for a lobular architecture, can not be extracted from 
the available literature. The WHO 2002 classification recognizes neither of them as distinct 
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Because there is no consistency in the literature on the exact histological criteria to diagnose 
angiosarcoma of bone,4-6 and because it is uncertain if there still remains a category between 
epithelioid haemangioma/haemangioendothelioma and angiosarcoma, our aim was to delineate 
further the malignant end of vascular tumours of bone. We collected a large series of cases with 
follow-up and investigated whether based on histological and/or clinical criteria we could 
better define high-grade angiosarcoma of bone.
Material and methods
Clinico-pathologic data and histologic review
Eighty tumours, from 74 patients, diagnosed as angiosarcoma of bone were collected from the 
archives of the departments of Pathology of the Rizzoli Institute, Bologna, Italy (58 tumours 
from 53 patients), the Netherlands Committee on Bone Tumours (18 tumours in 18 patients), 
and University Hospitals, Leuven, Belgium (four tumours in three patients). The cases were 
originally diagnosed between 1964 and 2006. All clinical, radiological and pathological data 
were reviewed. All tumour samples were reviewed by three pathologists (J.V.M.G.B., P.C.W.H. 
and C.D.M.F.) and included in this study when the tumour showed histological features of 
malignancy, defined by atypia, hyperchromasia, mitoses and/or atypical mitoses,4-6 and stained 
for at least for one endothelial marker, leaving 42 tumours (14 biopsies and 28 resection 
specimens) from 38 patients in which the diagnosis angiosarcoma of bone could be confirmed. 
Based upon histology [epithelioid haemangioma (n = 12), epithelioid haemangioendothelioma, 
or other diagnosis (n = 20) such as epithelioid sarcoma] and/or absence of at least one positive 
endothelial marker (n = 6), 38 tumours (34 patients) were excluded. All specimens were handled 
according to the ethical guidelines described in the Code for Proper Secondary Use of Human Tissue 
in the Netherlands of the Dutch Federation of Medical Scientific Societies. As accepted in the 
literature, epithelioid haemangioendotheliomas and so-called haemangiopericytomas of bone 
are considered to be separate entities and therefore excluded from this study.3-6, 8, 9, 11, 15-20
Histology
Histological slides [haematoxylin and eosin (H&E)] were available for all 42 tumours. Various 
histological parameters as outlined in Table 1 were assessed systematically.
Tissue Microarray
Tissue microarrays (TMAs) were assembled from formalin-fixed, paraffin embedded tissue using 
standard procedures21, 22 using a 0.6-mm-diameter punch (Beecher Instruments, Silver Spring, 
MD, USA). As formalin-fixed, paraffin-embedded tissue was available from 38 patients with 
vascular tumours of bone, two tissue blocks of different tumours were available in four patients, 
the arrays contained 42 tumours with four cores of each lesion whenever possible. Also, six 
tissue cores of tonsil and seven tissue cores of bowel were included for orientation and control 
purposes. Using a tape-transfer system (Instrumedics, Hackensack, NJ, USA), 4-μm sections 
were transferred to glass slides.
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Table 1. Histological features of angiosarcoma of bone assessed in the total group (42 tumors of 38 
patients) and scored in the group of patients with follow-up (FU) data available (33 tumors from 31 
patients) associated with clinical outcome.
Angiosarcoma of bone Angiosarcoma of bone 
Total group (n=42) with FU (n=33)
No. % No. % P-value
Solid growth pattern
  Present 36 85.7 27 81.8 0.443
  Absent 6 14.3 6 18.2
Mature bloodvessels
  Present 24 57.1 20 60.6 0.043*
  Absent 18 42.9 13 39.4
Epithelioid morphology
  Present 39 7.1 31 93.9 0.054
  Absent 3 92.9 2 6.1
Intracytoplasmatic vacuoles
  no 1 2.4 1 3 0.399
  Filled 1 2.4 1 3
  Empty 6 14.3 5 15.2
  Filled and empty 34 81.0 26 78.8
Extravasation of erythrocytes 
  Present 40 4.8 32 97 0.443
  Absent 2 95.2 1 3
Iron deposition
  Present 41 2.4 32 97 0.443
  Absent 1 97.6 1 3
Atypia
  Mild 2 4.8 2 6.1 0.900
  Moderate 26 61.9 19 57.6
  Severe 14 33.3 12 36.4
Nucleolus
  1-3 small 27 64.3 221 63.6 0.011*
  macronucleolus 15 35.7 11 36.4
Mitotic figures
  < 3/10 HPF 22 52.4 16 48.5 0.002*
  ≥ 3/10 HPF 20 47.6 17 51.5
Atypical mitotic figures
  Present 13 31.0 11 33.3 0.443
  Absent 29 69.0 22 66.7
Necrosis
  Present 21 50.0 17 51.5 0.895
  Absent 21 50.0 16 48.5
Stromal component
  Loose connective tissue 12 28.6 11 33.3 0.258
  Dens 8 19.0 7 21.2
  Myxoid 1 2.4 1 3
  No stroma 4 9.5 4 12.1
  Admixture 11 26.2 10 30.4
  Not evaluable 6 14.3 0 0
Lymphocytic infiltrate
  Present 41 97.6 32 97 0.443
  Absent 1 2.4 1 3
Eosinophilic infiltrate
  < 5/10 HPF 23 54.8 17 51.5 0.021*








Immunohistochemistry (IHC) was performed on the TMAs. TMA slides were stained with 
antibodies against CD31, CD34, von Willebrand Factor (vWF), smooth muscle actin (SMA), 
D2-40 (podoplanin) and keratinAE1/AE3. Immunohistochemical reactions were performed 
according to standard laboratory methods.23 For each antibody a positive and negative external 
control was included. The antibodies, their sources, antigen retrieval methods, dilutions, positive 
and negative external control used are documented in Table 2. Staining was evaluated as positive, 
defined as 25% of individual tumour cells or more being positive, or negative.
Table 2. Antibodies used for immunohistochemical analysis
Antibody Clone Dilution Antigen retrieval Source 
CD31 JC70A 1:200 citrate Dakocytomation
CD34 QBEnd/10 1:200 - Neomarkers
vWF - 1:400 citrate Dako
SMA ASM-1 1:2000 - Progen
D2-40 D2-40 1:100 citrate Covance
Cytokeratin AE1/AE3 - 1:200 citrate Neomarkers
Statistical analysis
Overall survival could be calculated for 31 patients for whom follow-up data were available 
from the date of diagnosis to the date of death or last information. Of these 31 patients, nine 
biopsies and 22 resection specimens were evaluated for different histological parameters as 
described previously. Univariate analysis of the histological parameters was performed using 
the chi-square test for dichotomous variables. Survival was evaluated by Kaplan-Meier analysis 
and the log-rank test. Values of P ≤ 0.05 were considered statistically significant. Variables that 
achieved significance (P ≤ 0.05) were entered subsequently into a multivariate analysis using 
the Cox-regression model [described as odds ratios (OR) with 95% confidence intervals (95% 
CI), together with the P–values]. Cox-regression analysis was carried out with clinical outcome 





Angiosarcoma of bone has a wide age distribution, ranging from the second to the eighth 
decade, with two small peaks at the sixth and eighth decade (range 12-78 years; median: 51; 
Figure 2A). There is a slight preference for males (23 males versus 15 females). The majority of 
patients presented with local pain and/or swelling. One patient already presented with metastasis 
at the time of diagnosis. Five patients developed metastasis later in the course of their disease. 
In three patients, the metastatic status is unknown. Of all 38 patients, 33 (86.8%) were treated: 
14 (36.8%) had only surgery and 12 (31.5%) had surgery combined with chemotherapy and/or 
48
3
radiotherapy. One patient (2.6%) received only chemotherapy and one (2.6%) only radiotherapy. 
Three patients (7.9%) did not receive any therapy, two of these patients (5.3%) refused therapy. 
Therapy data of two patients (5.3%) are lacking.
Radiological appearance and localization
Radiological data were available for 26 patients. The overall appearance of the tumours 
was a destructive osteolytic mass with irregular borders. Only 16 tumours (61.5%) showed 
cortical disruption, and of those patients only five (31.3%) tumours showed extension into the 
surrounding soft tissue.
Eleven patients (29%) had multifocal lesions. In seven of them (64%) contiguous bones were 
affected mostly located in the lower extremities (n = 6), followed by spine (n = 1). Four of them 
(36%) had disseminated disease, involving distant bones. None of the 11 patients with multifocal 
lesions had lymph node involvement. Twenty-seven patients (71%) had solitary lesions. Of all 
patients with solitary tumours the long and short tubular bones (74%) were mostly affected, 
followed by pelvis (15%), axial location (7%) and trunk (4%; Figure 2B).
Figure 2 A, Age distribution of patients with angiosarcoma of bone (n = 38) and B, Skeletal distribution 
of solitary angiosarcoma of bone in 27 patients.
Histology
Angiosarcoma of bone showed variable histological patterns, of which the features were assessed 
systematically, and shown in Table 1. The majority (85.7%) of the cases showed a solid growth 
pattern and 57.1% demonstrated the presence of mature blood vessels, all lined by atypical 
endothelial cells, within the tumour (Figure 3A). Ninety-three per cent of the angiosarcomas 
displayed epithelioid morphology (Figure 3B). The most common histological feature was the 
presence of intracytoplasmatic vacuoles, either filled with erythrocytes or empty (Figure 3E). 
In 95.2% of the cases there was extravasation of erythrocytes resulting in iron deposition. All 
tumours showed cytonuclear atypia, which was scored mild, moderate or severe. Most of the 
angiosarcomas showed vesicular nuclei (95.2%). In 64.3% these nuclei contained one to three 
small nucleoli (Figure 3C), while in 35.7% macronucleoli (Figure 3D) were found. When the 
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tumour contained a nucleolus that was half the size of a small lymphocyte or larger (≥ 4μm) 
in 75% of the tumour cells or more, the tumour was labelled as having a macronuclolus. Half 
of the tumours contained necrotic areas. A variable inflammatory infiltrate was present in all 
cases, consisting generally of lymphocytes, although an eosinophilic infiltrate (five or more 
eosinophilic granulocytes/10 HPF) was present in 45.2% of the cases (Figure 3F). The infiltrate 
ranged from 5 to 60 eosinophilic granulocytes/10HPF. Mitotic activity ranged from 0 to 9 per 
10 HPF (median: 2).
Figure 3. Different histological features of vascular tumours of bone: A, the presence of mature bloodvessels; 
B, epithelioid morphology; C, one to three small nucleoli in tumour cells (arrows); D, macronucleoli in 
tumour cells; E, presence of intracytoplasmatic vacuoles (arrows); F, presence of an eosinophilic infiltrate 




Angiosarcomas of bone were positive for CD31 in 38 of 40 (95%), for CD34 in 15 of 38 (39%), 
and for vWF in 21 of 35 (60%) cases. All tumours stained positively for at least one endothelial 
marker. Twenty-two of 36 tumours (61%) showed positive staining of individual tumour cells 
for SMA. D2-40 immunoreactivity was seen in 11 of 35 angiosarcomas (31%), while 27 of 39 
cases (69%) were positive for keratin. All keratin-positive angiosarcomas showed an epithelioid 
morphology. However, nine angiosarcomas with epithelioid morphology did not show any 
positive staining for keratin. Due to tissue loss we were not able to evaluate two tumours (one 
patient) for CD31, tree tumours (three patients) for keratin, four tumours (three patients) for 
CD34, six tumours (five patients) for SMA, seven tumours (six patients) for D2-40 and seven 
tumours (seven patients) for vWF staining.
Statistical analysis
Median follow-up, counted from the date of diagnosis, was 12 months (range 1.4- 207.7 
months). Within six months after diagnosis 32% of the patients had died of disease. The 1-, 2- 
and 5-year survival rates were 55%, 43% and 33%, respectively (Figure 4). Univariate analysis 
of the histological parameters associated with clinical outcome (alive or dead of disease) are 
documented in Table 1.
Figure 4. Kaplan-Meier overall survival curve of all patients for whom follow-up data were available 
(n = 31).
Kaplan-Meier survival analysis revealed a significant difference in overall survival when the 
tumour had three or more mitoses per 10 HPF (P = 0.0001) or a macronucleolus (P = 0.010). 
Moreover, the presence of fewer than five eosinophilic granulocytes/10 HPF was also associated 
with poor survival (P = 0.003). Kaplan-Meier survival analysis in relation to immunophenotype 
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did not reveal any significant differences for CD31, CD34, vWF, SMA or keratin. However, 
angiosarcomas of bone that were positive for D2-40 showed a worse outcome (P = 0.046). Cox-
regression analysis showed that the most predictive combination of histological variables for 
poor survival was three or more mitotic figures per 10 HPF, a macronucleolus and the presence 
of fewer than five eosinophilic granulocytes/10 HPF (Table 3). Angiosarcomas containing these 
three histologic features showed an even more aggressive course compared to the overall group, 
with a 5-year survival rate of 0%.
Table 3. Cox-regression analysis of independent variables associated with poor survival.
Histological variables Odds Ratio 95% CI P-value
Macronucleolus 2.46 0.813 - 7.440 0.111
Mitotic figures ≥ 3/ 10 HPF 3.86 1.076 - 13.847 0.038
Eosinophilic infiltrate < 5/ 10 HPF 4.21 1.418 - 12.497 0.010
OR, Odds ratio; 95% CI, 95% confidence interval; HPF, high-power field.
Discussion
Vascular tumours of bone consist of a spectrum of clinicopathological entities ranging from 
benign haemangioma at one end to angiosarcoma at the other end. Intermediate between 
haemangioma and angiosarcoma is the clinicopathological entity epithelioid haemangioma 
which has been well described recently14 and which is now generally accepted.24 There 
is no consistency in the literature on the exact histological criteria with which to diagnose 
angiosarcoma of bone.4-6 In addition, it is uncertain if there still remains a clinically delineated 
category between epithelioid haemangioma and angiosarcoma. We therefore attempted to 
delineate further malignant vascular tumours of bone by studying a large series of angiosarcomas.
Within the EuroBoNet consortium we collected a large series of vascular tumours with 
previous diagnoses other than (epithelioid) haemangioma, epithelioid haemangioendothelioma 
and haemangiopericytoma of bone.
Twelve cases (15%) originally diagnosed as angiosarcoma were reclassified as epithelioid 
haemangioma. Follow-up data available of 11 patients revealed that all of these patients survived 
(follow-up range: 8.2 - 449 months) and none of them developed a local recurrence or 
metastasis. There were no tumours that were intermediate between epithelioid haemangioma 
and angiosarcoma. This is consistent with the recent reclassification of 23 vascular tumours of 
bone within the International Society for the Study of Vascular Anomalies (ISSVA),24 although 
in this study three cases were reported that could not be classified, while one case was still 
labelled haemangioendothelioma of bone.
In our series, the presence of metastases are not very well documented, on the one side due to 
rapidly progressive disease leading to death from disease without further clinical investigation 
and on the other side due to the fact that for some of the older cases more limited clinical or 
radiological investigations were performed. However, in patients with rapidly progressive disease 
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leading to death from disease, presumably metastases were presumed to be present. Therefore, 
the presumed metastatic rate is 61%.
To date, there is no consensus in the literature regarding the exact histological criteria defining 
angiosarcoma of bone. Wenger and Wold4 stated that tumours with high-grade cytological atypia 
and brisk mitotic activity should be classified as angiosarcomas. O’Connell et al.6 proposed 
marked nuclear atypia and abundant mitotic figures, including atypical forms, as the most 
important histological criteria. However Evans et al.5 recommended nuclear hyperchromasia, 
pleomorphism and high mitotic activity (>5 mitoses/10 HPF) as histological criteria to define 
angiosarcoma of bone. In our series of angiosarcomas of bone, cytonuclear atypia was found in 
all tumours, nuclear hyperchromasia in 45.2% and mitotic activity ranged from 0 to 9 mitoses 
per 10 HPF, thus qualifying for the diagnosis of angiosarcoma of bone. In three tumours no 
mitoses could be detected, although for those cases only a very small biopsy specimen was 
available. In these three cases cytonuclear atypia was prominent.
Within the group of angiosarcomas of bone we identified three high-risk histological 
parameters. Three or more mitoses per 10 HPF (P = 0.0001), a macronucleolus (P = 0.010) and 
the presence of fewer than five eosinophilic granulocytes per 10 HPF (P = 0.003) correlated 
with poor prognosis on multivariate analysis. Furthermore, a subset of angiosarcomas of bone 
containing the combination of these features showed an even more aggressive course. Therefore, 
our data show that within the spectrum of vascular tumours of bone three or more mitoses 
per 10 HPF, macronucleoli and fewer than five eosinophilic granulocytes per 10 HPF predict 
aggressive behaviour and poor outcome (Figure 1).
Almost one-third of the patients had multifocal disease, which is consistent with the literature.4, 
17, 25 Although the cause and biological mechanism of multifocal disease still remains unknown, 
in our series multifocal disease is not associated with a better prognosis as suggested in some 
reports for haemangioendothelioma and epithelioid haemangioendothelioma of soft issue.4, 13, 18
Vascular tumours variably express CD31, CD34 and vWF.26-28 In our series 95% showed positive 
staining for CD31, suggesting that this is the best diagnostic marker for vascular tumours of 
bone. However, two out of 42 (5%) vascular tumours of bone showed positive staining for CD34 
but lacked staining of CD31 or vWF. Therefore, a panel of these three markers is suggested 
for diagnostic use. The keratin positivity, seen in 69% of the cases which we examined, was 
very striking. Keratin expression has been documented in non neoplastic endothelial cells,29 in 
epithelioid vascular neoplasms,11, 30 and in up to 35% of angiosarcomas of soft tissue, independent 
of an epithelioid morphology,11, 31-35 as well as in various other sarcomas, such as Ewing sarcoma.36 
Our findings suggest a higher rate of keratin positivity in angiosarcomas of bone. Because these 
lesions have a tendency to occur multifocally (contiguous or disseminated), based on likelihood 
the radiologist will suggest metastatic carcinoma or multiple myeloma. This, combined with the 
histology demonstrating epithelioid cells (92.9%), a solid growth pattern (85.7%) and keratin 
positivity (69%), may easily lead to an erroneous diagnosis of metastatic carcinoma (Figure 5).
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Figure 5. Illustrating the radiological and histological similarities between a metastatic carcinoma (A, A’, 
B and C) and a multifocal angiosarcoma of bone (D, D’, E, F). A, A’ and D, D’: conventional X-rays 
exhibiting multifocal osteolytic bone lesions (arrows); B and E: haematoxylin and eosin staining of the 
tumour cells (scale bar: 50 μm); C and F: keratin AE1/AE3 staining of the tumour cells (scale bar: 50 μm).
D2-40 is a monoclonal mouse antibody reacting against human podoplanin, a mucine 
transmembrane protein.37 It was first described as a selective marker against lymphatic 
endothelium; however, today it is known to be present in a variety of neoplasms.37-40 The 
expression of D2-40 in a subset of soft tissue angiosarcomas has been reported in the literature, 
mainly in angiosarcomas exhibiting a hobnail or epithelioid morphology.41, 42 This indicates that 
a subset of angiosarcomas display lymphangiogenic differentiation, and are therefore designated 
as lymphangiosarcoma by some authors.41, 43 Lymphangiogenic differentiation as displayed by 
D2-40 expression was suggested to be an indicator of aggressive behaviour for angiosarcoma 
of soft tissue.44 We demonstrate the existence of lymphangiogenic differentiation in 31% of 
angiosarcomas of bone, even though it has been shown previously that normal lymphatic vessels 
are absent in bone.45 Similar to its soft tissue counterpart, D2-40 expression is associated with a 
worse prognosis of angiosarcoma of bone.
In conclusion, we describe a series of angiosarcomas of bone characterized by mitotic activity 
and nuclear atypia, defining the malignant end of the spectrum of vascular tumours of bone. 
These tumours have a 5-years survival rate of 33%. More specifically, three or more mitosis 
per 10 HPF, the presence of a macronucleolus and the presence of fewer than five eosinophilic 
granulocytes per 10 HPF, are risk factors for poor prognosis, and the finding of all three of 
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these histological risk factors in the same lesion decreases the 5-year survival rate to 0%. The 
majority of angiosarcomas of bone show epithelioid morphology and positive staining for 
cytokeratin is seen in a large subset of these tumours. As these lesions have the tendency to 
occur multifocally (29% of cases in this series), radiologists and pathologists should be aware not 
to misinterpret them as metastatic carcinoma (Figure 5). Although a panel of vascular markers 
is useful to diagnose these lesions, CD31 is the most commonly expressed vascular marker and 
lymphangiogenic differentiation, as shown by the presence of D2-40, seems to predict a more 
aggressive course.
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Angiosarcomas constitute a heterogeneous group of highly malignant vascular tumors. 
Angiosarcoma of bone is rare and poorly characterized. For angiosarcoma of soft tissue, some 
pathways seem to be involved in tumor development. Our aim was to evaluate the role of 
these pathways in angiosarcoma of bone. We collected 37 primary angiosarcomas of bone and 
used 20 angiosarcomas of soft tissue for comparison. Immunohistochemistry was performed on 
constructed tissue microarrays to evaluate expression of CDKN2A, TP53, PTEN, BCL2, CDK4, 
MDM2, cyclin D1, β-catenin, transforming growth factor-β (TGF-β), CD105, phospho-Smad1, 
phospho-Smad2, hypoxia-inducible factor-1a (HIF-1a), plasminogen activator inhibitor 
type 1 (PAI-1), VEGF, CD117 and glucose transporter-1 (GLUT-1). PIK3CA was screened 
for hotspot mutations in 19 angiosarcomas. In nearly 55% of the angiosarcoma of bone, the 
retinoblastoma (Rb) pathway was affected. Loss of CDKN2A expression was associated with 
a significantly worse prognosis. No overexpression of TP53 or MDM2 was found, suggesting 
that the TP53 pathway is not important in angiosarcoma of bone. Angiosarcoma of bone 
showed highly active TGF-β signaling with immunoreactivity for phospho-Smad2 and PAI-1. 
Although the phosphatidylinositol 3-kinase (PI3K)/Akt pathway seems to be active in both 
tumor groups, different mechanisms were involved: 41% of angiosarcoma of bone showed a 
decrease in expression of PTEN, whereas in angiosarcoma of soft tissue overexpression of KIT 
was found (90%). PIK3CA hotspot mutations were absent. In conclusion, the Rb pathway is 
involved in tumorigenesis of angiosarcoma of bone. The PI3K/Akt pathway is activated in 
both angiosarcoma of bone and soft tissue, however, with a different cause; PTEN expression is 
decreased in angiosarcoma of bone, whereas angiosarcomas of soft tissue show overexpression of 
KIT. Our findings support that angiosarcomas are a heterogeneous group of vascular malignancies. 
Both angiosarcoma of bone and soft tissue may benefit from therapeutic strategies targeting the 
PI3K/Akt pathway. However, interference with TGF-β signaling may be specifically relevant in 
angiosarcoma of bone.




Angiosarcoma is a rare malignant neoplasm composed of cells that demonstrate endothelial 
differentiation accounting for less than 1% of all sarcomas.1,2 Although angiosarcoma can occur 
at any anatomical site throughout the body, it is most commonly found in the skin of the head 
and neck region and its underlying superficial soft tissue.1,2 In all, 20-40% are located within 
the deep muscles of the extremities.1-4 Angiosarcoma of bone is extremely rare and accounts 
for <1% of all malignant bone tumors.5-7 Angiosarcomas present with widely varying signs 
and symptoms. Although their clinical behavior is rather unpredictable, it has been generally 
accepted that they can be extremely aggressive.1,2,8-11
Angiosarcomas constitute a highly heterogeneous group of tumors. At present, there is 
an increasing role for cellular and molecular features in the classification of tumors.1 These 
features do not only have an impact on the identification and diagnosis of tumors, but can as 
well have some therapeutic implications.12 So far, there are relatively few studies investigating 
cellular and molecular changes within angiosarcoma of bone. Single-case reports and small 
studies have shown the possible involvement of cell cycle regulators, such as cyclin D1,13 and 
tumor-suppressor genes such as CDKN2A and TP53,1,14-21 in sporadic angiosarcoma of skin, 
soft tissue and visceral angiosarcomas suggesting a possible role in tumorigenesis in a subset of 
angiosarcomas. Moreover, a subset of angiosarcomas harbor specific genetic alterations based 
on either their anatomical site or exposure to radiation.22-24 In that perspective, high levels of 
MYC amplification are found in 55-100% of angiosarcomas secondary to radiation exposure or 
chronic lymphedema after breast surgery and radiation, which is in 25% associated with FLT4 
(FMS-like tyrosine kinase-4 encoding for VEGFR3) amplification.22-24 In addition, KDR (kinase 
insert domain receptor, VEGFR2) mutations are present in 10% of angiosarcoma of the breast, 
either primary or secondary to radiation exposure.22,23 These findings implicate that, based on 
tumor-specific alterations, angiosarcoma of soft tissue is highly heterogeneous. In angiosarcoma 
of bone, molecular studies are absent. Therefore, it is still unclear whether angiosarcoma of 
bone is a true separate entity or is similar to primary angiosarcoma of deep soft tissues. We 
therefore examined the expression of a large panel of oncogenes, tumor-suppressor genes, and 
signaling molecules and performed hotspot mutation analysis for PIK3CA in angiosarcoma of 
bone. Results were compared to angiosarcoma of soft tissue. Our aim was to identify potential 




Formalin-fixed paraffin-embedded tissue of 37 tumors from 33 patients, with the confirmed 
diagnosis of angiosarcoma of bone were collected from the archives of the Departments of 
Pathology of the Rizzoli Institute, Bologna, Italy (33 tumors from 30 patients), and University 
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Hospitals, Leuven, Belgium (4 tumors from 3 patients) as previously well characterized and 
described.25 For comparison, 20 angiosarcomas of soft tissue from 20 patients were collected 
from the archives of the Department of Pathology of University Hospitals, Leuven, Belgium 
(14 tumors from 14 patients) and Leiden University Medical Center (6 tumors from 6 patients). 
Fresh frozen tumor tissue of six angiosarcomas of soft tissue (from six patients) was available for 
mutation analysis. All specimens were handled according to the ethical guidelines described in 
‘Code for Proper Secondary Use of Human Tissue in the Netherlands’ of the Dutch Federation 
of Medical Scientific Societies.
Tissue Microarray
Four tissue microarrays were assembled by standard procedures26,27 using a 2 mm-diameter punch 
(3DHistech, Budapest, Hungary; three tissue microarrays) or a 0.6 mm-diameter punch (Beecher 
Instruments, Silver Spring, MD, USA; one tissue microarray) containing 37 angiosarcomas of 
bone and 20 angiosarcomas of soft tissue with four cores of each lesion whenever possible. Also 
six tissue cores of tonsil, seven tissue cores of bowel and three cores of liver were included for 
orientation and control purposes. Using a tape-transfer system (Instrumedics, Hackensack, NJ, 
USA), 4-μm sections were transferred to glass slides.
Immunohistochemistry
Immunohistochemistry was performed on tissue microarray slides with different antibodies 
for oncogenes, tumor-suppressor genes, and signaling molecules which were selected based on 
their possible role in angiosarcoma of soft tissue, or based on their role in angiogenesis (Table 1). 
Immunohistochemical reactions were performed according to standard laboratory methods.28 
For each antibody a positive and negative external control was included. The antibodies, their 
sources, antigen retrieval methods, dilutions, positive and negative external controls used are 
documented in Table 1. As negative control, sections were stained without adding the primary 
antibody. The intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong) and percentage 
of positive neoplastic cells (0 = 0%, 1 = 1-24%, 2 = 25-49%, 3 = 50-74%, 4 = 75-100%) 
were evaluated. Lost tissue cores were excluded from the analysis. Since decalcification could 
compromise the immunohistochemical result, we attempt to counteract this phenomenon 
by excluding the tissue samples with a negative internal control. The sum of intensity and 
percentage was used for analysis. Data were collected through homemade software.29
DNA Isolation and Mutation Detection
DNA was isolated from formalin-fixed paraffin-embedded material from 13 angiosarcomas 
of bone, and from fresh frozen material from six angiosarcomas of soft tissue, as described 
previously.30 The Custom TaqMan® Assay Design Tool (Applied Biosystems, Nieuwerkerk a/d 
Ijssel, The Netherlands) was used to detect seven different KRAS, three PIK3CA and one 
BRAF mutations as described previously.31 Raw data from the LC480 software were imported 
into an inhouse–created Microsoft Excel 2003 spreadsheet to define the mutation status as 
described in detail previously.31









































































































































































































































































































































































































































































































































































































































































































































































The results of the immunohistochemical analysis were correlated to clinicopathological data 
available for the angiosarcomas of bone, which were documented previously.25 The correlation 
between immunohistochemical markers and the specific location of the tumors (bone versus 
soft tissue) was performed using global testing and the non-parametric Mann-Whitney U 
two-independent sample test. Global testing was used to determine whether a pre-specified 
group of genes were differentially expressed between angiosarcoma of bone and soft tissue.32 
Kruskal-Wallis H test (non parametric K independent sample test) was performed to evaluate 
the correlation between immunohistochemical markers within the different subgroups based 
on the origin (bone, soft tissue, head and neck region, or visceral involvement). Subsequently, 
immunohistochemical markers were combined into different pathways and by global testing we 
evaluated the correlation between these pathways and the two different groups of angiosarcoma 
(bone versus soft tissue) and corrected the results for multiple testing. Values of P<0.005 (corrected 
for multiple testing) were considered statistically significant. The data were analyzed using R 
(R Development Core Team (2011). R: A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://
www.R-project.org/), Global testing32 and SPSS 17.0 software (SPSS inc., Chicago, Illinois, 
USA). As described previously, follow-up data were available of 31 patients with angiosarcoma 
of bone.25 Survival was evaluated by Kaplan-Meier analysis and logrank test. Values of P≤0.05 
were considered statistically significant.
Results
Patient Characteristics
Patient characteristics of both angiosarcoma of bone and soft tissue are summarized in Table 2. 
All patient characteristics for angiosarcoma of bone have been described in detail previously.25 
Based on the location of the angiosarcoma of soft tissue, the patients could be divided into 
three different subgroups: seven patients had an angiosarcoma located within the head and neck 
region, eight patients had an angiosarcoma of deep soft tissue and five patients had a visceral 
angiosarcoma. None of the patients had a history of radiation, that is, for other cancers, and/ or 
chronic lymphedema at the location of the angiosarcoma.
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Table 2. Clinical and treatment characteristics of angiosarcoma of bone compared to angiosarcoma of 
soft tissue
Angiosarcoma Bone Soft tissue
n (%) n (%)
Total number of patients 33 20
  Male 22 (67) 11 (55)
  Female 11 (33) 9 (45)
Age range 12-75 y 30-91 y
  Mean 51.6 y 67.4 y
  Median 54.6 y 69.5 y
Follow-up (months) range 1.7 - 207.7 NK
  mean follow-up (months) 37.3 NK
  median follow-up (months) 12 NK
Local recurrence 8 (24) 4 (20)
Metastases
  at time of diagnosis 1 -
  during course 5 8
  not known 3 12
Treatment 30 (91) 20 (100)
  Surgery 12 (37) 17 (85)
  Surgery + chemotherapy 8 (24) 1 (5)
  Surgery + radiotherapy 4 (12) -
  Surgery + chemo- and radiotherapy 1 (3) -
  Chemotherapy 1 (3) 2 (10)
  Radiotherapy 4 (12) -
No treatment 2 (6) -
Treatment not known 1 (3) -
5-Year survival 33% NK
Abbreviations: n, patient numbers; NK, not known; y, year.
Cell Cycle Regulators in Angiosarcoma of Bone
Nearly 55% of the angiosarcoma of bone showed a defect in the retinoblastoma (Rb) pathway, 
affecting either CDKN2A, cyclin D1 or both. A total loss of protein expression of CDKN2A 
(sumscore 0, with positive internal control) was detected in 49% (16/33) of angiosarcomas 
of bone. Six percent (2/33) of the angiosarcomas of bone demonstrated overexpression of 
cyclin D1 (sumscore ≥ 6), of which one tumor showed normal CDKN2A expression and 
one tumor showed a total loss of CDKN2A protein expression. Kaplan-Meier survival analysis 
demonstrates that patients showing loss of CDKN2A expression (sumscore 0) have a significantly 
worse survival (P = 0.017; Figure 1). Overexpression of CDK4 (sumscore ≥ 6) did not occur 
in angiosarcoma of bone (0%). None of the angiosarcomas of bone showed overexpression 
(sumscore ≥ 6) of TP53 (Figure 2) or MDM2. The anti-apoptotic protein BCL-2 was only 
weakly expressed in the majority of angiosarcoma of bone.
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4 Figure 1. Kaplan-Meier survival analysis demonstrates a significantly worse survival for patients with 
angiosarcoma of bone showing loss of CDKN2A expression (sumscore 0).
Figure 2. Dot plots and immunohistochemical results for TP53, CD117 en PTEN in angiosarcoma 
of bone (ASB) compared with its soft tissue (ASST) counterpart. (a) TP53 shows no overexpression in 
angiosarcoma of bone, whereas three angiosarcomas of soft tissue show clear TP53 overexpression (sumscore 
> 6). Although some angiosarcomas of bone show positivity for TP53, clear overexpression was not seen 
(b), in contrast to angiosarcoma of soft tissue (c); (d). Angiosarcomas of bone show a significant lower 
expression of CD117 than angiosarcomas of soft tissue; (e) weak expression of CD117 in angiosarcoma of 
bone compared to high expression in angiosarcoma of soft tissue (f); (g) A subset of angiosarcomas of bone 
show a decrease in expression (sumscore ≤ 3) of PTEN. Low expression (h) and normal expression (i) of 
PTEN in angiosarcoma of bone, as well as low expression of PTEN in an angiosarcoma of soft tissue (j) 
(scale bars 50 μm).
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Signaling Pathways in Angiosarcoma of Bone
Transforming growth factor-β (TGF-β) signaling was highly active in angiosarcoma of bone; all 
tumors showed immunoreactivity for the ligand TGF-β1 and the downstream targets phospho-
Smad2 and plasminogen activator inhibitor type-1 (PAI-1; Figure 3). Dot plots for all antibodies 
are shown in Figure 4. In addition, nuclear expression of phospho-Smad1, which is indicative 
of active BMP signaling, was found in 68% of the angiosarcomas of bone (sumscore > 0). 
Endoglin (CD105) was expressed (sumscore > 0) by the tumor cells in the majority (97%) of 
the tumors. Moreover, 41% of the angiosarcomas of bone showed a decrease in expression of 
PTEN (sumscore ≤ 3) suggesting involvement of the phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway (Figure 2). There was no evidence of active canonical Wnt signaling as we did not find 
nuclear localization of β-catenin in the vast majority of the tumors. As for cell survival signaling, 
both the hypoxia-inducible factor)-1a as well as the glucose transporter-1 were expressed in 
only a few tumors. On the other hand, VEGF was widely and strongly expressed (Figure 4).
Figure 3. Difference in protein expression (sumscore) for TGF-β (a), phosphoSmad2 (b), PAI-1 (c) and 
phosphoSmad1 (d) between angiosarcoma of bone (ASB) and soft tissue (ASST) illustrated by dot plots; 
(e) Angiosarcoma of bone showing a strong TGF-β expression; (f) Angiosarcoma of bone showing a strong 
phosphoSmad2 expression (scale bars: 50 μm).
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Figure 4. The difference in protein expression (sumscores) of all studied antibodies between angiosarcoma 
of bone (ASB) and soft tissue (ASST) illustrated by dot plots and their corresponding P-value.
Angiosarcoma of Bone versus Angiosarcoma of Soft tissue
When combining immunohistochemical markers belonging to the same pathway essential in 
cell signaling, proliferation and survival, global testing demonstrates a significant difference in 
expression for TGF-β pathway and PI3K/Akt pathway between angiosarcoma of bone and soft 
tissue (Table 3). The TGF-β signaling is more active in angiosarcoma of bone compared to its soft 
tissue counterpart as shown by global testing, which is based on difference in phospho-Smad2 
expression between angiosarcoma of bone and soft tissue (Figure 5). The PI3K/Akt pathway 
seems to be involved in both angiosarcoma of bone and soft tissue, but through a different 
mechanism. The PI3K/Akt pathway in angiosarcoma of bone is affected by decreased expression 
of PTEN (sumscore ≤ 3), whereas in angiosarcoma of soft tissue this is mainly associated with 
overexpression of CD117. Decreased expression of PTEN is seen in 11 of 27 angiosarcomas 
of bone (41%) as compared to 1 of 15 angiosarcomas of soft tissue (7%) (P = 0.049; (Figure 
2). Only 17% (5/29) of the angiosarcomas of bone show expression of CD117, compared to 
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90% (17/19) of the angiosarcomas of soft tissue (Figure 2) Global testing indeed demonstrates 
a significant difference in the overall immunohistochemical expression pattern (including all 
markers tested) between angiosarcoma of bone and soft tissue (P = 0.0004), which is mainly due 
to CD117 being predominantly expressed in soft tissue angiosarcoma (P = 0.00001; Figure 5). 
In addition, global testing shows that there is an apparent difference in expression for phospho-
Smad2, PTEN and TGF-β between both tumor groups (Figure 5). The difference in protein 
expression between angiosarcoma of bone and soft tissue of all antibodies are illustrated by dot 
plots documented in Figure 4. In 75% of the angiosarcomas of soft tissue the Rb pathway is 
affected, either by loss of CDKN2A (sumscore 0, 12/20; 60%) and/or overexpression of cyclin 
D1 (sumscore ≥ 6, 5/19; 26%). Only six percent (3/18) of the angiosarcomas of soft tissue show 
overexpression of TP53 (sumscore ≥ 6). Tumors overexpressing TP53 were mainly located in the 
head and neck region (2/3).
Table 3. The different pathways based on a combination of different immunohistochemical markers that 
are used for global testing between angiosarcoma of bone and angiosarcoma of soft tissue.
Pathways Markers P-value adjusted
TGF-β TGF-β+phospho-Smad2+PAI-1 0,003
BMP phospho-Smad1 0.946
Rb Cyclin D1+CDK4+CDKN2A 0.505
TP53 BCL2+MDM2+TP53 0.166
PI3K/Akt CD117 + PTEN 0.0000002
The significant P-values are shown in bold.
Figure 5. Global testing (R) shows a significant difference (P = 0.00001) in immunohistochemical 




Mutation Analysis in Angiosarcoma 
Since the PI3K/Akt signaling pathway seems to be differently activated between angiosarcoma 
of bone and soft tissue, we continued to analyze for mutations in PIK3CA. However, no hotspot 
mutations were detected in angiosarcoma of bone or soft tissue. Moreover, there were no 
mutations detected for KRAS and BRAF.
Discussion
Dysregulation of the Rb/CDKN2A and/or TP53 pathway are the most common alterations 
found in almost all types of human cancer.33 Our results show that in angiosarcoma of bone, the 
Rb pathway is disrupted in 55% of the cases, mainly by loss of protein expression of CDKN2A 
(49%) or overexpression of cyclin D1 (6%), contributing to uncontrolled cell proliferation and 
tumorigenesis. We additionally show that, unlike in angiosarcoma of soft tissue, in angiosarcoma 
of bone the TP53 pathway is not important. The involvement of the Rb pathway in a small 
majority of angiosarcoma of bone is consistent with the hypothesis that angiosarcomas belong 
to the category of sarcomas with complex genomic profiles, which frequently have alterations 
in the Rb/CDKN2A and/or TP53 pathways.34,35 
Moreover, inactivation of CDKN2A is associated with a more aggressive behavior in many 
cancers, including for instance Ewing sarcoma,34,36,37 and osteosarcoma.38,39 Here, we demonstrate 
that also patients with angiosarcoma of bone showing loss of expression of CDKN2A have a 
significantly worse prognosis. To date, few studies have reported the possible role of CDKN2A 
and TP53 in tumor development in a subset of angiosarcomas of soft tissue.15-20,37,40-42 Recently, 
it has been shown that Ink4/Arf deficiency in mice is associated with the development of 
angiosarcoma, lymphoma and fibrosarcoma.43
By global testing, we demonstrate that TGF-β pathway (TGF-β1/phospho-Smad2/PAI-
1) is highly active in angiosarcoma of bone and therefore could play an important role in 
tumorigenesis. TGF-β1 is the major isoform present in bone and, among others, involved in 
bone formation.44 It binds and activates ALK5, one of its specific type I receptors, and thereby 
inducing phosphorylation of Smad2/Smad3, resulting in the expression of PAI-1.45 To date, it 
is accepted that the TGF-β signaling pathway plays an important role during embryogenesis, 
cell differentiation and maintenance of homeostasis during adult life, but it also prohibits 
uncontrolled cell proliferation.45,46 Deregulation of this pathway causes resistance to the TGF-β 
mediated growth arrest and gives rise to malignancies.47-49 However, the molecular mechanisms 
provoking this deregulation, that is, genetic and epigenetic aberrations, and the underlying 
oncogenic activities of TGF-β still remain unclear.49 Our findings suggest possible therapeutic 
options for angiosarcoma of bone, because inhibitors of the TGF-β pathway (Figure 6) are 
available.50 By now, multiple pre-clinical and clinical studies are investigating the inhibition of 
the oncogenic TGF-β signaling as a therapeutic approach in different types of cancer.50
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Figure 6. A simplified overview of the TGF-β pathway (left) and the PI3K/Akt (right) pathway and possible 
therapeutic strategies to inhibit the pathway. TGF-β can be inhibited by ligand traps (soluble receptor 
ectodomain constructs), neutralizing antibodies and ALK5/TβRII kinase inhibitors. In addition, ligand 
production can be prevented by blocking translation of TGF-β mRNA with antisense oligonucleotides. 
The PI3K/Akt pathway can be inhibited by pure PI3K inhibitors, dual PI3K/mTOR inhibitors, AKT 
inhibitors, and mTOR inhibitors e.g. rapamycin and analogs (rapalogs). More specifically, receptor tyrosine 
kinases such as KIT can be blocked by a tyrosine kinase inhibitor (TKI).
Pathway analysis further demonstrates that the PI3K/Akt pathway, is highly active in both 
angiosarcoma of bone and soft tissue (Figure 6). However, the differences in protein expression 
suggest that activation occurs through different mechanisms. In angiosarcoma of bone 41% show 
decreased expression of the tumor-suppressor PTEN, compared to only 7% in angiosarcoma of soft 
tissue. However, in angiosarcoma of soft tissue, the tyrosine kinase receptor KIT is overexpressed 
in 90%, whereas this is infrequent (17%) in angiosarcoma of bone. This is corresponding to 
previous studies, reporting that 20% to 58% of the soft tissue angiosarcomas show CD117 
expression,51,52 whereas normal adult endothelial cells lack CD117 overexpression.52-54 To date, 
there are no KIT and/or PDGFRA mutations detected in angiosarcoma of soft tissue.52,54,55 Of 
note, there is one report of a very good response to imatinib (Glivec, a specific tyrosine kinase 
inhibitor) in angiosarcoma of soft tissue.55 We show limited expression of CD117 in a minority 
of angiosarcoma of bone, suggesting that a specific tyrosine kinase-inhibitor, such as imatinib, 
could be a therapeutic option for angiosarcoma of soft tissue but not for angiosarcoma of bone.
In angiosarcoma of bone on the other hand we demonstrate decreased expression of 
PTEN. To date, there is only one report of a human PTEN gene mutation in one out of 
two angiosarcomas of the liver containing a single nucleotide substitution in exon 7.56 A 
recent publication demonstrates that about 10% of the PTEN-haploinsufficient zebrafishes 
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develop hemangiosarcomas and these tumors have an activated PI3K/Akt signaling,57 thereby 
illustrating the possible role of PTEN in the development of vascular tumors. Although it would 
be interesting to evaluate possible PTEN mutations within angiosarcoma of bone, mutation 
analysis could not be performed in our study, since there was not enough more DNA available.
The PI3K/Akt pathway is a signal transduction cascade that plays a role and regulates a large 
variety of important physiological processes, such as cell proliferation and metabolism, adhesion, 
survival, protein synthesis, motility and angiogenesis.58 Genetic aberrations, such as PIK3CA 
mutation, have been described, which constitutively activate this pathway and thereby potentially 
induce malignancies.58,59 As the PI3K/Akt pathway is activated in both angiosarcoma of bone 
and soft tissue, we additionally examined PIK3CA for hotspot mutations. No mutations were 
found. Of note, recent publications have shown the presence of PIK3CA mutations in vascular 
anomalies and benign vascular lesions.60,61
The activated PI3K/Akt pathway in angiosarcomas provides a rationale for the use of inhibitors 
of the PI3K/Akt pathway in these patients (Figure 6).62,63 The serine/ threonine kinase 
mammalian target of rapamycin (mTOR) is a kinase downstream in the PI3K/Akt pathway 
and therefore an important regulator of cell proliferation, metabolism, and protein synthesis. 
The mTOR activity can be inhibited by rapamycin (sirolimus) and analogs (rapalogs), for 
example, Temsirolimus/CCI-779 and everolimus/RAD001. Beuvinck et al demonstrated in 
human tumor xenografts that everolimus inhibits angiogenesis by preventing the proliferation 
of endothelial cells.63 So far, there is only one report demonstrating the anti-proliferative effect 
of rapamycin in angiosarcoma cell lines.64 Additionally, new drugs such as pure PI3K inhibitors, 
dual PI3K-mTOR inhibitors, Akt inhibitors and mTOR kinase inhibitors are evolving and 
passing through the early phases of clinical development.58 Our findings would support further 
studies into the effectiveness of these inhibitors in angiosarcoma of bone. However, thus far, no 
cell lines derived from angiosarcoma of bone are available.
In conclusion, we demonstrate that angiosarcoma of bone is different from angiosarcoma of 
soft tissue at the molecular level, suggesting that the underlying mechanism of tumorigenesis 
between both groups may be different. This supports the previous finding that angiosarcomas 
are a heterogeneous group of malignant vascular tumors with possible different subgroups and 
corresponding expression profiles.22,23 We demonstrate that in 55% of the angiosarcoma of 
bone the Rb pathway is involved in tumorigenesis, mainly by the loss of protein expression 
of CDKN2A which seems to be related with a significantly worse prognosis. The TP53 
pathway seems of no importance in angiosarcoma of bone. Moreover, by global testing we 
demonstrate that the TGF-β pathway is more active in angiosarcoma compared to its soft tissue 
counterpart. The PI3K/Akt pathway is active in both angiosarcoma of bone and soft tissue, 
and we here demonstrate that while in angiosarcoma of soft tissue overexpression of KIT is 
involved, in angiosarcoma of bone PTEN expression is decreased. Our results provide rationale 
for therapeutic strategies including TGF-β and/or PI3K/mTOR inhibitors to improve the 
generally poor prognosis of patients with angiosarcoma of bone.
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Background: Molecular genetic studies on rare tumour entities, such as bone tumours, often 
require the use of decalcified, formalin-fixed, paraffin-embedded tissue (dFFPE) samples. 
Regardless of which decalcification procedure is used, this introduces a vast breakdown of DNA 
that precludes the possibility of further molecular genetic testing. We set out to establish a robust 
protocol that would overcome these intrinsic hurdles for bone tumour research.
Findings: The goal of our study was to establish a protocol, using a modified DNA isolation 
procedure and quality controls, to select decalcified samples suitable for array-CGH testing. 
Archival paraffin blocks were obtained from 9 different pathology departments throughout 
Europe, using different fixation, embedding and decalcification procedures, in order to preclude 
a bias for certain lab protocols. Isolated DNA samples were subjected to direct chemical labelling 
and enzymatic labelling systems and were hybridised on a high resolution oligonucleotide chip 
containing 44,000 reporter elements.
Genomic alterations (gains and losses) were readily detected in most of the samples analysed. 
For example, both homozygous deletions of 0.6 Mb and high level of amplifications of 0.7 Mb 
were identified.
Conclusions: We established a robust protocol for molecular genetic testing of dFFPE derived 
DNA, irrespective of fixation, decalcification or sample type used. This approach may greatly 
facilitate further genetic testing on rare tumour entities where archival decalcified, formalin 
fixed samples are the only source.




The introduction of high-throughput, high-resolution molecular screening tools had tremendous 
impact on molecular genetic studies both for constitutional and tumour genetic investigations 
[1,2]. Whilst the accessibility of good quality samples for constitutional genetic studies is often 
achievable, for cancer genetic investigations it has remained a hurdle especially for those dealing 
with rare tumour entities. A comprehensive study of rare cancers, such as bone tumours, requires 
the use of archived tissue materials such as formalin fixed paraffin embedded tissue (FFPE) [3-5]. 
It is well known that the quality of FPPE-derived DNA is both fixation time- and fixative-
dependent and is highly variable between different institutions. 10% buffered formalin is a 
commonly used fixative in routine diagnostic labs. Long term storage of this fixative leads to 
the formation of formic acid and methanol by the Cannizzaro-reaction. Formic acid promotes 
the breakdown of the DNA and thus inferior quality is extracted from these tissue samples. To 
process bone derived tumour samples, an extra decalcification step is necessary to remove the 
Ca2+ containing matrix part of the tissue. This can be achieved either by EDTA treatment or by 
an extensive formic acid treatment. EDTA treatment is a labour-intensive procedure and takes 
up to several weeks of incubation. The treatment introduces limited breakdown of DNA but 
because of its lengthy procedure it is impractical for routine diagnostics. The formic acid-based 
decalcification procedure introduces a tremendous breakdown of DNA within these samples. 
As a result, most of these samples are usually regarded as unsuited for molecular biological 
testing. The formic acid-based decalcification has been the golden standard procedure at many 
institutions, meaning that most of the archival material collected from multiple sources has 
been treated in this way. The goal of our study was was to establish a modified DNA isolation 
protocol with quality controls enabling array-CGH testing on decalcified samples irrespective 
of fixation and decalcification steps used. Isolated DNA samples were labelled using two FFPE 




Samples were selected for molecular cytogenetic testing from various partner institutions 
within the EuroBoNet consortium http://www.eurobonet.eu for different projects (rare 
chondrosarcoma subtypes of bone and primary angiosarcoma of bone) dealing with decalcified 
FFPE (dFFPE) samples. Samples used in this study represent both tumours with high cellularity 
and a low extracellular matrix proportion as well as samples with low cellularity and an excessive 
extracellular matrix composition. Sample collection dates varied from 1990 until 2008. Samples 
were all fixed in 10% buffered formalin but the exact fixation times and conditions are not 
known (Table 1). For one case (Nr 10) array comparison using DNA isolated from dFFPE 
tissue and the corresponding frozen tissue part was possible. All samples were handled in a 
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coded fashion, and all procedures were performed according to the ethical guidelines, ‘’Code 
for Proper Secondary Use of Human Tissue in the Netherlands’’ (Dutch Federation of Medical 
Scientific Societies).





Material Cellularity Extracellular 
matrix
Decalcification
1 Rare chondrosarcoma 2004 dFFPE High Low Formic acid
2 Rare chondrosarcoma 2007 dFFPE High Low Formic acid
3 Rare chondrosarcoma 2007 dFFPE Low High Formic acid
4 Rare chondrosarcoma 1996 dFFPE Low High Formic acid
5 Rare chondrosarcoma 1997 dFFPE High Low Formic acid
6 Rare chondrosarcoma 2005 dFFPE Low High Formic acid
7 Rare chondrosarcoma 2005 dFFPE High Low Formic acid
8 Rare chondrosarcoma 2004 dFFPE Moderate Moderate Formic acid
9 Rare chondrosarcoma 2006 dFFPE Moderate Moderate Formic acid
10 Rare chondrosarcoma 2000 dFFPE Moderate Moderate Formic acid
11 Rare chondrosarcoma 1996 dFFPE Moderate Moderate Formic acid
12 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
13 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
14 Rare chondrosarcoma 1994 dFFPE High Moderate Formic acid
15 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
16 Rare chondrosarcoma 2007 dFFPE High Moderate Formic acid
17 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
18 Rare chondrosarcoma 2001 dFFPE High Moderate Formic acid
19 Rare chondrosarcoma 1994 dFFPE High Moderate Formic acid
20 Rare chondrosarcoma 1996 dFFPE High Moderate Formic acid
21* Rare chondrosarcoma 2000 Frozen Moderate Moderate None
22** Rare chondrosarcoma 1996 Frozen Moderate Moderate None
23 Chondrosarcoma 2001 Frozen High High None
24 Chondrosarcoma 2003 Frozen low High None
25 Primary angiosarcoma 2007 Frozen High Low None
26 Primary angiosarcoma NA dFFPE High Low Formic acid
27 Primary angiosarcoma 2007 dFFPE High Low Formic acid
28 Primary angiosarcoma 2007 FFPE High Low None
29 Primary angiosarcoma NA FFPE High Low None
30 Primary angiosarcoma 2007 FFPE High Low None
31 Primary angiosarcoma NA dFFPE High Low Formic acid
32 Chondrosarcoma 1990 dFFPE Low High Formic acid
* Corresponding frozen sample Nr 10
** Corresponding frozen sample Nr 11
***NA: not available




Five to ten 0.2 mm FFPE punches or two to five 20 μm thick dFFPE sections were collected 
depending on tissue type and tumour content. From each block a 4 μm consecutive section 
was cut and stained using standard haematoxylin and eosin (HE) staining to visualise target 
cells and served as control. An optimized DNA isolation protocol was developed based on the 
use of Macherey-Nagel Nucleospin Tissue kit. Briefly, sections/punches were collected into 
an Eppendorf tube and were deparaffinised using two cycles of xylene incubation, 15 min 
each at room temperature, followed by two steps of 100% ethanol incubation, 15 min each. 
Samples were then dried and 200 μl PK1 buffer supplemented with Proteinase K (0.4 mg/ml) 
was added to each tube and incubated for 18 hours at 56 °C. On day two, 200 μl buffer B3 
was added to each vial. Samples were vortexed vigorously, incubated at 70°C for 10 min and 
vortexed again. By these means, most tissue pieces were dissolved. When visible particles were 
left (typically bone remnants), samples were centrifuged for 5 min at 11.000 × g and supernatant 
was transferred to a new tube. Before loading samples to a DNA binding column, 210 μl 100% 
ethanol was added. At this step, a partial precipitation within the solution was observed in some 
of the samples. For DNA binding, samples were centrifuged for 1 min at 11.000 × g. In some 
cases, repeated centrifugation steps were necessary. Flow-through was discarded and columns 
were washed by adding 500 μl BW solution followed by 1 min 11.000 × g centrifugation step, 
followed by a second wash step using 600 μl B5 buffer and centrifugation. To elute the DNA 50 
μl preheated (70°C) MQ solution was added to the column and incubated at room temperature 
for 5 min followed by a centrifugation step at 11000 × g for 1 min. DNA isolation from frozen 
tissue was performed as described earlier [6].
Sample assessment
DNA concentrations were measured using a Nanodrop ND-1000 spectrophotometer and 500 
ng was electrophoresed in a 1% agarose gel stained with ethidium bromide. 
Sample labelling
Agilent Oligo aCGH Labeling Kit for FFPE Samples (Agilent) utilising ULS labelling system
Labelling was done according to the manufacturer’s recommendations with some modifications. 
In brief, for 44k Agilent arrays (Agilent Technologies, Santa Clara, CA), 500 ng DNA was 
chemically labelled with Universal Linkage System (ULS) Cy3 (test) or Cy5 (reference)-dyes. 
Before labelling, reference samples were heat fragmented in order to achieve equal fragment 
sizes in both test and reference sample. The labelled samples were then purified using the Agilent 
KREApure columns. Labelling efficiency was calculated using a Nanodrop Spectrophotometer 
measuring A260 (DNA), A550 (Cy3) and A649 (Cy5).
BioPrime Total FFPE Genomic Labelling System (Invitrogen)
Labelling was done according to the manufacturer’s recommendations with some modifications. 
In brief, 500 ng DNA was used for labelling, instead of the recommended 1 μg DNA. 
Labelling with both 150 ng and 500 ng DNA was done for one sample (Nr 13). Random 
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prime (RP) labelling was done by using the BioPrime Total FFPE Genomic Labelling System 
(Invitrogen Corporation, Carlsbad, CA) Labelling efficiency was calculated using a Nanodrop 
Spectrophotometer measuring A260 (DNA), A550 (Cy3) and A649 (Cy5). Heat-fragmented 
DNA from a commercial source (Promega Corporation, Madison, WI) was used as a reference. 
Samples were labelled with Alexa Fluor 3 mix (test sample) and Alexa Fluor 5 mix (reference 
sample). For both ULS- and RP-system-labelled test and reference samples were mixed and 
hybridized as a gender mismatch to show dynamic range of hybridisation on the X and Y 
chromosomes. Two samples were labelled both with the random prime kit and with ULS (Nr 
10 and Nr 18).
Hybridisation, scanning and, data extraction
Hybridisation was performed on a 4 × 44k Agilent oligo array Chip at 65°C for 40 hours. Slides 
were washed with Oligo aCGH Wash Buffer 1 at room temperature for 5 min followed by a 
1 min wash with Oligo aCGH Wash Buffer 2 at 37°C. Finally, slides were dried without using 
the stabilisation and drying solution. Slides were scanned using an Agilent Scanner with 5 μm 
scan resolution. Scan images were processed with Feature Extraction Software and Genomic 
Workbench (Agilent Technologies, Santa Clara, CA). All samples, irrespective of quality, were 
processed for further comparisons.
Interphase FISH confirmation
To confirm one of the array-CGH results of case Nr 26, a two-colour interphase FISH 
experiment was done. A BAC-clone (RP1-80K22) located at 8q24.21 covering the MYC gene 
locus (detected in red) in combination with an alpha satellite probe specific to the centromeric 
region of chromosome 8 (detected in green) were used as described earlier [7].
Statistical analysis
Log2 transformed ratio values were extracted from the scan images and processed using the 
Feature Extraction Software package and Genomic Workbench (Agilent). The exported log2 
transformed ratio values were used for further comparison. Correlations were calculated using 
Pearson coefficients and systematic bias calculations were done by using Bland-Altman plots 
using the SPSS 16.0 for Windows software package. For the Bland-Altman plots the differences 
between the two individual reporters measured by two experiments on the y axis were plotted 
against the mean log2 ratio of the two on the x axis. This test allows the investigation of 
systematic bias. Relatively small differences and little bias are represented by a “flat profile”. For 
the comparison of the resulting array-CGH profiles we used the CGHCall R script developed 
by van de Wiel et al. [8].




DNA quality and quantity assessment
DNA concentration was estimated using the Nanodrop system and equal amounts of DNA were 
electrophoresed in a 1% agarose gel. The absorption based measurement using the Nanodrop 
system showed inconsistent results when values were compared to agarose gel images. Figure 
1 shows a diverse range of DNA fragment sizes for all samples. Samples with moderate (for 
example nr 3 and 27) to severe (sample nr 17, and 31) DNA degradation showed acceptable 
CGH profiles. 
Figure 1. Quality and quantity assessment of DNA samples: Image of a 1% agarose gel separation after 
ethidium bromide staining depicting several representative tumour samples for testing. L1 and L2 represent 
1kb+ and 50bp ladders, respectively. C1, C2, C3 are high molecular weight genomic DNA samples with 


















1 131.0 1.84 2.47 134.5 0.97 OK
2 153.0 1.84 2.42 130.7 1.17 OK
3 31.9 1.88 2.67 24.9 1.28 OK
4 10.9 1.66 0.41 4.5 2.41 NP
5 13.6 2.08 1.57 3.9 3.51 NP
6 44.7 1.8 1.38 20.5 2.18 NP
7 9.8 2.06 1.92 9.0 1.08 NP
8 44.0 1.1 0.3 3.1 14.36 NP
9 57.5 1.57 0.82 3.8 14.94 Poor
10 540.0 1.78 1.9 346.9 1.56 OK
11 164.0 1.63 1.24 19.5 8.42 Poor
12 102.0 1.76 1.98 19.3 5.27 OK
13 485.0 1.84 2.34 270.5 1.79 OK
14 291.0 1.8 2.3 127.8 2.28 OK
15 430.0 1.69 2.17 76.3 5.64 Poor
16 208.0 1.81 2.21 135.9 1.53 OK
17 269.0 1.84 2.35 192.3 1.40 OK
18 63.0 1.73 2.11 9.7 6.48 Poor
19 215.0 1.75 2.12 146.6 1.47 OK
20 285.0 1.7 2.37 170.4 1.67 OK
21 1376.0 1.78 1.28 565.6 2.43 OK
22 88.6 1.67 0.91 68.1 1.30 OK
23 259.8 1.8 1.75 286.8 0.91 OK
24 496.4 1.7 1.8 523.9 0.95 OK
25 30.6 1.7 1.6 25.2 1.22 NP
26 172.0 1.8 2.11 NP NP OK
27 306.0 1.75 1.98 NP NP OK
28 203.0 1.89 2.31 NP NP OK
29 132.9 1.78 2.05 NP NP OK
30 300.0 1.8 1.96 NP NP OK
31 71.0 1.67 0.89 NP NP OK
32 47.5 1.71 0.68 NP NP Poor
C1 500 1.8 1.95 462.9 1.08 NP
C2 250 1.8 1.95 238 1.05 NP
C3 50 1.8 1.95 45 1.11 NP
* Sample ID corresponds to the sample label in Figure 1
** Nanodrop concentration/Gel-based concentration
*** NP: Not performed
In general, DNA concentration was overestimated particularly for cartilaginous tumour samples 
with high extracellular matrix composition. In these cases relatively low concentrations were 
measured (typically in the range of 2-15 ng/μl) (Table 2) but determining the concentration 
based on the corresponding gel image suggested that these measurements were an over estimate 
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(Figure 1) (for example: samples nr 9, 11, 15 and 18). As for all labelling reactions, the initial 
amount of starting material is a crucial factor. We corrected the DNA concentration measured 
by Nanodrop using the integral of the UV-excited ethidium bromide fluorescence obtained 
from the agarose gel images. For these measurements, known amounts of reference DNA 
samples were loaded. The correction factor between the two types of measurements, especially 
at the lower concentration range, was as high as 10 fold resulting in significant over estimation 
of sample concentration for labelling and consecutive testing.
Comparison of different labelling approaches
Different comparisons were made based on the type of samples available. A three-way 
comparison was made for Nr 10 with DNA collected from both frozen and dFFPE material. 
DNA from frozen tissue was labelled using a random primer labelling kit and DNA from 
dFFPE tissue was labelled with both the random primer labelling kit designed for FFPE samples 
and ULS labelling kit for FFPE samples (Figure 2A, Figure 3). The different labelling schemes 
showed an overall good correlation, the Pearson correlation coefficient varied between 0.542 
and 0.682 and showed a better correlation between the ULS-FFPE vs RP frozen (0.682) than 
the RP frozen vs RP-FFPE reaction (0.542). Very good agreement was observed between the 
two different labelling reactions using dFFPE samples (0.669). Side-by-side comparative whole 
genome overview of the array-CGH results showed the variation of the reporter signals was 
highest (black dots represent individual reporter elements) in the case of FFPE-RP labelling, 
followed by FFPE-ULS and Fr-RP. In all three profiles almost identical aberrations were present 
(see Table 3 for an overview of the genome-wide genomic aberrations). Since for routine 
applications the amount of DNA for testing is often limited, we compared the influence of 
lower amounts of starting material for labelling using 500 ng and 150 ng dFFPE-isolated DNA 
for the FFPERP kit (Nr 13). These results were compared to ULS labelling reaction using 500 
ng of DNA (Figure 2B). Based on the comparison of the overall profiles, the best correlation 
was observed between the two FFPE-RP reactions (0.873) using different input for labelling 
(150 vs 500 ng dFFPE DNA for FFPE-RP kit) followed by a 0.694 between the 500 ng FFPE-
ULS and 150 ng FFPERP. This correlation shows that the type of labelling bias, introduced by 
the labelling kit of choice, makes the overall profile more alike suggesting that ULS labelling 
of samples will result in a comparable profile of other ULS samples while the FFPE-RP kit 
will have its own bias and similar profiles for comparison between different samples. In contrast 
to this, the influence of sample storage (FPPE vs frozen) was stronger than the influence of 
labelling kit used (FFPE-RP or frozen-RP vs ULS) as we observed better correlation between 
the independent labelling reaction (ULS, FFPE-RP) than between the frozen RP and FFPE-
RP labelling reaction (Figure 2A). Poor correlations and corresponding array profiles were 
seen for samples with very low amounts of DNA irrespective of labelling reactions (Figure 2E 
and samples 9, 11, 15 and 18 in Table 2). For these reactions a minimum of 50 to 100 ng DNA 
was used. These results indicate the possible presence of substances influencing the efficiency 
of both the chemical and enzymatic labelling reactions. Because of the poor array performance 
using very low DNA concentrations (samples 9, 11, 15 and 18), five other samples with similarly 
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low DNA concentrations (samples 4, 5, 6, 7, and 8) were not tested as indicated in Table 2. For 
sample nr 2 and nr 17 the Pearson correlation coefficient varied between 0.704 and 0.476 
(Figure 2C and 2D), respectively. Despite the weaker correlation for case 17, both arrays showed 
similar profiles and similar gains and losses were detected.
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Figure 2. Array-CGH plots of decalcified FFPE samples after ULS or RP labelling. For all plots: Upper 
right: Correlation plots of log2 ratios for each reporter between experiments, with linear regression and 
Pearson’s correlation coefficients given. Lower left: Bland-Altman plots of the differences between two 
reporters measured by two experiments on the y axis against the mean log2 ratio of the two on the x axis. 
Standard deviation of mean differences is plotted in purple, the mean in black. 
A: Correlation plots of sample Nr 10 comparing hybridisation of random prime and ULS based labelling 
of FFPE and RP labelling of frozen tissue derived DNA samples. B: Correlation plots of sample Nr 13 
using FFPE isolated DNA samples with ULS, 150ng RP and 500ng RP labelling. C, D Correlation plots 
of samples Nr 2 and Nr 17 using FFPE isolated DNA samples with ULS or RP labelling reactions. E: 
Correlation plot of sample Nr 18. This sample showed a great degree of discrepancy for the estimated DNA 
concentration between the absorption based and the gel based measurements. 
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Figure 3. Side-by-side comparative whole genome overview of the array-CGH results from case Nr 10. A: 
Array CGH profile of FFPE tissue isolated DNA sample after ULS labelling (FFPE-ULS). B: Array CGH 
profile of FFPE tissue isolated DNA sample after using a Random Prime labelling especially designed 
to label FFPE samples (FFPE-RP). C: Array-CGH profile of frozen tissue isolated DNA after standard 
Random Prime Labelling reaction (Fr-RP).
Normalized log2-ratios are plotted with the scale on the right axis. Vertical bars indicate loss and gain 
probabilities. Probability scale is on the left axis; reversed (‘1–’) for the gains. Segments are plotted as 
horizontal blue lines. Segments with a bar extending beyond the middle axis (probability >0.5) are called 
as gain or losses. All plots were generated using the CGHCall R software package. 
The variation of the reporter signals was the highest (black dots represent individual reporter elements) 
in case of FFPE-RP labelling (see also Figures 2a) followed by FFPE-ULS and Fr-RP. In all three profiles 
almost identical calls were present (see Table 3 for details on the called regions).
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1 p36.33 - p33 749422 46786807 1053 + + + +
1 p12 - q23.3 119416284 160645328 539 + NC** + +
2 q33.2 - q37.3 204593489 242169652 575 - + + NC**
4 p16.3 - q13.3 146653 70631034 683 + + + +
5 p15.33 - q35.3 1163403 180617248 2104 + + + +
6 p22.1 - p21.1 26128906 44328148 558 + NC** + +
7 p22.3 - q36.3 289341 158602640 2056 + + + +
9 p24.3 - p13.3 322256 33155616 370 - + + +
9 q33.3 - q34.3 129159725 140128884 293 + NC** + +
10 p15.3 - q26.3 138006 135222624 1739 - + + +
11 p15.4 - q25 2906039 133951511 2213 + + + +
12 q13.11 - q14.1 47340134 56637091 379 + + + +
14 q11.2 - q32.33 19508645 106330010 1394 + + + +
15 q25.3 - q26.1 86577905 91761128 104 + + + +
16 p13.3 - q24.3 36566 88572953 1741 + + + +
17 p13.3 - q25.3 295150 78154619 2163 + + + +
18 p11.32 - q23 170029 76083258 875 + + + +
19 p13.3 - q13.43 231880 63389940 2096 + + + +
20 p13 - q13.33 73854 62363774 1115 + + + +
21 p11.1 - q22.3 10013063 46646924 549 + + + +
22 q11.1 - q13.33 14433273 49525271 833 + + + +
22 q13.1 37688858 37715585 3 - + NC** +
* according to NCBI hg18 
** NC: not called 
Interphase FISH
In two different samples, we readily detected a high level of amplification of the MYC locus and 
a homozygous deletion of the CDKN2A/CDKN2B loci with estimated sizes of 0.7 Mb and 0.6 
Mb, respectively (Figure 4A, C). The two-colour Interphase FISH performed on dFFPE tissue 
sections of case 26 showed a significant increase of signal involving BAC-clone RP1-80K22 on 
one chromosome arm only (Figure 4B). This pattern is compatible with the amplification of 




Figure 4. Detection of small aberrations in MYC and CDKN2A/CDKN2B loci. A: Array-CGH showed 
a high level of amplification. The amplified region of was about 700kb in size involving the MYC locus 
on the long arm of chromosome 8. Arrows point out an enlargement of the CMYC locus. B: Interphase 
FISH verification using centromere 8 specific probe (green) and MYC locus specific BAC probe (red) on 
the corresponding dFFPE section. The red arrow indicates signals of the amplified MYC locus and white 
arrow points to the normal locus. C: Array-CGH result of a case with homozygous deletion. The estimated 
size of the homozygous deleted area was about 600kb involving the CDKN2A/CDKN2B loci on the 
short arm of chromosome 9. Arrows point out the region of the homozygous deletion, containing the 
CDKN2A/CDKN2B loci.




We have established and successfully applied a robust protocol to study heavily degraded 
DNA, obtained from decalcified FFPE samples, collected from various institutions using an 
oligonucleotide-based chip platform. Both formic acid based decalcification and fixation with 
non-buffered formalin solution similarly degrade tissue DNA. As the average fragment length of 
the DNA obtained from these samples is often less than 200 bps, these are regarded as unsuited 
for further molecular DNA testing [4,5,9]. In this study we used oligonucleotide based array 
chips containing reporter elements of ~60 bps. For optimal hybridisation the fragment length 
of the labeled DNA sample should be similar in size as the reporter elements (60-150 bps) [3]. 
Because enzymatic labelling is introducing further fragmentation during labelling, we applied 
the Universal Linkage System (ULS) labelling technology, which is a direct chemical labelling, 
without introducing further fragmentation [9,10]. In addition, we compared the ULS labelling 
system to a commercially available random primer (RP) labelling kit especially developed for 
FFPE tissue derived DNA. The overall reproducibility of the two FFPE labelling systems tested 
was excellent (Figure 2). With both kits we were able to obtain good results using 500 ng of 
starting material in contrast to the 1 μg DNA recommended by the vendors. The RP labelling 
has the benefit of amplifying the samples during the labelling reaction. By using as little as 
150 ng degraded dFFPE DNA template for the reaction, we obtained similar results to using 
500 ng (Figure 2B). However, further reduction of the starting material, especially in cases 
with discrepancies between estimated DNA concentrations in different measuring methods, 
resulted in poor results. The use of less than 500 ng DNA for ULS labelling resulted in too weak 
signals and is therefore not recommended. Samples labelled with the RP kit showed higher 
fluorescence intensities after scanning as compared to the ULS labelled samples. However, the 
overall variance of the log2 ratio distribution of the signal was higher as compared to the ULS 
system (Figure 3A, B). For one case (Nr 10), we had access to both frozen and dFFPE samples. 
By comparing three kinds of labelling systems a good correlation was observed between all 
labelling systems and samples (Figure 3, Table 3). We showed that, irrespective of the fragment 
size of the DNA, all samples with sufficient quantity were eligible for testing. Since correctly 
estimated DNA oncentration is more critical for successful testing than the quality of the 
DNA (i.e. fragment size), DNA concentrations were established by using two independent 
approaches. For some samples we observed discrepancies between the absorption-based DNA 
concentration measurement and the estimation based on ethidium bromide stained gel imaging. 
In general, the absorption based system tends to overestimate the final DNA yield resulting in a 
suboptimal amount for testing (Figure 1). This observed difference might, in part, be explained 
by the presence of negatively charged matrix glycoproteins such as chondroitin 4-sulphate, 
chondroitin 6-sulphate and keratan sulphate in some of the tumour samples. Some of these 
matrix glycoproteins may have similar charges as DNA and consequently could bind to the 
purification columns when the total DNA content of the sample was low. None of the used 
labelling systems gave reliable array profiles in cases with high over estimates of concentration. 
In these cases, in addition to the low DNA concentration, other factors might interfere with 
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the labelling reaction and could be responsible for the failure. The low amount of DNA might 
be compensated for by a whole genome amplification step using DOP-PCR, GenomePlex 
or Phi29 polymerase based reactions. However, it has been shown by others that when using 
good quality FFPE samples, DOP-PCR results in amplification biases and GenomePlex was 
suitable in only 58% of the analysed cases [9,11]. The use of multiplex PCR based pre-screening 
of FFPE samples may be used to select samples, however, it is noteworthy that most of our 
samples were degraded beyond the exclusion limits of those QC reactions and would not 
provide a good prediction [4,5,9]. There are several reports using FFPE samples for genomic 
profiling either on BAC array [4], oligonucleotide based array or the Illumina Golden Gate 
SNP array systems [6,12,13]. The Golden Gate system has a relatively low resolution consisting 
of approximately 6000 SNP reporter elements with an average physical distance of about 500 
kb. Due to the increased variation of signal ratio values, extensive smoothing steps (i.e. averaging 
of multiple probes for a given segment) are routinely applied to even out these variations. In 
turn, the overall resolution of these platforms decreases and most of the changes reported will 
concern whole chromosome arms or chromosome regions over at least 15-20 Mb in size. In 
contrast to these limitations, the procedure we established readily detected both homozygous 
deletions and high level of amplifications of 0.6 and 0.7 Mb in size, respectively (Figure 4).
Conclusions
We developed a reliable DNA isolation and labelling procedure using decalcified, formalin-fixed, 
paraffinembedded tissue from various clinical specimens. Using two independent techniques 
(gel-based and absorptionbased), we showed that the estimation of DNA concentration is a 
more critical step in sample quality assessment than DNA quality (assessed by the degree of 
fragmentation). In our assessment, both the directchemical-labelling-based ULS kit and the 
modified random-prime labelling kit worked equally well.
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Molecular genetic studies on vascular tumors are rare. Recently, possible involvement of MYC 
and KDR has been documented in a subset of angiosarcomas of soft tissue. We performed 
a cytogenetic analysis of primary angiosarcomas of bone (n=13) and soft tissue (n=5) using 
high density array-Comparative Genomic Hybridization (array-CGH). Regions of interest 
were validated by Fluorescence In Situ Hybridization (FISH). Antibodies for candidate genes 
(SKI, MYC, KDR, and MAPK9) were selected and immunohistochemistry was performed. Six 
angiosarcomas of bone and four angiosarcomas of soft tissue showed chromosomal losses, gains 
and high level of amplifications. Cluster analysis identified two groups: a group with a complex 
genetic profile and a group with only few genetic aberrations. Five regions of interest were 
selected, which were located at chromosomes 1p36.23, 2q32-34, 5q35, 8q24 and 17q21.32-
24.2. Interphase FISH confirmed the high-level of amplifications. Immunohistochemical 
analysis showed high expression of MYC, MAPK9 and SKI in 26%, 95% and 83%, of the 
tumors, respectively. There were no differences between the two groups with regards to location, 
immunohistochemical expression nor survival. In summary, we identified two subgroups of 
angiosarcomas: those with few or no gross aberrations and those which show numerous genetic 
aberrations consisting of chromosomal losses, gains and high level of amplifications or complex 
aberrations. The most common finding was amplification of 2q and 17q in both angiosarcoma 
of bone and soft tissue, suggesting overlap in tumorigenesis irrespective of their location. We 
show MYC amplification in primary angiosarcoma indicating this is not entirely specific for 
radiation induced angiosarcoma.




Angiosarcoma is a rare malignant neoplasm composed of cells that demonstrate endothelial 
differentiation, accounting for less than 1% of all sarcomas (Fletcher et al., 2013; Weiss and 
Goldblum, 2008). The exact mechanism of tumorigenesis still remains unclear. However, one 
presumes that these tumors may arise from normal endothelium or at least cells with features 
of normal endothelium (Fletcher et al., 2013; Manner et al., 2010). Angiosarcoma occurs most 
frequently at the skin in the head and neck region, however it can arise at any anatomical site 
including the viscera and deep soft tissue (Fletcher et al., 2013; Weiss and Goldblum, 2008). 
Angiosarcoma primary of bone is extremely rare (Dorfman et al., 1971; Huvos, 1991; Mulder 
et al., 1993), and has a tendency to occur multifocal and has a more aggressive course(Verbeke 
et al., 2011; Vermaat et al., 2011). Thus, angiosarcomas are heterogeneous at the clinical and 
morphological level. Recent studies have suggested that this heterogeneity might be based 
on a different underlying molecular mechanism associated with the anatomical site of the 
tumor. KDR mutations are seen in angiosarcoma of the breast whereas high-levels of MYC 
amplification, with or without co-amplification of FLT4, are seen in secondary angiosarcoma 
after irradiation or chronic lymphedema (Antonescu et al., 2009; Guo et al., 2011; Manner et 
al., 2010).
Sarcomas are divided in two main categories based on their genetic abnormalities: i) tumors 
with a near-diploid karyotype and simple genetic alterations, such as specific translocations (e.g. 
synovial sarcoma) and mutations (e.g. gastro-intestinal stromal tumor sarcoma), which cause 
transcriptional deregulation or altered signaling and ii) tumors with complex and unbalanced 
karyotypes (e.g. osteosarcoma) (Borden et al., 2003; Helman and Meltzer, 2003; Taylor et al., 
2011). To date, only a few number of angiosarcomas, mostly of soft tissue, have been genetically 
studied. To this point, only complex karyotypes and no recurrent chromosomal alterations 
have been described in angiosarcoma of soft tissue (Baumhoer et al., 2005; Cerilli et al., 1998; 
Fletcher et al., 1991; Gil-Benso et al., 1994; Kindblom et al., 1991; Schuborg et al., 1998; Van den 
Berg et al., 1994; Wong et al., 2001; Zu et al., 2001). It is therefore suggested that angiosarcomas 
belong to the group of sarcomas with a complex genetic profile (Helman and Meltzer, 2003). 
However, it may be that tumors lacking chromosomal genetic alterations were not reported, 
resulting in a biased representation of the literature. Dunlap and colleagues reported the first 
cytogenetic aberration in angiosarcoma of bone. They identified a unique clonal chromosomal 
rearrangement t(1;14)(p21;q24) in a primary angiosarcoma of the tibia, although a germline 
translocation was not excluded here (Dunlap et al., 2009). Here we report the first series of 
primary bone angiosarcomas with full molecular characterization. Our aim was to elucidate 






Twenty five tumor samples (from 22 patients), either frozen or formalin-fixed paraffin-
embedded (FFPE) material, with the diagnosis of angiosarcoma of bone were collected from 
the archives of the departments of Pathology of the Rizzoli Institute, Bologna, Italy (20 tumors, 
all FFPE material), University Hospitals Leuven, Leuven, Belgium (one tumor, frozen material), 
and Leiden University Medical Center, Leiden, the Netherlands (four tumor samples from one 
patient with multifocal disease, frozen material). Six tumor samples of angiosarcoma of soft 
tissue (from six patients) were collected from the archives of the department of Pathology of 
University Hospitals Leuven, Leuven, Belgium (three tumors, both frozen and FFPE material) 
and Leiden University Medical Center (three tumors, frozen or FFPE material) for comparison. 
The cases were originally diagnosed between 1964 and 2008. All clinical, radiodiagnostical and 
pathological data were reviewed, as described previously (Verbeke et al., 2011). All tumor samples 
were originally revised by 3 pathologists (Verbeke et al., 2011) and included in this study when 
the tumor had a clear-cut histology and tumor cells stained at least for one endothelial marker. 
Based on the histology (epithelioid hemangioma (n=1), epithelioid hemangioendothelioma 
(n=1), or other diagnosis (n=2) such as epithelioid sarcoma) and/or the presence of a disease 
specific genetic aberration (n=1; Ewing-like sarcoma with EWSR1-NFATc2 amplification) five 
tumor samples (from five patients) were excluded, leaving 20 tumor samples of angiosarcoma 
of bone (from 17 patients) and six tumor samples from angiosarcoma of soft tissue (from six 
patients). All specimens were handled according to the ethical guidelines described in “Code 
for Proper Secondary Use of Human Tissue in the Netherlands” of the Dutch Federation of 
Medical Scientific Societies.
Tissue microarray (TMA) construction
Four TMAs were assembled from formalin-fixed, paraffin embedded tissue using standard 
procedures (Verbeke et al., 2011) using a 2 mm-diameter punch (3DHistech Ltd., Budapest, 
Hungary; 3 TMAs) or a 0.6 mm-diameter punch (Beecher Instruments, Silver Spring, MD, 
USA; 1TMA) as previously extensively described (Verbeke et al., 2011; Verbeke et al., 2013) 
containing 42 angiosarcomas of bone and 19 angiosarcomas of soft tissue. Using a tape-transfer 
system (Instrumedics, Hackensack, NJ, USA), 4-μm sections were transferred to glass slides.
DNA isolation
DNA was isolated from 20 angiosarcomas of bone and six angiosarcomas of soft tissue, as 
described previously (de Jong D. et al., 2011). Four μm consecutive sections were cut, either 
from frozen tissue and/ or FFPE, and stained using standard hematoxylin and eosin (HE) to 
confirm a tumor content of at least 70%. DNA concentrations were measured using a Nanodrop 
ND-1000 spectrophotometer and quality was checked after electrophoresis separation using a 
1% agarose gel stained with ethidium bromide.




From case L2258, a multifocal angiosarcoma, life cells were available after surgical intervention 
(amputation). Tumor samples were collected from five different sites and samples subjected 
to short term culture followed by chromosome harvesting according to protocols described 
(Szuhai et al., 2009). Metaphase cells were obtained from three samples (annotated as L2258 A, 
D and E) and subjected to multicolor COBRA-FISH karyotyping analysis as described earlier 
(Szuhai and Tanke, 2006).
Array-CGH analysis
ULS labeling of DNA, derived from decalcified FFPE tissue sections, was performed as 
previously described (de Jong D. et al., 2011) using the Agilent Oligo array-CGH Labeling Kit 
for FFPE Samples (Agilent Technologies, Santa Clara, CA). Labeling of DNA, derived from 
frozen tissue sections, was done using the BioPrime Total Genomic Labeling System (Invitrogen 





 (Cy3) and A
649
 (Cy5). As a reference, DNA 
from a commercial source (Promega Corporation, Madison, WI) was used. Labeled test and 
reference samples were mixed and hybridized as a gender mismatch to show dynamic range of 
hybridization on the X and Y chromosomes. Hybridization was performed on an Agilent 4x44k 
oligo array at 65°C for 40 hours. Slides were washed with Oligo array-CGH Wash Buffer 1 at 
room temperature for 5 min followed by a 1 min wash with Oligo array-CGH Wash Buffer 
2 at 37°C. Finally, slides were dried without using the stabilization and drying solution. Slides 
were scanned using Agilent Scanner with 5μm scan resolution. Scan images were processed 
with the Feature Extraction Software and analyzed by using Genomic Workbench (Agilent 
Technologies, Santa Clara, CA) and data was deposited via CanGEM (Scheinin et al. (2008) 
Nucleic Acids Research 36:D830-D835). Altered regions were calculated using the array-CGH 
analysis tool in Chipster v1.4.6 (http://chipster.csc.fi/). The minimum number of probes per 
called segment was 5. To identify common regions the maximum amount of information loss 
allowed was 0.01, as described by van de Wiel et al (van de Wiel and Wieringen, 2007). Samples 
were divided into 2 groups, angiosarcoma of bone (black) and angiosarcoma of soft tissue (red) 
to see if these would cluster together in the wecca (weighted clustering of called array-CGH 
data) plot (Figure 1A).
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6 Figure 1A. Weighted clustering of called array-CGH data (WECCA) for the individual samples. The 
samples are divided into two groups: angiosarcoma of bone in black and angiosarcoma of soft tissue in red. 
On top the clustering is depicted of these groups. The green and grey bars on the left represent different 
chromosome segments with their called aberrations. Called losses are shown in red, gains in blue, and 
unaltered regions in black. Note that the size of a displayed chromosome is proportional to the size of 
the called region and not to the actual size; 1B. Amplification of the MYC gene locus (detected in red) 
was confirmed by FISH on L2134. In green the centromeric region of chromosome 8 is detected; 1C. 
High level amplification of chromosomes 2q31.1and 17q23.2 and a co-localization of the two probes was 
observed in L2138.
Confirmatory Fluorescence In Situ Hybridization (FISH)
Based on the array-CGH results, interphase FISH using region specific BAC clones on the tissue 
samples and the TMAs was performed to confirm the results. In short, slides were deparaffinized 
for 2 x 10 min in xylene, following dehydration and 30 min incubation in NaSCN at 90°C. After 
washing with PBS slides were treated for 30 min with 0.4% pepsin. Slides were washed with 
PBS, dehydrated and air-dried. To confirm some of the array-CGH results, two-color interphase 
FISH experiments were done. A BAC-clone (RP1-80K22) located at 8q24.21 covering the 
MYC gene locus (detected in red) in combination with an alpha satellite probe specific to the 
centromeric region of chromosome 8 (detected in green) was used as described earlier (Rossi et 
al., 2007). In order to validate the amplification of 2q31.1 and 17q23.2 in L2138, BAC-clones 
were used covering these regions. RP11-472A3 (detected in green) was located on 2q31.1 and 
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RP11-651H20 (detected in red) was located on 17q23.2. After validation of the amplification 
on whole sections from the two respective cases, these probes were also hybridized on the 
TMAs. All evaluable nuclei of the tissue cores were examined.
Immunohistochemistry
Based on the array-CGH results, antibodies for some candidate genes (SKI, MYC and MAPK9) 
were selected and immunohistochemistry was performed on the TMAs. Because KDR (kinase 
insert domain receptor, a.k.a. VEGFR2) mutations were described in primary angiosarcoma of the 
breast (Antonescu et al., 2009), the KDR immunoreactivity was also analyzed on the TMAs. 
Immunohistochemical reactions were performed according to standard laboratory methods 
(Pansuriya et al., 2011). For each antibody a positive and negative external control was included. 
The antibodies, their sources, antigen retrieval methods, dilutions, positive and negative external 
controls used are documented in Table 1. As negative control, sections were stained without 
adding the primary antibody. The intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong) 
and percentage of positive neoplastic cells (0 = 0%, 1 = 1-24%, 2 = 25-49%, 3 = 50-74%, 4 = 
75-100%) were evaluated. Lost tissue cores were excluded from the analysis. As decalcification 
could compromise the immunohistochemical result, we attempt to counteract this phenomenon 
by excluding the tissue samples in which an expected positive internal control was negative and 
tissue samples without a positive internal control that were negative for multiple antibodies. The 
sum of intensity and percentage was used for analysis.
Table 1. List of antibodies used for immunohistochemical analysis
Antibody Clone Dilution AR Blocking Source Positive control
c-MYC Y69 1:8000 EDTA - Epitomics Burkitt lymphoma
MAPK9 1:2000 Citrate - Abcam Breast carcinoma
SKI 1:6000 Citraat NGS 10% Bioconnect Kidney
KDR 55B11 1:125 EDTA - Cell Signaling Tonsil
Results
Patient Characteristics
Patient characteristics of both angiosarcoma of bone and soft tissue are summarized in Table 2.
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Table 2. Summary of clinicopathological characteristics of all angiosarcoma of bone and soft tissue
Sample ID F/FFPE* Age/sex Diagnosis Primary localisation
L2129 F 46/F Multifocal epitheloid angiosarcoma Bone - foot
L2258 F 39/F Multifocal angiosarcoma Bone - foot
L4089 FFPE 41/M Angiosarcoma Bone - metacarpal bone
L4091 FFPE 59/M Angiosarcoma Bone - femur
L4093 FFPE 72/M Angiosarcoma Bone - pubic bone
L4094 FFPE 56/M Angiosarcoma Bone - femur
L4095 FFPE 60/M Angiosarcoma Bone - femur
L4096 FFPE 35/M Angiosarcoma Bone - tibia
L4097 FFPE 74/F Angiosarcoma Bone - femur
L4098 FFPE 32/M Angiosarcoma Bone - sacrum
L4099 FFPE 54/F Angiosarcoma Bone - tibia
L4100 FFPE 54/M Angiosarcoma Bone - femur
L4103 FFPE 52/M Angiosarcoma Bone - femur
L2134 F/FFPE 79/F Angiosarcoma Soft tissue - leg
L2138 F/FFPE 67/M Angiosarcoma Soft tissue - retroperitoneum
L2165 F 37/M Angiosarcoma Soft tissue - heart
L2369 F 31/M Angiosarcoma Soft tissue - muscle arm
L4104 FFPE 42/F Angiosarcoma Soft tissue - spleen
F: frozen; FFPE: formalin-fixed paraffin-embedded
Array-CGH analysis
Twenty tumor samples of angiosarcoma of bone and six tumor samples of angiosarcoma of 
soft tissue were analyzed on a 44K oligonucleotide array chip (Agilent). However due to bad 
DNA quality the array-CGH failed in seven tumor samples of angiosarcoma of bone (from 5 
patients) and in one tumor sample of angiosarcoma of soft tissue (from 1 patient). Alterations 
were observed in 6 out of 13 angiosarcomas of bone and 4 out of 5 angiosarcomas of soft 
tissue, varying from full complex genetic profiles with random gains and losses of whole 
chromosomes (2 angiosarcomas of bone: L4093 and L4099; and 2 angiosarcomas of soft tissue: 
L2165 and L4104) to tumors showing only smaller altered regions (2 angiosarcomas of bone: 
L4094 and L4098; and 2 angiosarcomas of soft tissue: L2134 and L2138). Two tumors (L2129 
and L4097, both angiosarcoma of bone) only showed a single chromosome gain as aberration. 
Seven angiosarcomas of bone (L2258, L4089, L4091, L4095, L4096, L4100 and L4103) and one 
angiosarcoma of soft tissue (L2369) did not show any alterations, despite a percentage of tumor 
cells >70%. Cluster analysis demonstrated two distinct subgroups of angiosarcoma: one group 
of tumors with a complex genetic profile and a second group with only few genetic aberrations 
or a normal genetic profile (Figure 1A).
Alterations found in more than 25% of the cases were considered as recurrent genomic changes. 
However, none of the genomic alterations reached the 25% cut off. An overview of all genomic 
changes and wecca plots of all analyzed samples are shown in Figure 1A. Cluster analysis did not 
show a genetic difference between angiosarcoma of bone and soft tissue, indicating the absence 
of a genomic pattern specific for either bone or soft tissue angiosarcoma.
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High level of amplifications/ homozygous deletions
High level of amplification was observed in two angiosarcomas of bone (L4094 and L4098) at 
2q31.1 and at 17q23.2 (Table 3). Also in one angiosarcoma of soft tissue (L2138), amplicons 
located in these regions were observed (Table 3). The minimal common region on chromosome 
2 includes several genes (listed in Table 3). The amplicon on chromosome 17 harbors even 
more genes (amongst others USP32, listed in Table 3). One angiosarcoma of soft tissue (L2134) 
showed high level amplification at region 5q35 (Table 3), which includes the MAPK9 gene, and 
an amplicon at region 8q24.2, containing the MYC gene (amongst others). One angiosarcoma 
(L2165) of soft tissue showed an amplicon at region 1p36, containing the SKI gene (Figure 1A 
and Table 3). In two cases a homozygous deletion of the CDKN2A/CDKN2B locus was found 
(L4093 and L4094). Start and end position of the critical minimal region of amplification and 
homozygous deletion are provided in Table 3. 
Multicolor (COBRA)-FISH karyotyping
In total 22 metaphase cells were analyzed, from L2258 A (12 metaphase cells), D (5 metaphase 
cells) and E (5 metaphase cells), respectively. All analyzed cells showed a seemingly normal 
karyotype, no balanced rearrangements were detected by this technique (data not shown). These 
results were in line with the array-CGH findings.
Confirmatory FISH
To confirm some of the array-CGH results, two-color interphase FISH experiments were done. 
The amplification of the MYC gene locus could be verified in case L2134 (Figure 1B), however, 
no other cases on the TMAs showed a MYC amplification. The amplification of 2q31.1 and 
17q23.2 was verified in L2138. Also a clear co-localization was observed between the two 
probes used, suggesting a more complex rearrangement in this tumor (Figure 1C) that leads 
to co-amplification of the joined genomic regions. Interphase FISH with these probes on the 
TMAs did not reveal a second case with similar amplification and co-localization pattern of 
the probes. Amplification of both probes was confirmed in two tumor samples that were also 
analyzed with array-CGH (L4094, L4098) (Data not shown).
Immunohistochemistry
Irrespective of the interphase FISH results, 18.5% (5/27) of the angiosarcomas of bone showed 
expression of c-MYC (sumscore ≥ 3) as compared to one third (11/33) of the angiosarcomas 
of soft tissue. An overview of the number of positive tumors and percentages for the different 
antibodies used on the TMAs is given in in Table 4. The majority of angiosarcomas of bone 
showed expression for MAPK9 (sumscore ≥ 3; 87.5%; 28/32) and SKI (sumscore ≥ 4; 85.1%; 
23/27). Also angiosarcoma of soft tissue showed a similar expression percentage for MAPK9 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4. Immunohistochemistry results of all analyzed angiosarcomas of bone and soft tissue present on 
the different TMAs.
Angiosarcoma of bone Angiosarcoma of soft tissue P-value
n % n %
c-MYC 5/27 18,5 11/33 33,3 ns
MAPK9 28/32 87,5 35/37 94,6 ns
SKI 23/27 85,1 29/35 82,9 ns
KDR 8/27 29,6 23/33 69,7 0,002
ns = not significant
As mutations in KDR were previously described in angiosarcomas of soft tissue, especially of the 
breast (Antonescu et al., 2009), we investigated whether KDR overexpression was also present 
in angiosarcoma of bone, and especially in the subgroup with relatively few genetic aberrations. 
The expression of KDR was significantly different (p = 0.002) between angiosarcoma of bone 
and soft tissue: Only 29.6% (8/27) of the angiosarcomas of bone showed overexpression of 
KDR (sumscore ≥ 6) as compared to more than two third (69.7%; 23/33) of the angiosarcomas 
of soft tissue. There was however no statistically significant difference in expression of KDR, 
nor of MYC, MAPK9, SKI, or any of the previously identified markers p53, p16, D2-40 and no 
difference in survival (performed previously (Verbeke et al., 2011; Verbeke et al., 2013)) between 
tumors with few genomic aberrations and tumors with complex genetic changes although 
numbers of cases in the different subgroups are very small (Table 5).
Table 5. Correlation of the cluster analysis, based on the array-CGH results, with present (SKI, KDR, 
MAPK9 and MYC) and previously (TP53, CDKN2A and D2-40) described immunohistochemical 
analysis and the relation with the corresponding survival data as published previously (Verbeke et al., 2011; 
Verbeke et al., 2013)
  Simple karyotype Complex karyotype P-value
Bone versus Soft Tissue 11 versus 3 2 versus 2
Range median overall survival (months) 2 - 207 4 - 49
TP53 overexpression 1/10 (10%) 0/3 (0%) 0,640
Lack of CDKN2A expression 4/10 (40%) 1/3 (33%) 0,793
D2-40 expression 6/8 (75%) 2/2 (100%) 0,429
MYC amplification 3/10 (30%) 1/3 (33%) 0,913
Overexpression of KDR 3/10 (30%) 1/3 (33%) 0,913
Expression of SKI 8/10 (80%) 2/3 (66%) 0,631
Expression of MAPK9 10/10 (100%) 3/3 (100%) -




We report the first large series of primary bone angiosarcomas with full molecular characterization, 
as cytogenetic studies of these tumors so far are limited to case reports (Dunlap et al., 2009). 
We previously demonstrated that the TGF-beta pathway is more active in angiosarcoma of 
bone compared to its soft tissue counterpart and that the PI3K/Akt pathway is involved in 
both angiosarcoma of bone and soft tissue, but through a different mechanism: decreased 
expression of PTEN in angiosarcoma of bone and overexpression of KIT in angiosarcoma of 
soft tissue (Verbeke et al., 2013). In the current study we show that there is no evident molecular 
genetic difference between angiosarcoma of bone and angiosarcoma occurring primarily in 
soft tissue (Figure 1A). This suggests that either alterations not detectable by array-CGH, or 
the microenvironment which differs between bone and soft tissue, may cause the previously 
detected differences in signaling pathways in angiosarcomas. Instead, we identified two different 
subgroups of primary angiosarcomas: one group of angiosarcomas with a complex genetic 
profile and a second group of angiosarcomas with only few genetic aberrations (Figure 1A). 
Since sarcomas with complex karyotypes usually have a defective Retinoblastoma (Rb) and/
or TP53 pathway (Helman and Meltzer, 2003; Perot et al., 2010), we questioned whether the 
angiosarcomas with complex changes also more often demonstrated alterations in the Rb and/
or TP53 pathway, results which were available from our previous immunohistochemical study 
(Verbeke et al., 2013). We described that the Rb pathway was disrupted in 55% of angiosarcomas 
of bone which was mainly caused by lack of protein expression of CDKN2A. Interestingly, only 
two of the 18 cases showed a detectable involvement of the CDKN2A/2B region (homozygous 
deletion in L4093 and L4094, one with a complex and one with a simple genetic profile, 
respectively) indicating the involvement of other mechanisms leading to the loss of CDKN2A 
protein expression. Angiosarcomas of bone showing lack of expression of CDKN2A had also a 
significantly worse prognosis (Verbeke et al., 2013). In contrast to angiosarcoma of soft tissue, the 
TP53 pathway seemed not important in angiosarcoma of bone (Verbeke et al., 2013). Here we 
show that there is no statistically significant difference in lack of CDKN2A protein expression 
nor TP53 overexpression between angiosarcomas with complex genetic alterations and those that 
are genetically more simple (Table 5). Interestingly, neither was correlation found with survival, 
location in bone or soft tissue, nor with expression of D2-40, a marker of lymphangiogenic 
differentiation which previously showed to be an indicator of aggressive behavior and worse 
prognosis (Table 5) (Verbeke et al., 2011).
It is interesting that a subset of angiosarcomas lacks genetic aberrations detectable at array-
CGH. Pre-analytic inaccuracies might be anticipated as we included tumor samples with a 
tumor percentage of 70% or more. As all cases were reviewed by three expert pathologists 
(Verbeke et al., 2011) and since both groups of tumors, with or without a complex genetic 
profile, showed a similar overall survival, misdiagnosis seems unlikely. Balanced genomic 
rearrangements, such as balanced translocations and inversions, and point mutations in the 
DNA are not detected by array-CGH. However, multicolor (COBRA)-FISH karyotyping did 
not detect any cytogenetically visible balanced rearrangements in case L2258 (A, D and E) 
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displaying multifocal lesions. Although this supports our array-CGH findings, the presence of 
cryptic structural rearrangements or point mutations cannot be excluded. We investigated the 
expression of KDR, which was shown to be mutated in angiosarcoma of soft tissue, especially 
the breast (Antonescu et al., 2009), and did not detect a higher number of cases with KDR 
overexpression in the angiosarcomas with simple karyotypes.
Previously, a clear genomic difference between primary angiosarcomas and angiosarcomas 
secondary to radiation or lymphedema was well documented (Guo et al., 2011). It was initially 
suggested that MYC amplification is a specific feature of secondary angiosarcomas (Guo et al., 
2011). MYC amplification was shown to upregulate the miR-17–92 cluster, which subsequently 
downregulates thrombospondin-1 (THBS1), a potent endogenous inhibitor of angiogenesis, 
and thereby mediating the angiogenic phenotype of angiosarcoma (Italiano et al., 2012).
We here report the presence of MYC amplification in one angiosarcoma of soft tissue (L2134) 
without any history of radiation therapy or chronic lymphedema. This is in line with recent 
studies also demonstrating the presence of MYC amplification in a small subset of non-
radiation induced angiosarcomas, primary cutaneous angiosarcomas and a subset of primary 
hepatic angiosarcomas(Ginter et al., 2014; Italiano et al., 2012; Shon et al., 2014). In addition 
to MYC, coamplification of FLT4 (encoding VEGFR3) at 5q35 was identified in 25% of 
secondary angiosarcomas, and not in other types (Guo et al., 2011). Our case (L2134) with 
MYC amplification also revealed a high level of amplification at region 5q, containing the FLT4 
and the MAPK9 (JNK2) gene. The protein JNK2 belongs to the JNK kinase family and in 
response to different stimuli, such as cytokines and growth factors, these proteins are activated 
by a series of phosphorylation events and subsequently activate several nuclear and non-nuclear 
proteins, including MYC, p53, and cell death regulators of the Bcl-2 family in the mitochondria 
(Bubici and Papa, 2014). Therefore, JNK signaling pathways do not only play a role in normal 
physiological processes, but are also involved in cancer pathogenesis (Bubici and Papa, 2014). 
Several studies have shown a potential role for JNK2 in tumor cell survival (Barbarulo et al., 
2013; Raciti et al., 2012). We demonstrated high protein expression of MAPK9 (JNK2) in 87-
94% of the angiosarcomas, irrespective of genomic amplification. This may be explained by the 
high expression of TGF-beta in angiosarcoma of bone that we previously identified (Verbeke 
et al., 2013), as TGF-beta can activate JNK2 (Galliher et al., 2006) thereby contributing to 
increased tumor cell survival. A potential role of JNK2 in angiogenesis has not been described 
yet.
Very recently, a next generation sequencing (NGS) approach revealed recurrent mutations in 
PTPRB in 26% of the analyzed cases with co-occurring PLCG1 mutations in 3 of those cases 
(Behjati et al., 2014). Interestingly, these mutations only occurred in either known secondary 
angiosarcomas and/ or angiosarcomas with a MYC amplification. These data again confirm that 
secondary and/or MYC amplified angiosarcomas should be regarded as a separate subgroup. 
Our study included only one such case, as we selected primary angiosarcomas. It would be 
interesting to subject these cases to NGS, however, the archival formic acid decalcified FFPE 
material is not suited for NGS yet.
Array-CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone
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One angiosarcoma of soft tissue (L2165) showed an amplicon at region 1p36. Amongst many 
other genes, this region contains SKI (Sloan Kettering Institute proto-oncoprotein). The Ski 
proto-oncogene (alternative name Proto-oncogene c-Ski or c-Ski) is involved in many signaling 
pathways (Bonnon and Atanasoski, 2012) and its most well-known function is to negatively 
regulate TGF-beta signaling. In this study we demonstrate that both angiosarcoma of bone 
and soft tissue show a high expression of Ski. This finding is consistent with a previous report 
of Ski expression in hemangiomas (TM et al., 2009). Interestingly, our previous findings show 
that the TGF-beta pathway is highly active in angiosarcoma especially in angiosarcoma of bone 
(Verbeke et al., 2013). Thus, despite high expression of Ski, TGF-beta signaling is not suppressed. 
Although the precise mechanism is unclear one could speculate that other mechanisms are 
operable overruling the suppression of TGF-beta signaling by Ski in angiosarcoma of bone, and 
that Ski may contribute to tumorigenesis through other mechanisms. It has been demonstrated 
that Ski can promote cancer progression and is highly expressed in different human solid 
tumors, e.g. leukemia, gastro-intestinal cancers and melanoma (Bonnon and Atanasoski, 2012; 
Wang et al., 2013). It has been suggested that overexpression of Ski plays a role in tumor growth 
and angiogenesis in diffuse type gastric cancer (Kiyono et al., 2009), however its exact role in 
angiogenesis remains unclear.
Although the threshold for recurrent aberrations was not reached, three cases showed a high 
level of amplification of chromosome 2q and chromosome 17q (Table 3). By gene amplification 
cancer cells are allowed to promote expression of genes that are involved in tumor development 
and progression. High level amplification of 17q23 is described in many tumor types (Andersen 
et al., 2002; Parssinen et al., 2007) and especially in breast carcinomas it is associated with tumor 
progression and poor prognosis (Andersen et al., 2002; Barlund et al., 1997; Isola et al., 1995; 
Parssinen et al., 2007). So far, the high level amplification of chromosome 2q32-34 has not been 
described. Both amplified regions contain a large number of possible candidate genes (Table 
3). To date, multiple genes have been proposed that could play a role in tumor development 
and progression (Parssinen et al., 2007). It has been hypothesized that not a single target gene 
is responsible for, or contributes to, tumor pathogenesis, but the simultaneous overexpression of 
multiple genes could lead to growth advantages of cancer cells (Parssinen et al., 2007).
In conclusion, we report the molecular genetic characterization of the first series of primary 
angiosarcoma of bone, in comparison to soft tissue. We identified two different subgroups: one 
group of angiosarcomas with a complex genetic profile and a second group of angiosarcomas 
with only few genetic aberrations: mainly high level amplifications. No evident molecular 
difference was found between both angiosarcoma of bone and soft tissue. We confirm that 
although MYC amplification first was described in radiation therapy and chronic lymphedema 
associated angiosarcomas, it can occur in a subset of primary angiosarcomas and is therefore 
not entirely specific for radiation induced angiosarcoma. Moreover, our data indicate that 
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Hemangiopericytoma (HPC) was first described as a neoplasm with distinct morphologic 
features, presumably composed of pericytes. In soft tissue, it is accepted that most such lesions 
are solitary fibrous tumors (SFTs), monophasic synovial sarcomas (SSs) or myofibromatoses. 
It is unclear whether HPC of bone exists. We reviewed nine primary “HPC” of bone from 
4 institutions diagnosed between 1952 and 2002. Immunohistochemistry was performed for 
CD31, CD34, von Willebrand factor, smooth muscle actin, keratin AE1/AE3 and epithelial 
membrane antigen. There were 4 male and 5 female patients between 21 and 73 years. All 
tumors were located within bone, either sited within spine or extremities. All tumors showed 
thin-walled branching vessels surrounded by undifferentiated spindle or round cells. These cells 
showed variation in their morphologic pattern: 6 tumors showed a pattern-less architecture 
and varying cellularity, consistent with SFT; 3 of 5 cases examined were CD34-positive. 
Three tumors showed more densely packed sheets and fascicles of poorly differentiated cells, 
resembling SS, of which 2 showed focal staining for keratin AE1/AE3 or epithelial membrane 
antigen. Fluorescent in-situ hybridization confirmed the presence of SS18 rearrangement 
in 1 of 2 tumors examined. In conclusion, similar to their soft-tissue counterpart, HPC-like 
features in bone are a non-specific growth pattern rather than a true diagnosis. We confirm the 
existence of 2 entities: SFT and SS of bone. Both are characterized by distinct morphology and 
immunohistochemical profile. SFT of bone is located within spine and has a better prognosis, 
whereas SS of bone is located within long bones having a poor prognosis.




Hemangiopericytoma (HPC) was first described as a type of vascular tumor by Stout and 
Murray in 1942.29 It was suggested that these lesions were derived from Zimmerman’s pericytes, 
so-called modified smooth muscle cells.29 Histologically, this tumor was characterized by 
endothelial-lined tubes or endothelial sprouts surrounded by rounded or spindle-shaped cells 
typically supported by a meshwork of reticulin fibers.29 Originally, this tumor was primarily 
described within soft tissue, but over the years investigators reported occasional cases occurring 
as solitary lesions within the bone as well.
For many years, HPC was a generally accepted histologic entity, although the diagnosis was 
merely based on its architectural pattern. However, Fletcher8 and others investigators13,23 showed 
that many soft tissue tumors could mimic a HPC-like growth pattern, including, among others, 
lesions such as synovial sarcoma (SS) and mesenchymal chondrosarcoma, and therefore, stated that 
HPC should be regarded as a nonspecific growth pattern instead of a true histologic diagnosis. 
This is, however, a controversial issue.7 Electron microscopy showed pericytic differentiation in 
only a minority of cases diagnosed as HPC.5 Basal lamina-like materials, cytoplasmic processes, 
cytoplasmic filaments, discrete basal lamina, and poorly formed intercellular junctions were 
the most frequently found features in these lesions and some soft tissue pathologists have used 
the presence of basement membrane at electron microscopy to distinguish HPCs from solitary 
fibrous tumor (SFT).5
Since the era of immunohistochemistry, true pericytic differentiation could not be confirmed in 
the majority of the cases4,20,28 and on the basis of the immunohistochemical profile, a subgroup 
of HPCs could be reclassified as infantile myofibromatosis.8,19 Furthermore, the majority of so-
called HPCs seemed to be indistinguishable from SFTs, a spindle-cell tumor most commonly 
arising in the pleura although extrapleural locations are now extensively described,19 leading to 
a substantial overlap between both entities. 
Today, HPC is no longer recognized in the 2002 World Health Organization Classification 
of Soft Tissue and Bone Tumors, and as stated, so-called HPCs of soft tissue should be better 
classified as typically rather cellular examples of SFT.9, 10 However, it is not clear whether HPC 
of bone represents a true, separate entity or is comparable with its soft-tissue counterpart, and 
should be regarded as a nonspecific growth pattern and therefore reclassified as, for example, 
SFT of bone. We collected a series of cases diagnosed as HPC of the bone between 1952 
and 2005 in 4 different bone tumor referral centers with the goal of reviewing the histology 
and radiology. Immunohistochemistry and Fluorescent in-situ hybridization (FISH) were 
performed to investigate whether HPC of the bone is a distinct entity, or, similar to its soft-tissue 
counterpart, represents a growth pattern that can be observed in SFT, SS or myofibromatosis 




Clinico-pathologic Data and Histologic Review
Sixteen tumors (from 16 patients) diagnosed as HPC of bone were collected from the archives 
of the departments of pathology of the Rizzoli Institute, Bologna, Italy (8 tumors), The 
Netherlands Committee on Bone Tumours (4 tumors), Rigshospitalet, Copenhagen, Denmark 
(2 tumors) and The Royal National Orthopaedic Hospital, London, UK (2 tumors). The cases 
were originally diagnosed between 1952 and 2005. All clinical, radiologic and pathologic data 
were reviewed. All tumor samples were reviewed by three pathologists (J.V.M.G.B., P.C.W.H. 
and C.D.M.F.) who were blinded towards any clinical data except for age, sex, and affected bone. 
Only cases with delicate, thin-walled branching blood vessels with a staghorn-like architecture 
surrounded by non-atypical, round to spindle-shaped cells with uniform, bland nuclei were 
included in the study. As 2 tumors did not show this true HPC-like growth pattern, they 
were excluded from this study. Furthermore, tumors were excluded when no tissue blocks 
were available (2 cases), the histologic appearance was too badly preserved due to heavily 
decalcification (2 cases) or a primary meningeal HPC had been documented prior to the bone 
lesion (1 case). Nine remaining cases were included in the study (Table 1). All specimens were 
handled according to the ethical guidelines described in “Code for Proper Secondary Use of 
Human Tissue in the Netherlands” of the Dutch federation of Medical Scientific Societies.





Location Therapy LR Metastases LFU 
(y)
Status
1 F, 21 sacrum curettage - - 5 NED
2 M, 40 sacrum resection - lung, bone, after 3y 5 NED
3 M, 50 vertebra Th12 resection yes, after 15, 17, 19 and 20y lung, liver, ST, after 21y 22 DOD
4 M, 44 humerus resection yes, after 4, 5 and 20y lung, after 20y 13 NED
5 F, 73 fibula amputation - lung, after 0.25y 1.5 DOD
6 F, 31 vertebra L4 resection - - 4 NED
7 M, 44 sacrum chemo+radiation - - 7 DOD
8 F, 21 humerus resection - lung, after 6y 7 DOD
9 F, 55 sacrum radiation - - 11 NED
Case No.: case number; F: female; M: male; LR: local recurrence; y: years; ST: soft tissue; LFU (y): length 
follow-up in years; DOD: death of disease; NED: no evidence of disease.
Radiology
All available radiologic data were reviewed. In one case, radiologic data was not accessible any 
more. In one patient only a magnetic resonance imaging scan was available and therefore the 
imaging was suboptimal for radiologic evaluation.




Formalin-fixed, paraffin-embedded tissue (FFPE) was available for all tumors and 
immunohistochemistry was performed for CD31, CD34, von Willebrand factor, smooth muscle 
actin (SMA), keratin AE1/AE3, and epithelial membrane antigen (EMA). For each antibody a 
positive and negative control was included. Immunohistochemical reactions were performed 
according to standard laboratory methods.3 The antibodies, their sources, antigen retrieval 
methods, and dilutions used are documented in Table 2. Immunoreactivity was evaluated as 
focal positive, diffuse positive or negative.
Table 2. Antibodies Used for Immunohistochemical Analysis
Antibody Clone Dilution AR Source + & - control
CD31 JC70A 1:10000 Citrate Dakocytomation Tonsil
CD34 QBEnd/10 1:30000 - Neomarkers Tonsil
Cytokeratin AE1/AE3 - 1:500 Citrate Neomarkers Colon
Epithelial membrane antigen E-29 1:10000 Citrate Dako Tonsil
Smooth muscle actin ASM-1 1:8000 - Progen Colon
Von Willebrand factor - 1:8000 Citrate Dako Tonsil
AR: antigen retrieval; + & - control: positive and negative control.
FISH
FISH was performed on paraffin-embedded 4 μm sections of tumor tissue of all patients 
according to previously described standard laboratory methods.27 A 10μL Locus Specific 
Identifier SS18 (SYT) probe (Vysis, Inc, Downers Grove, IL) was used. Tissue from 2 tumors 
was repeatedly lost during this process; therefore, nuclei were isolated from the FFPE material 
according to standard laboratory methods.17 Fluorescence signals were analyzed using a Leica 
DM RXA fluorescence microscope (Leica Mikroskopie & Systeme GmbH, Wetzlar, Germany) 




Based on histology, 2 principal morphologic patterns were recognized (Fig. 1). Six tumors 
demonstrated a pattern-less architecture and varying cellularity (hypo- and hypercellular areas) 
(Fig.1A). These tumors consisted of monomorphic, round to spindle-shaped tumor cells (Fig. 
1B). All tumor cells had uniform, bland nuclei and limited amounts of palely eosinophilic 
cytoplasm with indistinct cell borders. None of the 6 tumors showed nuclear overlapping. 
Five tumors had less than 4 mitoses per 10 high-power fields (HPF) and only 1 tumor had 5 
mitoses/10 HPF. This pattern closely resembled SFT of soft tissue.10 In contrast, 3 tumors were 
characterized by a more fascicular arrangement of quite uniform nonpleomorphic spindle-
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shaped tumor cells (Figs. 1G, H). The tumor cells had a sparse amount of cytoplasm, indistinct 
cell borders, and showed sometimes overlapping nuclei. The mitotic activity ranged from 3 
to 5 mitoses/10 HPF. Necrosis was not seen. This pattern resembled monophasic SS of soft 
tissue.10 The cases and their suggested diagnosis based on histomorphology are listed in Table 
3. No distinctive “grungy” calcified matrix, fat, or osteoclasts were seen which would suggest 
phosphaturic mesenchymal tumor.11
Figure 1. The 2 principal morphologic patterns that are recognized: solitary fibrous tumor-like tumor 
showing a varying cellularity and a monomorphic tumor cell population [(A-B) haematoxylin and eosin 
staining; scale bar: 50μm; case number 2] and SS-like tumor showing a fascicular arrangement of non-
atypical, spindle-shaped tumor cells [(G-H) haematoxylin and eosin staining; scale bar: 50μm; case number 
5], and their corresponding immunohistochemical profile as listed in table 3: (C, I): CD34; (D, J): EMA; (E, 
K): keratin AE1/AE3; (F, L): SMA (scale bars: 50μm). Inset in (K): SS18-fluorescent in-situ hybridization 
showing a break-apart of the probes and confirming the diagnosis of SS. SS indicates synovial sarcoma.




























































































































































































































































































































































































































All clinical data are summarized in Table 1. Tumors morphologically resembling SFT of bone 
had a wide age distribution, ranging from the third till the sixth decade (range: 21 to 55y; 
median: 42y) and an equal sex distribution (3 males and 3 females). Tumors morphologically 
resembling SS of bone had an age distribution ranging from the second till the eighth decade 
(range: 21 to 73y; median: 44y). There were 2 females and 1 male.
Radiologic Appearance and Localization
All patients presented with a solitary, osteolytic bone lesion with a geographic or moth-eaten 
pattern of bone destruction. Furthermore, in all 7 tumors, for which conventional radiology 
was available, cortical disruption and extension into the adjacent soft tissue was present. In all 
tumors, the bulk of the tumor mass was located within the bone and the majority of tumors 
showed only limited extension into the soft tissue, in keeping with a primary bone tumor with 
soft tissue extension rather than a soft tissue tumor with bone invasion (Fig. 2). In only 2 of 6 
SFT-like tumors, small areas of mineralization were seen, suggestive of residual pre-existent bone 
fragments rather than mineralization by the tumor itself, whereas 1 of 2 SS-like tumors showed 
focal mineralization. However, none of these radiologic criteria were characteristic for either 
SFT or SS-like tumors.
All SFT-like tumors were located within the spine: either the sacrum (4 tumors), the lumbar 
spine (1 tumor), or the dorsal spine (1 tumor). Both vertebral tumors were located within 
the corpus of the vertebra and showed expansion into the arch and an adjacent vertebra. All 
SS-like tumors were located in the extremities, especially the long tubular bones, without any 
predilection for diaphysis, metaphysis, or epiphysis. Clinically and radiologically, there were no 
signs of osteomalacia or any other metabolic bone disorder.
Patients Follow-up
In all patients, follow-up data was available, ranging from 1.5 to 22 years (median: 7 y; Table 
1). All patients were treated, either with surgery: curettage (case 1) or margin free resection/
amputation (cases 2 to 6 and 8), or when inoperable with chemotherapy combined with 
radiotherapy (case 7) or radiotherapy only (case 9) (Table 1). Only one patient with an SFT-like 
tumor (case 3) and one with an SS-like tumor (case 4) developed a local recurrence after 15 
and 4 years, respectively. Five patients developed metastases ranging from 0.25 to 21 years after 
the initial diagnosis (median: 6 y). All patients with SS-like tumors developed lung metastases, 
whereas only 2 patients with a tumor resembling SFT developed metastases. In one of these SFT 
patients (case 2), the metastases were located within the lungs and bone, whereas the other (case 
3) developed metastases within the lungs, liver, and soft tissue. Only the primary tumor in case 
3 had more than 4 mitoses/10 HPF.
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Figure 2. Radiologic appearance of the two different entities: solitary fibrous tumors of bone [(A, B) case 
number 9] and synovial sarcoma of bone [(C) case number 5] showing that the bulk of the tumor mass 
is located within the bone, corresponding with a primary bone tumor. A, Anteroposterior conventional 
radiograph of the sacrum showing an ill-defined osteolytic lesion (arrows) in the area of the first and 
second sacral vertebra with loss of delineation of the sacral foramina on the right. B, The computed 
tomography slice demonstrates the intra-osseous origin of the tumor, the anterior cortical interruption 
and the subsequent soft-tissue extension. C, Anteroposterior conventional radiograph of the knee showing 
an ill-defined osteolytic lesion arising in the medullar cavity of the proximal fibula. There is a permeative 
cortical destruction and a periosteal reaction with possible extension into the soft-tissue extension (arrow).
Immunohistochemistry
Three of 5 tumors resembling SFT showed diffuse or more focal staining for CD34 (Fig. 1C). 
One tumor showed focal staining for SMA (Fig. 1F). Three and 2 tumors showed focal staining 
for EMA and keratin AE1/AE3 (Figs. 1D, E), respectively. Two tumors resembling SS showed 
either focal-positive staining for EMA or keratin AE1/AE3 (Figs. 1J, K). The keratin-positive 
tumor showed some focal staining for CD34. The other 2 tumors were negative for CD34 (Fig. 
1I). All tumors showed focal-positive staining for SMA (Fig. 1J). None of the 9 tumors showed 
expression of CD31 or von Willebrand factor. Results of immunohistochemical analysis for all 
cases are listed in Table 2.
FISH
Only 1 tumor showed in 82 nuclei a break-apart of probes flanking the SS18 (SYT) gene, 
confirming the diagnosis of SS (Fig. 1K inset). One tumor having morphology consistent with 
SS failed repeatedly, probably because of decalcification effects. In 6 tumors, 1 resembling SS 
and 5 resembling SFT (including those showing focal positivity for keratin and EMA), an SS18 
rearrangement was not detected. Results of the FISH analysis for all cases are listed in Table 2.
Discussion
Although the existence of HPC of bone has been reported, mainly in single case reports, they 
are extremely rare.31,33 The largest series consisted of 11 cases and was described by Wold and 
colleagues in 1982.33 However, to date there is no consensus whether this entity truly exists. 
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Today, it is accepted that the “so-called” HPC of soft tissue merely represents a nonspecific growth 
pattern, instead of a true, specific entity. Over the years, it has become clear that many tumors 
exhibit this growth pattern.8,10,13 As true pericytic differentiation could not be confirmed in the 
majority of the tumors, it has been stated that most of these lesions should be classified as SFT, 
monophasic SS, and (infantile) myofibromatosis or myofibroblastic lesions.8,10,13,18 In addition, a 
hemangiopericytomatous vascular pattern is seen in phosphaturic mesenchymal tumor.11 We 
therefore collected a series of so-called HPC of bone to see whether these were distinctive 
lesions, or that, similar to its soft-tissue counterpart, also in bone this is a nonspecific growth 
pattern. In addition, in neuropathology, there is a current shift from meningeal HPC toward 
meningeal SFT. It is well known that these tumors tend to metastasize to bone.16 Therefore, we 
excluded all patients with brain surgery or confirmed meningeal HPC/SFT in their medical 
history.
The histologic review of the 9 bone tumors with a strict hemangiopericytomatous vascular 
pattern suggested the existence of 2 categories: 6 tumors consistent with the morphology of 
SFT and 3 tumors consistent with the morphology of SS. To support or confirm these diagnoses, 
immunohistochemistry and SS18-FISH were performed.
Within the group of tumors reminiscent of SS, 2 of 3 tumors either showed focal keratin or 
EMA expression, which is more or less consistent with the literature.10 One tumor also showed 
focal staining for CD34. Although most SS are negative for CD34, positivity has been reported 
in a minority of cases, up to 7.7%, mainly of monophasic or poorly differentiated types. 2,6,22,26 
Positivity for SMA has also been described in up to 21% of the SSs.26 As SMA can be present in 
either SS or SFT, it is not a useful marker for distinguishing between these diagnoses.
SS is characterized by a tumor-specific translocation t(X;18)(p11.2;q11.2) leading to the SS18-
SSX fusion gene which is present in 90 to 95% of the SSs. SS18-FISH was performed and the 
presence of a break in the SS18 gene confirmed the diagnosis of SS and therewith the existence 
of primary SS of bone. However, we could demonstrate the tumor-specific translocation in only 
1 of 2 cases evaluated. Both FISH and reverse transcription-polymerase chain reaction can be 
used to detect the SS-specific translocation in FFPE material.1,30 It has been shown that FISH is 
slightly less sensitive compared with reverse transcription-polymerase chain reaction, which may 
explain the negative result in one tumor.1,30 Alternatively, as 5% to 10% of the SSs lack this tumor-
specific translocation, we can not rule out another complex genetic aberration not detectable by 
the FISH-probe used. Nevertheless, the morphology and the immunohistochemical profile in 
this SS18-negative tumor (case 4), suggest SS. In the third case the FISH failed repeatedly, most 
probably due to heavy decalcification methods or poor fixation of the specimen. This tumor 
(case 8) also did not show any immunoreactivity for keratin AE1/AE3 or EMA. Furthermore, 
this tumor was negative for CD34, although the numerous blood vessels present within the 
tumor were positive. Thus, although the morphology, mitotic rate and clinical behavior were 
consistent with SS, immunohistochemistry and molecular diagnostics could not definitively 
support reclassification of this tumor.
Immunohistochemistry in the group of tumors reminiscent of SFT revealed 3 tumors with either 
diffuse (2 tumors) or focal (1 tumor) staining for CD34, whereas 2 tumors were CD34 negative. 
A Reappraisal of Hemangiopericytoma of Bone
123
7
One tumor did not show any immunoreactivity for CD34, repeatedly, and also the internal 
control (blood vessels) was negative, suggesting loss of antigenicity for this marker possibly due 
to heavy decalcification. Although CD34 is the most useful marker to diagnose SFT,10,24 it is 
expressed by many other spindle-cell neoplasms, such as neurofibromas, gastrointestinal stromal 
tumors, spindle cell lipoma and dermatofibrosarcomas protuberans.14,25 In addition, expression 
of CD34 in SFT is rather variable ranging from 80% to 95% of cases in the literature,10,13 
which may explain the 2 CD34-negative tumors. So far, it has not been elucidated why a small 
percentage of SFT are CD34 negative. Although expression of keratin and SMA is rare, these 
markers have been reported to be positive in about 2% to 3% of SFT, whereas EMA can be 
positive in up to 20% to 35% of the tumors.10 We found EMA positivity in 3 of 5 and keratin 
positivity in 2 of 5 bone tumors with SFT like morphology. It may therefore be that SFT 
of bone is more often negative for CD34 and more often positive for EMA as compared to 
morphologically similar tumors arising in soft tissue. Alternatively, these cases represent other 
entities. However, none of the EMA-positive cases demonstrated a break in the SS18 gene and 
none of the CD34-negative cases had the characteristic features of phosphaturic mesenchymal 
tumor.
Unfortunately, there is no specific immunohistochemical marker or a specific genetic aberration 
that can be used to further support the diagnosis of primary SFT of bone. Cytogenetic 
aberrations are uncommon in small SFTs but are more common (and also heterogeneous) in 
the larger ones.21
Despite the fact that this is a multicenter study, numbers are small and statistical analysis is 
not meaningful. However, our studies suggest that SS of bone tends to have a predilection for 
the long tubular bones. In contrast, SFT of bone is located within the spine, in particular the 
sacrum or lower lumbar region. It has been reported that SS metastasizes in about 40%, most 
often to lungs and bone.10 All 3 SSs in our series metastasized to the lungs, whereas only one 
SFT metastasized to lungs and bone and one SFT metastasized to lungs, liver, and soft tissue. 
According to the literature SS has a 5-year survival of 36% to 76% and a 10-year survival of 20% 
to 63%.10 Although the number of SS cases in this study is very limited, the survival curve of 
our 3 patients shows a similar pattern. Two of 3 SS died 1.5 and 7 years after diagnosis (cases 5 
and 8, respectively). For SFT there is not always a consistent correlation between morphology 
and biologic behavior. It has been stated that 10% to 15% of the tumors behave aggressively for 
which increased mitotic rate (4 or more mitoses/10 HPF) was reported to be the most useful 
predictive factor.12,15,32. In our series, 2 patients with SFT died due to progressive disease.
In conclusion, comparable to their presumed soft-tissue counterpart, we believe that HPC 
of bone should be regarded as a nonspecific growth pattern. Metastatic disease, in particular 
metastasis of meningeal HPC/SFT, should be excluded. Two entities formerly classified as HPC 
of bone can be distinguished: primary SFT and primary SS of bone, respectively. SFT of bone 
is characterized by a pattern-less architecture and variable cellularity, and often shows diffuse 
CD34 positivity. These tumors, mostly located within the spine, tend to have a better prognosis. 
SS of bone is characterized by a more spindled and fascicular morphology, often with focal 
keratin or EMA positivity. These tumors are located within the long bones and have a poor 
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prognosis. The latter can be confirmed by SS18-FISH, if nonaggressive decalcification methods 
are used.
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Chapter 1 emphasizes the need for more specific morphological, immunohistochemical and/or 
molecular tools to support the classification of the different vascular tumours of bone. Because 
vascular tumours of soft tissue are more common and more easily accessible for research, these 
have been better delineated at the morphological as well as molecular level over the past years. 
Vascular tumours of bone need decalcification for adequate routine histological analysis, which 
has a severe negative impact on DNA quality. It is still unclear whether vascular tumours of bone 
are comparable to their soft tissue counterparts simply differing in location, or whether they 
should be regarded as different entities with their own molecular profile and clinical behaviour.
Chapter 2 summarizes all different histological types of vascular tumours of bone based on 
radiological imaging, histology and their genetic profile, as far as available, before the WHO 
classification 2013. Based on the available literature a classification scheme was proposed, which 
was later on adopted in the 2013 WHO classification1.
Characterization of angiosarcoma of bone based on morphology
In Chapter 3 we attempt to delineate the high-grade malignant vascular tumours of bone 
by systematic histological analysis of a large multi-institute series of angiosarcomas of bone. 
Previously, high-grade cytological or marked nuclear atypia, brisk mitotic activity with or 
without atypical forms were stated as important histological criteria for malignancy in vascular 
tumours of bone. However, exact quantifiable histological criteria were still lacking. In our 
series of angiosarcomas of bone, cytonuclear atypia was found in all tumours, nearly half of 
the tumours showed nuclear hyperchromasia and the mitotic activity ranged from 0 to 9 
mitoses per 10 HPF. Within this group we identified three high-risk histological parameters 
that correlated with poor prognosis on multivariate analysis: three or more mitoses per 10 
HPF, a macronucleolus and the presence of fewer than five eosinophilic granulocytes per 10 
HPF. Furthermore, a subset of angiosarcomas of bone containing the combination of these 
features showed an even more aggressive course. Nearly one third of the patients demonstrated 
multifocal disease. Angiosarcomas of bone showed a variable expression of the vascular markers 
CD31, CD34 and Factor VIII and more than two third showed cytokeratin positivity. In addition, 
the majority of tumours showed epithelioid morphology. The multifocal appearance combined 
with keratin positivity can easily mislead radiologists and pathologists to misdiagnose these 
tumours as metastatic carcinoma. Radiologically, well demarcated, multifocal osteolytic lesions 
with cortical destruction and marked soft tissue changes should trigger the radiologist to add a 
vascular tumour in the differential diagnosis and thereby also the pathologist to use additional 
immunohistochemistry to confirm the vascular nature of the tumour2.
Characterization of angiosarcoma of bone based on protein expression in comparison 
with angiosarcoma of soft tissue
In Chapter 4 we characterize angiosarcomas of bone based on protein expression of a large 
panel of oncogenes, tumour-suppressor genes, and signalling molecules. In addition, hotspot 
mutation analysis of PIK3CA, KRAS and BRAF was performed. In this thesis we demonstrate 
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that in more than half of the angiosarcomas of bone the Rb pathway is disrupted, either by 
loss of expression of CDKN2A or by overexpression of Cyclin D1. Unlike angiosarcoma of 
soft tissue, the TP53 pathway seems of no importance in angiosarcoma of bone. Disruption of 
the Rb pathway would suggest that angiosarcomas belong to the category of sarcomas with 
complex genetic profiles. In addition, we demonstrate that the TGF-beta pathway is highly 
active in angiosarcoma of bone and may play a role in tumourigenesis. This finding also suggests 
therapeutic options for angiosarcoma of bone, since inhibitors of the TGF-beta pathway are 
available. We also demonstrate that the PI3K/Akt pathway is active in angiosarcoma of bone 
and soft tissue, but differences in protein expression suggest different mechanisms of activation. 
In angiosarcoma of bone this could be explained by the decreased expression of PTEN in 
nearly half of the tumour samples, compared to 7% in angiosarcoma of soft tissue. Although a 
single case concerning an angiosarcoma of the liver has been reported to contain a PTEN gene 
mutation, it is so far unclear whether PTEN mutations are present in angiosarcoma of bone. It 
is known that genetic aberrations in the PI3K/Akt pathway, such as PIK3CA mutations, have 
the potential to cause malignancies. The possible role of PI3K/Akt pathway in angiosarcoma of 
bone provides a rationale for the use of PI3K/Akt pathway inhibitors although future studies 
are needed to reveal its value. In angiosarcoma of soft tissue the tyrosine kinase receptor KIT is 
overexpressed in 90%, compared to only 17% in angiosarcoma of bone. Although there is one 
report of a very good respons to imatinib (Glivec) in angiosarcoma of soft tissue, no KIT or 
PDGFRA mutations have been detected in angiosarcoma of soft tissue3.
Characterization of angiosarcoma of bone at the molecular level in comparison 
with angiosarcoma of soft tissue
Formic acid based decalcification which is routinely used in daily diagnostics in most pathology 
labs for tissues containing bone decreases the quality of the DNA by degrading it. The length of 
DNA fragments obtained from these samples are often less than 150-200 base pairs, hampering 
molecular testing. In order to characterize our retrospective series of angiosarcomas of bone, 
mostly consisting of decalcified FFPE blocks, we had to circumvent this technical hurdle. We 
therefore first optimized and validated the array CGH technique on various heavily decalcified 
formalin-fixed, paraffin embedded bone tumours of multiple institutions in Chapter 5. In 
this thesis we use oligonucleotide based array chips containing reporter elements of ~60 base 
pairs. Because enzymatic labelling can cause further fragmentation of the DNA, two different 
labelling techniques are tested. The first is a direct chemical labelling (Universal Linkage System) 
without further fragmentation of the DNA, while the second method is a commercially available 
random primer labelling kit especially developed for formalin-fixed, paraffin embedded tissue 
derived DNA. Both labelling methods show a good reproducibility and show similar results 
by using 500ng starting material. Furthermore, the DNA concentrations are measured by two 
independent methods: absorption-based DNA concentration measurements and ethidium 
bromide stained gel-imaging. We demonstrate that the estimation of the DNA concentration is 
more important for successful testing than the quality (fragment size) of DNA obtained from 
formalin-fixed, paraffin embedded tissue.
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After optimization, in Chapter 6 we applied this technique to create genomic profiles of the 
first large series of angiosarcomas of bone in comparison to a small group of angiosarcomas 
of soft tissue. In this study we demonstrate no evident molecular genetic difference between 
angiosarcoma of bone and soft tissue. In contrast, we identify two groups of angiosarcomas: 
angiosarcomas with a complex genetic profile and a second group of angiosarcomas with only 
few genetic aberrations. Although previous results in this thesis indicate a possible role of the 
Retinoblastoma (Rb) pathway and/or TP53 pathway, here we show no correlation between 
deregulation of the TP53/Rb pathway and a complex karyotype. One angiosarcoma of soft 
tissue demonstrates the presence of MYC amplification, without any history of radiation 
therapy or chronic lymphedema, and a high level of amplification at region 5q, containing 
the FLT4 and MAPK9 (JNK2) gene. We show high protein expression of MAPK9 (JNK2) 
in the vast majority of angiosarcomas (bone and soft tissue), irrespective of whether genomic 
amplification of this region was present or not. A possible role of JNK2 has not been described 
yet. However, it is known that TGF-beta can activate JNK2. Thus we hypothesize that the 
presence of JNK2 expression can be explained by the high expression of TGF-beta, which we 
demonstrate previously in Chapter 4. Another angiosarcoma of bone shows an amplicon at 
region 1p36, amongst others containing SKI (Sloan Kettering Institute proto-oncoprotein). SKI 
is not only involved in many signalling pathways (its most well known function is to negatively 
regulate TGF-beta signalling), but can also promote cancer progression and is highly expressed 
in different human solid tumours. Here we demonstrate high expression of SKI in both 
angiosarcoma of bone and soft tissue. Although previous reports suggest that overexpression of 
SKI plays a role in tumour growth and angiogenesis, its exact role in angiogenesis still remains 
unclear. Although the threshold for recurrent aberrations (25%) is not reached within our series, 
three angiosarcomas show a high level of amplification of chromosome 2q and 17q. High 
level amplification of 17q23 has been described in many tumour types, and especially in breast 
carcinomas it is suggested to be associated with tumour progression and poor prognosis. To date, 
high level amplification of 2q32-34 has not been described yet.
Haemangiopericytoma of bone: a true entity?
Since the 2002 World Health Organisation Classification of Tumours of Soft Tissue and Bone, 
haemangiopericytoma of soft tissue is no longer recognized as a separate entity and it has 
been accepted that these lesions should be classified as solitary fibrous tumour, monophasic 
synovial sarcoma, and (infantile) myofibromatosis or myofibroblastic lesions4. In Chapter 
7 we again exploit parallels between vascular tumours of bone by comparison with their 
soft tissue counterpart, by studying a relatively large series of cases previously diagnosed as 
“haemangiopericytoma of bone”. Based on histological review, two principal morphological 
patterns are recognized: one group of six tumours demonstrate a pattern-less architecture and 
varying cellularity with monomorphic tumour cells with bland nuclei that do not overlap and 
have a limited amount of pale eosinophilic cytoplasm with indistinct cell borders, consistent with 
the morphology of solitary fibrous tumours. A second group of three tumours are characterized 
by a fascicular arrangement of uniform non-pleomorphic spindle cells with a sparse amount 
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of cytoplasm, nuclear overlap and indistinct cell borders, consistent with the morphology of 
synovial sarcoma. These histological findings could in nearly all cases be confirmed by either 
immunohistochemistry and/ or molecular testing by SS18-FISH. At the time of evaluation of 
these tumours, no specific genetic aberration and/ or specific immunohistochemical marker 
was known to support the diagnosis of solitary fibrous tumour. Recently, a specific NAB2-
STAT6 gene fusion product has been described in solitary fibrous tumour of soft tissue and 
brain5. Moreover, an antibody directed against STAT6 is commercially available and proven 
useful to support the diagnosis of solitary fibrous tumour, as due to the fusion with NAB2, 
STAT6 which is normally localized in the cytoplasm, translocates to the nucleus6. In this thesis, 
we confirm that similar to its soft tissue counterpart, haemangiopericytoma in bone also merely 
represents a growth pattern rather than a true entity. Therefore, STAT6 immunohistochemistry 
and/or SS18 FISH should be used in the diagnostic work-up of spindle cell tumours of bone 
displaying a haemangiopericytomatous vascular pattern.
Future perspective
In this thesis we delineated the most malignant part of vascular tumours of bone, more specific 
angiosarcoma of bone. These are extremely rare tumours for which the collaboration with 
multiple different institutions is needed. Due to the partnership within the EuroBoNeT 
consortium, a European Commission granted Netwerk of Excellence for studying pathology 
and genetics of bone tumours that stimulates and promotes the multicentric collaboration 
within Europe, this research was possible.
Although we could identify in Chapter 3 three high-risk histological parameters that correlated 
with poor prognosis, not all angiosarcomas exhibit all three histological features and a small 
portion of these tumours have a different, even better, clinical course. To date, however, there 
is no evidence or supporting data that low-grade angiosarcoma or haemangioendothelioma of 
bone is a distinct or truly existing entity. Array-CGH analysis, performed in Chapter 6, could 
only identify two subgroups of angiosarcoma (with or without a complex genetic profile) 
which did not correlate with prognosis. Therefore, the results of the array-CGH do not provide 
diagnostic or prognostic markers that can assist in the classification of angiosarcoma of bone 
or that can distinguish angiosarcoma of bone with a poor prognosis (2-years survival 0%) from 
angiosarcoma of bone with a slightly better prognosis (5-years survival 33%). However, balanced 
genomic rearrangements, such as balanced translocations and inversions, and point mutations in 
the DNA are not detected by array-CGH. More recent molecular studies of distinct vascular 
entities, such as epithelioid haemangioendothelioma, pseudomyogenic haemangioendothelioma 
and even epithelioid haemangioma, have shown the presence of a specific balanced translocation 
in a vast majority of these tumours. In this perspective, Next Generation Sequencing (NGS) 
of angiosarcoma of bone would be very interesting: mainly to investigate whether recurrent 
genetic alterations are present in angiosarcoma of bone and if so, whether these alterations 
correlate with morphology and clinical outcome. Moreover, these genetic alterations could 
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elucidate the process of tumourigenesis and subsequently lead to new and better therapeutic 
options. However to date, this molecular procedure is not optimized for (decalcified) formalin-
fixed, paraffin embedded material.
In this thesis, we could not detect by multicolour (COBRA-)FISH karyotyping any 
cytogenetically visible balanced rearrangements in one case displaying multifocal lesions of 
angiosarcoma of bone (Chapter 5). However, recent studies have shown identical alterations 
in multifocal vascular lesions within the same patient: all multifocal lesions of an epithelioid 
haemangioendothelioma7 contained a translocation with an identical breakpoint, and multiple 
enchondromas and spindle cell haemangiomas in patients with Maffucci syndrome8 all contain 
the R132C hotspot mutation. These findings support the hypothesis of clonal disease and 
suggest that the tumour nodules are metastatic implants, rather than synchronous multiple 
neoplastic clones7. Testing of multiple tumour samples within a single patient using NGS could 
be interesting and may reveal the clonal evolution of these lesions.
Although it is still not fully elucidated whether angiosarcoma of bone is truly different 
from angiosarcoma of soft tissue, or should be regarded as the same entity with a different 
localization, we have shown in Chapter 6 that from the perspective of the array-CGH study, 
we could not demonstrate any evident molecular genetic difference between these two lesions. 
However, based on the immunohistochemical analysis performed in Chapter 4 there is a clear 
difference in protein expression between both tumour entities. Pathway analysis revealed that 
TGFbeta is more active in angiosarcoma of bone, whereas the PI3K/Akt pathway is active in 
both angiosarcoma of bone and soft tissue. Since these tumours have a similar morphology 
and genetic profile the difference in protein expression and pathway activation may be caused 
by epigenetic changes or the different tumour microenvironment, which may have possible 
therapeutic implications. In order to further evaluate these therapeutic options, there is an 
urgent need for in vitro models and it would be desirable to establish an angiosarcoma of bone 
cell line.
In this perspective we could conclude that the 2013 WHO classification of vascular tumours is 
merely a good start, but should not be regarded as an endpoint. In contrast to the 2002 WHO 
classification, epithelioid haemangioma is nowadays a well recognised entity with characteristic 
histological features and a favourable prognosis and therefore no longer merged into the group 
of angiosarcoma. However, angiosarcomas are still a heterogeneous group and further research 
(by next generation sequencing for example) is needed to elucidate underlying mechanisms that 
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Hoofdstuk 1 benadrukt de noodzaak voor meer specifieke morfologische, 
immuunhistochemische en/of moleculaire testen die de classificatie van de verschillende 
vaattumoren van het bot kunnen ondersteunen. Aangezien vaattumoren gelokaliseerd in de 
weke delen frequenter voorkomen en dus ook gemakkelijker beschikbaar zijn voor aanvullend 
onderzoek, zijn deze tumoren in de loop der jaren zowel morfologisch als op moleculair niveau 
beter omschreven. Vaattumoren gelokaliseerd in het bot moeten eerst ontkalkt worden voordat 
deze in de dagelijke praktijk histologisch onderzocht kunnen worden. Deze ontkalkingstechniek 
heeft echter een ernstige negatieve invloed op de DNA kwaliteit. Tot op heden is het nog steeds 
niet duidelijk of vaattumoren van het bot vergelijkbaar zijn met hun tegenhanger in de weke 
delen, en dus alleen verschillen in lokalisatie, of dat deze tumoren toch beschouwd dienen 
te worden als twee verschillende entiteiten met een afzonderlijk moleculair profiel en een 
verschillend klinisch gedrag.
Hoofdstuk 2 vat alle verschillende histologische subtypes van vaattumoren van het bot samen, 
gebaseerd op radiologische beeldvorming, histologie en indien bekend het genetisch profiel, 
zoals dit voor het verschijnen van de Wereld Gezondheid Organisatie (WGO) classificatie van 
2013 gebruikelijk was. Op basis van de destijds beschikbare literatuur is een classificatie schema 
voorgesteld welke later is overgenomen in de WGO classificatie van 20131.
Typering van angiosarcomen van het bot gebaseerd op morfologie
In Hoofdstuk 3 proberen we de hooggradige kwaadaardige vaattumoren (ook wel 
angiosarcomen genoemd) van het bot nader te omschrijven door een systematische histologische 
analyse van een grote groep van angiosarcomen van het bot, afkomstig uit verschillende centra 
voor bottumoren. Voorheen werden uitgesproken kernatypie en veelvuldig voorkomen van 
celdelingen, met of zonder atypische vormen, gebruikt als belangrijke histologische criteria om 
kwaadaardigheid in vaattumoren van het bot vast te stellen. Exact meetbare (kwantificeerbare) 
histologische parameters ontbreken echter nog steeds. In onze dataset van angiosarcomen 
van het bot is cytonucleaire atypie aanwezig in alle tumoren. Bijna de helft van de tumoren 
toont kern-hyperchromasie en de celdelingen varieren van 0 tot 9 celdelingen per 10 hoge 
vergrotingsvelden. Binnen deze groep stelden we, via multivariaat statistisch onderzoek, drie 
hooggradige histologische parameters vast die samenhangen met een slechte overleving, 
namelijk: 3 of meer celdelingen per 10 hoge vergrotingsvelden, een macrocronucleolus en de 
aanwezigheid van minder dan 5 eosinofiele granulocyten per 10 hoge vergrotingsvelden. Het 
deel van angiosarcomen van het bot die de combinatie van deze drie eigenschappen bevatten, 
toonden een ernstiger klinisch beloop. Bij nagenoeg een derde van de patiënten bleken 
meerdere botten aangedaan door de ziekte. Angiosarcomen van het bot tonen een wisselende 
expressie voor de vaatmarkers CD31, CD34 en Factor VIII en meer dan twee derde toont ook 
aankleuring voor cytokeratine. Daarnaast toont een grote meerderheid van de tumoren ook een 
epitheliaal-achtige, zogenaamd epitheloide, morfologie. Het multifocaal voorkomen (meerdere 
botten aangedaan), de epitheloide morfologie samen met de aankleuring voor cytokeratine kan 
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makkelijk tot de verkeerde diagnose van een uitgezaaide epitheliale tumor leiden. Beeldvorming 
van goed omschreven, osteolytische (waarbij het bot verdwijnt) afwijkingen die in meerdere 
botten voorkomen met ook onderbreking van de cortex en opvallende reactie van de omgevende 
weke delen moeten de radioloog ertoe aanzetten om vaattumoren in de differentiaal diagnose 
op te nemen, en de patholoog ertoe aansporen om bijkomstige immuunhistochemische markers 
toe te voegen om de vaat-differentiatie van de tumor te bevestigen2.
Typering van angiosarcomen van het bot gebaseerd op eiwitexpressie in vergelijking 
met angiosarcomen van de weke delen
In Hoofdstuk 4 typeren we de angiosarcomen van het bot door middel van eiwitexpressie 
gebaseerd op een grote groep van oncogenen, tumorsupressor genen en signaalmoleculen. 
Daarnaast werd een hotspot mutatie analyse verricht voor PIK3CA, KRAS en BRAF. In dit 
proefschrift tonen we aan dat meer dan de helft van de angiosarcomen van het bot een verstoring 
van de retinoblastoom (Rb) route laat zien, veroorzaakt door ofwel verlies van CDKN2A 
expressie ofwel door overexpressie van Cycline D1. In tegenstelling tot angiosarcomen van de 
weke delen, lijkt de TP53 route niet belangrijk bij angiosarcomen van het bot. De verstoring 
van de Rb route suggereert dat angiosarcomen behoren tot de groep van sarcomen met een 
complex genetisch profiel. Daarnaast tonen we ook aan dat de TGF-beta route erg actief is in 
angiosarcomen van het bot en dus een mogelijke rol speelt in de tumorontwikkeling. Aangezien 
er reeds producten voorhanden zijn die deze TGF-beta route kunnen blokkeren, impliceren deze 
bevindingen ook mogelijke therapeutische opties voor angiosarcomen van het bot. We tonen 
ook aan dat de PI3K/Akt route zowel in angiosarcomen van het bot als in de weke delen actief 
is, maar gezien het verschil in eiwitexpressie is er vermoedelijk een ander activatiemechanisme. 
In bijna de helft van de angiosarcomen van het bot kan dit verklaard worden door de afname 
van expressie van PTEN, terwijl dit slechts in 7% van de angiosarcomen van de weke delen 
wordt gezien. Hoewel er in de literatuur slechts bij één angiosarcoom van de lever een PTEN 
genmutatie is gerapporteerd, is het tot op heden onduidelijk of PTEN mutaties aanwezig zijn 
in angiosarcomen van het bot. Het is bekend dat genetische afwijkingen in de PI3K/Akt route, 
zoals PIK3CA mutaties, aanleiding kunnen geven tot kwaadaardige tumoren. De mogelijke 
rol van de PI3K/Akt route in angiosarcomen van het bot leidt tot de achterliggende gedachte 
dat stoffen die de PI3K/Akt-route kunnen blokkeren behulpzaam zouden kunnen zijn in de 
behandeling van deze tumoren. Nader onderzoek is hiervoor echter noodzakelijk. In 90% van 
de angiosarcomen van de weke delen wordt de tyrosine kinase receptor KIT tot overexpressie 
gebracht, dit is slechts in 17% van de angiosarcomen van het bot aanwezig. Er is één publicatie 
van een goede respons op imatinib (Glivec) in een angiosarcoom van de weke delen, ondanks 
dat er geen KIT of PDGFRA mutaties in deze tumoren werden aangetoond3.
Typering van angiosarcomen van het bot op moleculair niveau in vergelijking met 
angiosarcomen van de weke delen
In de meeste pathologie laboratoria gebeurt de ontkalking van botbevattend materiaal in de 




de DNA kwaliteit sterk vermindert. De lengte van de DNA fragmenten die van deze stalen 
verkregen worden, zijn vaak kleiner dan 150-200 baseparen, waardoor moleculaire testen 
enigszins bemoeilijkt worden. Ten einde onze groep van angiosarcomen van het bot, een groep 
die voornamelijk bestaat uit ontkalkt en in formaline gefixeerd en in paraffine ingebedde 
weefselblokjes, te kunnen typeren middels een moleculaire test, moesten we eerst deze technische 
hindernis omzeilen. Derhalve hebben we eerst de array-CGH techniek geoptimaliseerd en 
gevalideerd op verschillende bottumoren die in verschillende instituten uitgebreid ontkalkt zijn 
en vervolgens in formaline gefixeerd en in parafine ingebed, zoals beschreven in Hoofdstuk 5. 
In dit proefschrift gebruiken we oligonucleotide gebaseerde array chips die reporter elementen 
van ~60 baseparen bevatten. Omdat enzymatische labeling verdere fragmentatie van het 
DNA kan veroorzaken, worden twee verschillende labelingstechnieken uitgetest. De eerste 
methode betreft een directe chemische labeling (Universal Linkage System) zonder verdere 
fragmentatie van het DNA, terwijl de tweede methode een commercieel verkrijgbare ‘random 
primer labeling’ set is speciaal ontworpen voor DNA verkregen uit formaline gefixeerd en 
in paraffine ingebed weefsel. Beide labelingsmethodes bleken goed reproduceerbaar en tonen 
gelijkwaardige resultaten bij gebruik van 500 ng DNA als startmateriaal. Daarnaast werden de 
DNA concentraties op twee verschillende manieren gemeten: een DNA concentratie meting 
gebaseerd op absorptie, en ethidium-bromide gekleurde gel-electroforese. We tonen aan dat een 
schatting van de DNA concentratie belangrijker is voor een positief testresultaat dan de DNA 
kwaliteit (grootte van de fragmenten) van het DNA verkregen uit formaline gefixeerd en in 
paraffine ingebed weefsel.
Na optimalisatie, hebben we deze techniek toegepast in Hoofdstuk 6 om op deze manier het 
genomisch profiel te verkrijgen van een eerste grote groep van angiosarcomen van het bot, in 
vergelijking met een kleine groep van angiosarcomen van de weke delen. In deze studie tonen 
we aan dat er geen evident moleculair verschil is tussen beide groepen. Daarentegen stellen 
we vast dat er twee groepen angiosarcomen zijn, namelijk angiosarcomen met een complex 
genetisch profiel en angiosarcomen met weinig of geen genetische afwijkingen. Hoewel eerdere 
resultaten in dit proefschrift een mogelijk rol van de Rb en/of TP53 route suggereren, wordt er 
in deze studie geen verband aangetroffen tussen de Rb/TP53 route en een complex genetisch 
profiel. Eén angiosarcoom van de weke delen toont de aanwezigheid van MYC amplificatie, 
dit zonder een voorgeschiedenis van radiotherapie of chronisch lymphoedeem, en ‘high-level’ 
amplificatie van regio 5q, de regio die het FLT4 en MAPK9 (JNK2) gen bevat. In het overgrote 
deel van angiosarcomen (bot en weke delen) tonen wij hoge eiwit expressie aan van MAPK9 
(JNK2), onafhankelijk van de aan- of afwezigheid van genomische amplificatie van deze regio. 
Een mogelijke rol van JNK2 bij vaattumoren werd nog niet eerder beschreven, hoewel TGF-
beta JNK2 kan activeren. Daarom lijkt het aannemelijk dat de aanwezigheid van JNK2 expressie 
verklaard kan worden door de hoge expressie van TGF-beta, welke we reeds eerder in Hoofdstuk 
4 aangetoond hebben. Eén angiosarcoom van het bot toonde een amplificatie ter hoogte van 
regio 1p36, welke onder andere het SKI (Sloan Kettering Institute proto-oncoprotein)-gen 
bevat. SKI is niet alleen betrokken bij talrijke signaalroutes (de meest bekende functie is de 
negatieve regulatie van het TGF-beta signaal), maar kan ook kanker progressie bevorderen en 
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wordt in verschillende tumorsoorten hoog tot expressie gebracht. In dit onderzoek tonen we 
aan dat SKI in zowel angiosarcomen van het bot als de weke delen hoog tot expressie wordt 
gebracht. Hoewel er al eerdere publicaties zijn die suggereren dat de overexpressie van SKI een 
rol zou kunnen spelen in tumorgroei en bloedvatvorming, blijft de specifieke rol van SKI in de 
bloedvatvorming onduidelijk. Hoewel binnen onze groep de drempel (25%) voor terugkerende 
genetische afwijkingen niet bereikt werd, tonen 3 angiosarcomen een ‘high-level’ amplificatie 
van chromosoom 2q en 17q. High-level amplificatie van 17q23 is eerder al beschreven in 
verschillende tumorsoorten. Met name in borsttumoren wordt er verondersteld dat er een 
relatie is met tumor progressie en een slechte prognose. Tot op vandaag is high-level amplificatie 
van 2q32-34 niet eerder beschreven.
Haemangiopericytoom van het bot: een bestaande entiteit?
Sinds de 2002 WGO Classificatie voor Weke Delen en Bottumoren, is het haemangiopericytoom 
van de weke delen niet langer erkend als een unieke entiteit. Het is algemeen aanvaard dat deze 
afwijkingen beter ingedeeld worden als solitaire fibreuze tumoren, monofasisch synoviosarcoom 
en (infantiele) myofibromatosis of myofibroblastaire laesies4. In Hoofdstuk 7 vergelijken we de 
bottumoren met hun tegenhangers in de weke delen door een relatief grote groep van tumoren 
die eerder als “haemangiopericytoom van het bot” werden gediagnosticeerd te bestuderen. Op 
basis van een histologische herbeoordeling, worden er 2 histologische hoofdpatronen herkend: 
een groep van zes tumoren toont een patroonloze architectuur, variabele celrijkdom met 
monomorfe tumorcellen zonder opvallende kernen die ook geen overlap tonen en omgeven 
worden door een beperkte hoeveelheid eosinofiel cytoplasma en onscherpe celgrenzen, inpasbaar 
met de morfologie van een solitaire fibreuze tumor. Een tweede groep van drie tumoren wordt 
gekenmerkt door een bundelige opbouw van uniforme, niet pleiomorfe spoelvormige cellen 
met een geringe hoeveelheid cytoplasma, kernoverlap en onscherpe celgrenzen, overeenkomstig 
met de morfologie van een synoviosarcoom. Deze histologische bevindingen worden in de 
meerderheid van de gevallen ondersteund door immuunhistochemie en/of een moleculaire 
test, namelijk SS18-FISH. Op het moment van de evaluatie van deze tumoren was er nog geen 
specifieke translocatie en/of specifieke immuunhistochemische marker bekend die de diagnose 
van solitaire fibreuze tumor kon ondersteunen. Recent is er in solitaire fibreuze tumoren van de 
weke delen en de hersenen een specifieke NAB2-STAT6 fusieproduct beschreven5. Daarnaast is 
er ook een commercieel verkrijgbaar antilichaam gericht tegen STAT6, waarvan bewezen is dat 
het behulpzaam is bij het stellen van de diagnose van solitair fibreuze tumoren. Door de fusie 
met NAB2 transloceert STAT6, wat normaal gesproken in het cytoplasma aanwezig is naar de 
kern6. In dit proefschrift bevestigen we dat, net zoals in de weke delen, haemangiopericytoma 
van het bot louter staat voor een groeipatroon in plaats van een zuivere aparte entiteit. In 
dit opzicht is het gebruik van STAT6 immuunhistochemie en/ of SS18-FISH wenselijk in 






In dit proefschrift hebben we het meest kwaadaardige deel van de vaattumoren van het 
bot omschreven. Dit zijn uiterst zeldzame tumoren waardoor samenwerking met meerdere, 
verschillende instituten noodzakelijk is. Dankzij een samenwerking binnen het EuroBoNeT 
consortium, een door de Europese Commissie gesubsidieerd Netwerk van Excellentie voor het 
bestuderen van pathologie en genetica van bottumoren dat de multicentrische samenwerking 
binnen Europa stimuleert, was dit onderzoek mogelijk.
Alhoewel we in Hoofdstuk 3 drie hoog-risico histologische parameters konden aantonen 
die een verband tonen met een slechte prognose, tonen niet alle angiosarcomen deze drie 
kenmerken en een klein deel van deze tumoren toont een ander, zelfs iets beter, klinisch beloop. 
Tot op heden is er geen overtuigend bewijs voor het bestaan van laaggradige angiosarcomen 
van het bot, ook wel haemangioendotheliomen genoemd, als een separate entiteit. Array-CGH 
onderzoek, verricht in Hoofdstuk 6, toont enkel 2 subgroepen van angiosarcomen (met of 
zonder complex genomisch profiel) aan, waarbij er ook geen verband aantoonbaar was met 
de prognose. Hieruit leiden we af dat de resultaten van de array-CGH geen diagnostische of 
prognostische markers leveren die behulpzaam kunnen zijn bij de indeling van angiosarcomen 
van het bot of een onderscheid kunnen maken tussen angiosarcomen met een slechte prognose 
(2 jaarsoverleving 0%) en angiosarcomen met een enigzins betere prognose (5 jaarsoverleving 
33%). Hierbij dient opgemerkt te worden dat gebalanceerde genomische veranderingen, zoals 
gebalanceerde translocaties en inversies alsmede puntmutaties in het DNA, niet gedetecteerd 
worden middels array-CGH. Meerdere recente studies van specifieke entititeiten binnen de 
vaattumoren, zoals bijvoorbeeld het epitheloid haemangioendothelioom, pseudomyogeen 
haemangioendothelioom en zelfs het epitheloid haemangioom, hebben specifieke gebalanceerde 
translocaties in deze tumoren aangetoond. De Nieuwe Generatie Sequencing-technologie 
(Next Generation Sequencing, NGS) zou daarmee ook zeer interessant zijn voor toepassing 
op angiosarcomen van het bot: hoofdzakelijk om te bestuderen of specifieke genetische 
veranderingen aanwezig zijn in angiosarcomen van het bot en indien dit het geval is, of deze 
genetische veranderingen een verband tonen met de morfologie en het klinisch beloop. 
Daarnaast zouden specifieke genetische veranderingen opheldering kunnen geven omtrent 
de tumorgenese en daaruit zouden eventuele nieuwe therapeutische strategiëen kunnen 
voortvloeien. Tot op heden is deze techniek echter niet geschikt voor (ontkalkt) materiaal 
verkregen uit formaline gefixeerd en in paraffine ingebed weefsel.
Op basis van genomisch onderzoek van één angiosarcoom dat op meerdere plaatsen in de 
voet gelokaliseerd is, kunnen we in dit proefschrift geen cytogenetisch zichtbare gebalanceerde 
herschikking aantonen (Hoofdstuk 5). Recente studies hebben echter identieke veranderingen 
aangetoond in multifocale vaatlesies binnen één patiënt. Alle onderzochte tumoren van een 
epitheloid haemangioendothelioom bij een zelfde patiënt bevatten een translocatie met 
identiek breekpunt8, en meerdere enchondromen en spoelcellige goedaardige vaatafwijkingen 
(haemangiomen) in patienten met het Maffucci syndroom bevatten allen de R132C hotspot 
mutatie7. Deze bevindingen ondersteunen de gedachte van een klonale aandoening en 
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impliceren dat de tumor nodi eerder uitzaaiingen zijn, dan gelijktijdig ontstane tumorklonen8. 
NGS testen van meerdere tumorstalen van een zelfde patient zou in dit opzicht erg interessant 
en behulpzaam zijn in de ontrafeling van de klonale evolutie van deze lesies.
Hoewel het nog steeds niet duidelijk is of angiosarcomen van het bot nu daadwerkelijk 
verschillend zijn van angiosarcomen van de weke delen, of dat deze tumoren behoudens 
het verschil in lokalisatie toch als één groep beschouwd dienen te worden, hebben we in 
Hoofdstuk 6 aangetoond dat op basis van de array-CGH resultaten geen evident genetisch 
verschil aantoonbaar is tussen beide groepen. Op basis van het immuunhistochemisch onderzoek 
verricht in hoofdstuk 4 is er echter wel een duidelijk verschil in eiwitexpressie tussen beide 
groepen. We hebben aangetoond dat TGF-beta route actiever is in angiosarcomen van het bot, 
waarbij de PI3K/Akt route actief is in zowel angiosarcomen van het bot als de weke delen. 
Aangezien deze tumoren een gelijkwaardige morfologie en genetisch profiel hebben, kan 
het verschil in eiwitexpressie en activatie van verschillende routes veroorzaakt worden door 
epigenetische veranderingen of door verschillen in tumor-omgeving. Deze verschillen hebben 
mogelijk ook therapeutische implicaties. Om dit nader te onderzoeken is er behoefte aan goede 
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